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Abstract
Malignancies derived from follicular cells of the thyroid can be divided into well-differentiated
thyroid cancer (WDTC), poorly differentiated thyroid cancer and anaplastic (undifferentiated)
thyroid cancer (ATC). While the majority of thyroid cancers are well-differentiated in nature
and have an excellent prognosis, ATC is rare, nonresponsive to conventional therapies, and is
nearly universally fatal. In this study, I employed high-throughput screening of kinase
inhibitors to identify candidate drugs to control ATC and expanded these studies to include a
focus on studying the underlying progression from WDTC to ATC. Two compounds,
lestaurtinib (JAK2 inhibitor) and flavopiridol (pan-CDK inhibitor) were selected from the
high-throughput screen for follow-up studies. Our first study showed that lestaurtinib
demonstrated a potent antiproliferative effect and impeded cell migration and colony formation
in addition to causing cell cycle arrest following drug treatment. Ex vivo, we used the chick
chorioallantoic membrane model to demonstrate that lestaurtinib resulted in a significant
decrease in endpoint tumour volume and tumour vascularity, together highlighting an
antiproliferative and potentially antiangiogenic effect. In our second study, we found that
flavopiridol treatment in vitro had an antiproliferative effect and induced cell cycle arrest. In
vivo, flavopiridol decreased tumour volume and tumour growth over time using a patientderived xenograft model of ATC. Finally, we sought to determine whether the introduction of
a canonical PIK3CA (E545K) mutation, characteristically found at a higher mutation frequency
in ATC, would contribute to disease progression when expressed in a BRAF-mutant WDTC
cell line. In vitro, we demonstrated that the PIK3CA mutation resulted in an increase in cell
proliferation and the ability of cells to form colonies and migrate. When we compared both
cell lines for their tumorigenic capabilities in vivo using a cell line xenograft model, we found
i

that while the average tumour volume was higher in the PIK3CA group, the difference was not
significant. Collectively, this thesis identified two candidate therapeutic agents with potential
to improve patient outcomes and identified PIK3CA as a driver of thyroid cancer progression.

ii

Lay Abstract
Cancer derived from cells of the thyroid can be divided into well-differentiated thyroid cancer
(WDTC), poorly differentiated thyroid cancer and anaplastic (undifferentiated) thyroid cancer
(ATC). While the majority of thyroid cancers are well-differentiated in nature and have an
excellent outcome for patients, ATC is rare and does not respond to conventional therapies. In
this study, I used high-throughput screening of therapeutics to identify candidate drugs to
control ATC and expanded these studies to include a focus on studying the underlying
progression from WDTC to ATC. Two compounds, lestaurtinib and flavopiridol, were selected
from the high-throughput screen for follow-up validation studies. Our first study showed that
lestaurtinib demonstrated a potent antiproliferative effect and impeded the migration of cells
and ability to form colonies in addition to causing cell cycle arrest following drug treatment.
We then used the chick chorioallantoic membrane model to demonstrate that lestaurtinib
resulted in a significant decrease in tumour volume and vascularity. In our second study, we
found that flavopiridol treatment had an antiproliferative effect and induced cell cycle arrest.
When tested in a mouse model, flavopiridol decreased tumour volume and growth over time.
Finally, we sought to determine whether the introduction of a specific PIK3CA (E545K)
mutation, characteristically found at a higher mutation frequency in ATC, would contribute to
disease progression when expressed in a BRAF-mutant WDTC cell line. In vitro, we
demonstrated that the PIK3CA mutation resulted in an increase in cell proliferation and the
ability of cells to form colonies and migrate. When we compared both cell lines for their
tumorigenic capabilities in vivo using a cell line xenograft model, we found that while the
average tumour volume was higher in the PIK3CA group, the difference was not significant.
Collectively, this thesis identified two candidate therapeutic agents with potential to improve
patient outcomes and identified PIK3CA as a genetic driver of thyroid cancer progression.
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Chapter 1

1

Introduction

A version of this chapter has been published:
Pinto N, Black M, Patel K, Yoo J, Mymryk JS, Barrett JW and Nichols AC. 2014
Genomically driven precision medicine to improve outcomes in anaplastic thyroid
cancer. J Oncol 2014:936285. (http://dx.doi.org/10.1155/2014/936285).

1.1 Overview of Chapter 1
This thesis is focused on examining the underlying progression of welldifferentiated thyroid cancer to anaplastic thyroid cancer and identifying candidate
therapeutics with the potential to improve patient outcomes. In Section 1.2 of the
introductory chapter, thyroid malignancies are introduced including the genetic landscape
of the disease and the current treatment strategies available. In Section 1.3, anaplastic
thyroid cancer is introduced with an emphasis on the epidemiology, symptoms at
presentation and current treatment strategies. In this section I also discuss the current
understanding of the genomic landscape of this disease with a focus on the major pathways
involved in driving disease progression and how targeting these changes using highthroughput screening can be an essential tool for drug discovery in preclinical models of
disease. Section 1.4 summarizes the overall scope of this study on anaplastic thyroid cancer
and the major findings presented in this thesis with the overall goal and specific objectives
presented in Section 1.5.

2

1.2 Thyroid Cancer
1.2.1

The Thyroid Gland
The thyroid is an endocrine gland in the central part of the neck located below the

larynx. Structurally, the thyroid gland consists of two lobes, which are joined by an isthmus
in the middle (Fig 1.1). The thyroid gland itself is composed of two major cell types –
follicular cells and parafollicular cells, which are also known as C-cells (Fig 1.1). While
follicular cells are involved with using iodine for the synthesis of thyroid hormones
involved with regulation of metabolism, C-cells are involved with the production of
calcitonin and regulation of calcium within the body (Kondo et al. 2006). Nodules can
develop from both cell types and can either be classified as hyperplastic benign adenomas
or malignant lesions (Kondo et al. 2006; Nikiforov & Nikiforova 2011; Molinaro et al.
2017).

1.2.2

Classification of Thyroid Malignancies
Cancers arising from the thyroid are the most common endocrine malignancy. The

incidence of thyroid cancer has increased approximately 3-fold in the past 30 years and can
develop from the follicular cells or the parafollicular cells within the gland; with the
majority (>95%) being derived from follicular cells (Kondo et al. 2006; Mazeh et al. 2012;
Agrawal et al. 2014). Malignancies derived from the follicular cell can be further divided
into well differentiated thyroid cancer (WDTC), poorly differentiated thyroid cancer
(PDTC) and anaplastic (undifferentiated) thyroid cancer (ATC) (Bin Xu & Ghossein
2016). The majority of these cancer types derived from follicular cells are considered to be
well differentiated and are further divided into papillary thyroid cancer (PTC; overall
frequency 86%) and follicular thyroid cancer (FTC; overall frequency of 9%), with a much
lower frequency of PDTC and ATC (overall frequency of <2% and 1-2%, respectively)
(Table 1.1) (Nikiforov & Nikiforova 2011; Agrawal et al. 2014). While most cases of
thyroid cancer are of follicular cell origin and are considered sporadic, approximately 3.56.2% have familial origins, whereby an individual’s risk of developing thyroid cancer is
greater than 95% if there are three or more affected family members (Mazeh et al. 2012).
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Figure 1.1. Schematic of the anatomy of the human thyroid gland and surrounding
structures. The thyroid is an endocrine gland in the central part of the neck located below
the larynx. Structurally, the thyroid gland consists of two lobes, which are joined by an
isthmus in the middle. The thyroid gland itself is composed of two major cell types –
follicular cells and parafollicular cells and malignancies can develop from both, with those
derived from follicular cells being the most common. Well-differentiated thyroid cancer
subtypes are the most common and consist of follicular and papillary thyroid cancers,
followed by poorly differentiated and undifferentiated (anaplastic) thyroid cancers, which
is the rarest subtype. Patients with anaplastic thyroid cancer (ATC) often present with
major compression of structures in the neck including the trachea and esophagus. A large
proportion of patients also demonstrate invasion into the adjacent structures of the neck
including the trachea, esophagus, surrounding muscle and larynx. (Adapted from Cameron
JL [ed]: Current Surgical Therapy, 8th ed. Philadelphia, Mosby, 2004).

4

1.2.3

Lethality of Thyroid Malignancies
According to the Canadian Cancer Society, it is estimated that in 2017,

approximately 7,100 Canadians would be diagnosed with thyroid cancer, with 220 of those
dying from the disease (2017; Canadian Cancer Society). Overall, PTC is the most
prevalent type of thyroid cancer, with those diagnosed experiencing a 10-year survival of
95- 98%, followed by 90-95% for FTC, approximately 50% for PDTC and less than 10%
for ATC (Table 1.1) (Nikiforov & Nikiforova 2011). The high survival rates for welldifferentiated PTCs are in part due to their responsiveness to conventional therapies; with
approximately 90% of localized PTC cases cured using a combination of surgery and
radioiodine therapy (Paschke et al. 2015). Even with the presence of distant metastases,
radioiodine therapy can also be effective; with patients experiencing a 10-year survival of
approximately 90% with successful iodine uptake (Paschke et al. 2015).

1.2.4

Genetics of Well-Differentiated Thyroid Cancers
Cancer is a genetic disease and through large-scale collaborative efforts such as

The Cancer Genome Atlas (TCGA) Project, the genetic alterations underlying the most
common cancer types have been mapped and characterized (The Cancer Genome Atlas
Research Network et al. 2013). In 2014, The TCGA Project characterized the genomic
landscape of 399 PTC patient samples (Agrawal et al. 2014). Overall, a low frequency of
alterations was reported, with most tumours containing a single point mutation in an
oncogene or a kinase fusion; the most common mutations occurred in BRAF and RAS
(specifically HRAS and NRAS), which were noted to be mutually exclusive (Fig. 1.2)
(Agrawal et al. 2014). Other driver alterations found in this study which had not been
previously described in PTC included EIF1AX, PPM1D and CHEK2 genes (Fig. 1.2). The
overall low density of somatic mutations is thought to be responsible for the indolent
clinical behaviour observed in those diagnosed with PTC.
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Table 1.1. Prevalence and survival of thyroid cancers derived from follicular cells.
Well-differentiated (papillary thyroid cancer - PTC; follicular thyroid cancer - FTC),
poorly differentiated thyroid cancer (PDTC) and anaplastic thyroid cancer (ATC) are all
thyroid malignancies derived from the follicular cells of the thyroid gland. Welldifferentiated PTCs and FTCs are the most prevalent, followed by PDTC and
undifferentiated ATC. The overall 10-year survival percentages (%) remain highest for
both well-differentiated subtypes (PTC and FTC), while the poorly differentiated subtype
is approximately half of that of WDTC and ATC is lowest at less than 10% (Adapted from
Nikiforov and Nikiforova, Nature Reviews Endocrinology, 2011).
Characteristics
Cell type
Prevalence (%)
10-year survival (%)

PTC
80-85
95-98

FTC
PDTC
Follicular
10-15
<2
90-95
50

ATC
1-2
<10
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Figure 1.2. Genomic alterations in PTC primary tumours. Using data compiled from
The Cancer Genome Atlas (TCGA) Project, 399 PTC tumours (columns) were profiled for
single nucleotide variations (SNVs) with the names of the recurrently mutated genes listed
(rows), including the frequency of occurrence as a percentage in this study. Each patient
tumour profiled in this study is represented by a single grey vertical line. cBioPortal
(http://www.cbioportal.org/) was used to generate a visual “OncoPrint”.
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1.2.5

Summary
Thyroid cancer is the most common type of endocrine malignancy. These tumours

can be divided into those that are well-differentiated and either PTC or FTC, with PTC
tumours being the most common type of well-differentiated tumour. Overall, PTCs have a
low mutation burden and are typically driven by singular point mutations in an oncogene.

1.3 Anaplastic Thyroid Cancer
1.3.1

Overview
While well-differentiated subtypes of thyroid cancer are typically easily cured with

surgery with or without radioiodine, ATC is typically refractory to all therapies and thus
almost universally fatal (Molinaro et al. 2017). These tumours are frequently not
radioiodine-avid due to the undifferentiated nature of the cells. Despite attempted treatment
with surgery, external beam radiation and chemotherapy, most patients rapidly relapse
locally (in the thyroid bed), regionally (in the lymph nodes) or develop distant metastases
(in the lungs, mediastinum, liver, bone, kidneys, heart and adrenals, and brain) leading to
high mortality rates. This section will describe the current understanding of ATC including
the epidemiology, the clinical manifestation of disease, the disease staging and finally the
current understanding of the genetic landscape.

1.3.2

Epidemiology
Overall, ATC is very rare but arguably the most lethal human malignancy with a

median survival of 5-6 months and a subset of patients dying in as short of a period as days
or weeks after diagnosis (Nikiforov & Nikiforova 2011; Bin Xu & Ghossein 2016;
Molinaro et al. 2017). The majority of those diagnosed are over 50 years of age with a
female to male ratio of 1.5:2 (Molinaro et al. 2017).
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1.3.3

Clinical Manifestation
Patients diagnosed with ATC often present with dramatic local symptoms, which

are typically the result of major compression of structures in the neck. Such symptoms
include pain in the neck region, dysphagia, dyspnea, stridor and hoarseness (Molinaro et
al. 2017). Upon examination, patients with ATC present with a rapidly enlarging mass
centered on the thyroid gland, ranging in size from 3 to 20 cm in 97% of cases (Molinaro
et al. 2017). In 70% of patients, there is also invasion into the adjacent structures of the
neck including the trachea, esophagus, surrounding muscle and larynx (Fig. 1.1) (Giuffrida
& Gharib 2000; Glaser et al. 2016). Other more systemic symptoms include weight loss,
shortness of breath and findings of pulmonary metastases (Molinaro et al. 2017). A large
proportion (approximately 50%) of those diagnosed will have distant metastases at the time
of diagnosis and 25% will develop metastases as disease progresses (Glaser et al. 2016).
Local progression of disease resulting in suffocation is the most common cause of mortality
for those with ATC (Molinaro et al. 2017).

1.3.4

Disease Staging
The American Joint Committee on Cancer presents the guidelines for the

management of WDTC and ATC, supported by the American Thyroid Association (ATA),
where cancer staging is based on primary tumour (T), lymph node status (N) and distant
metastasis (M) (Table 1.2) (Smallridge et al. 2012; Tuttle et al. 2017). The combination
of T, N and M staging yields the overall staging group, which includes stages IVA, IVB
and IVC (Table 1.2). Localized disease that is intrathyroidal only is considered to be stage
IVA, while those demonstrating extrathyroidal extension or metastases to the cervical
lymph nodes are considered stage IVB, and those exhibiting distant metastases are stage
IVC (Table 1.2) (Tuttle et al. 2017).
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Table 1.2. Staging criteria used by the American Joint Committee on cancer for
thyroid carcinoma. Staging for papillary, follicular, poorly differentiated and anaplastic
thyroid carcinoma for primary tumour (T), lymph node status (N) and distant metastasis
(M). Prior to 2017, classification and staging of ATC was always T4 upon diagnosis;
however, this has been updated and now uses the same definitions of staging as those of
well-differentiated subtypes. Localized disease that is intrathyroidal only is considered to
be stage IVA. Those demonstrating extrathyroidal extension or metastases to the cervical
lymph nodes are considered stage IVB. Those exhibiting distant metastases are considered
stage IVC (Adapted from Tuttle et al., Thyroid, 2017).
Primary tumour (T)
TX
T0
T1
T2
T3

T criteria
Primary tumour cannot be assessed
No evidence of a primary tumour
< 2 cm, limited to thyroid
> 2 cm and < 4 cm, limited to thyroid
> 4 cm, limited to thyroid (T3a), or only extrathyroidal invasion of strap muscles (T3b)

T4

Gross extrathyroidal extension into major structures of the neck like soft tissues, larynx,
trachea, esophagus or recurrent laryngeal nerve (T4a) or prevertebral fascia, encasing the
carotid artery or mediastinal vessels (T4b)

Lymph node (N)
NX
N0
N1

N criteria
Regional lymph nodes cannot be assessed
No evidence of regional lymph nodes, metastasis
Metastasis to regional lymph nodes

Metastasis (M)
M0
M1

M criteria
No distant metastasis
Distant metastasis

Stage group
IVA
IVB
IVB
IVB
IVC

T stage is…
T1-T3a
T1-T3a
T3b
T4
Any T

N stage is…
N0/NX
N1
Any N
Any N
Any N

M stage is…
M0
M0
M0
M0
M1
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1.3.5

Conventional Therapies
The use of conventional therapies for treatment of patients with ATC may be

beneficial in the short-term to improve symptoms and quality of life; however, such
therapies are unable to prolong survival. The ATA guidelines suggest a multidisciplinary
approach to the clinical management of ATC including a combination of surgical resection,
radioiodine therapy and chemotherapy.
In the absence of distant metastases, primary surgery may be a management option,
particularly if the disease is completely intrathyroidal (Smallridge et al. 2012; Tuttle et al.
2017). If a complete resection is possible at baseline, followed by adjuvant therapy, cure
may be possible. More commonly, the majority of those diagnosed present with significant
extrathyroidal spread, often involving structures considered to be unresectable such as the
great vessels of the neck and prevertebral fascia (Fig. 1.1) (Smallridge et al. 2012; Tuttle
et al. 2017).
While radioiodine therapy is a cornerstone of treatment for those diagnosed with
WDTC subtypes, which are generally iodine-avid, ATC is almost universally iodine
negative due to its undifferentiated nature. Thus, the used of radioiodine therapy plays little
to no role in the management of ATC. Furthermore, ATC is typically considered highly
radioresistant; however, there are reports of responses to radiation alone when it is
delivered using hyper-fractionated techniques (Giuffrida & Gharib 2000). Radiation
appears to have the greatest benefit in the post-operative setting, as patients receiving
resection plus post-operative radiotherapy experienced significantly better survival rates
than those only biopsied followed by radiotherapy (Wein & Weber 2011). Chemotherapy
has been used concurrently with radiation therapy, or alone in the palliative setting.
Unfortunately, control of ATC with single chemotherapeutic agents has not been
successful, resulting in low response rates and systemic toxicities. There is currently no
standard regimen for the use of chemotherapeutics for patients with ATC, however,
evidence suggests that using combination therapy (e.g. doxorubicin with cisplatin) is
superior to using a single agent, with an observed 30% response in a small patient
population (Giuffrida & Gharib 2000; Keutgen et al. 2015). In a subset of patients, the
combination of surgery, chemotherapy and adjuvant radiotherapy has been shown to
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control local disease; however, overall patient survival rates remain unchanged (Wein &
Weber 2011; Keutgen et al. 2015). Taken together, these findings highlight the necessity
for new treatment modalities for patients with ATC.

1.3.6

Genetic Landscape
ATC is very rare and the genetic alterations underlying this disease remain very

poorly understood to date. Because of the lack of understanding related to the genetic
background of ATC, the conventional systemic therapies currently prescribed are mostly
independent of the genetic profiles of patient tumours. In recent years, a few studies have
focused on the genomic characterization of ATC and have been able to characterize a range
of genomic changes including single nucleotide variants (SNVs), copy number variations
(CNVs), gene fusions and promoter mutations, which all seem to collectively contribute to
the aggressive nature of ATC. This contrasts with the simple landscape of PTC; with
mainly singular genetic drivers (Kunstman et al. 2015; Jeon et al. 2016; Landa et al. 2016;
Pozdeyev et al. 2018).
Related to this, our group has created an international consortium including 14
national/international sites, titled the Global Anaplastic Thyroid Cancer Initiative
(GATCI), which has an overall goal of understanding the genomic and evolutionary
landscapes of ATC (Appendix 1). Our study included the characterization of 170 ATC
specimens (157 patient tumours and 13 ATC cell lines), as well as 26 differentiated thyroid
cancer specimens, which were found co-occurring with anaplastic components, and an
additional 112 PTCs. This cohort was characterized for copy number aberrations (CNAs),
whole-exome sequencing (WES) and RNA sequencing, and all tumours were subjected to
expert consensus pathology review. Overall this study showed that ATCs shared a genomic
origin with the well-differentiated co-occurring cancers and that certain mutations were
enriched in anaplastic components, suggestive of potential driver mutations involved in the
differential aggressive behaviour observed in these tumour types.
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1.3.6.1

Oncogenes

BRAF – The B-Raf proto-oncogene (BRAF) is a serine-threonine kinase belonging
to the family of RAF proteins and is found commonly mutated in 27 – 90% of ATCs
examined in recent genomics studies (Table 1.3) (Kunstman et al. 2015; Jeon et al. 2016;
Landa et al. 2016; Pozdeyev et al. 2018). Almost all changes involve a thymine to adenine
(T>A) transversion at position 1799, resulting in a nonsynonymous substitution of valineto-glutamate at the 600th residue (V600E) (Landa et al. 2016; Pozdeyev et al. 2018). The
BRAFV600E mutation results in constitutive activity of the BRAF kinase, which
phosphorylates and activates MEK and in turn activates ERK to produce constitutive
MAPK pathway stimulation (Nikiforov & Nikiforova 2011; Lee et al. 2013; Rosove et al.
2013).
RAS – Genetic alterations in Rat Sarcoma (RAS) genes (H-Harvey, K-Kirsten and
N-Neuroblastoma) are also common in both PTC and ATC (Table 1.3). In ATC samples
specifically, genetic alterations in RAS occur in 9 – 32% of patient samples (Table 1.3)
(Kunstman et al. 2015; Jeon et al. 2016; Landa et al. 2016; Pozdeyev et al. 2018). These
genes encode for guanosine triphosphate (GTP)-ase proteins at the inner cell membrane.
RAS proteins function as molecular switches, which when bound to guanosine diphosphate
(GDP) are inactive; however, when GDP is released and exchanged for GTP, become
activated and remain active until they hydrolyze GTP to GDP (Pylayeva-Gupta et al. 2011).
RAS mutations associated with thyroid cancers primarily occur in codons 12, 13 and 61;
where the first two changes cause an increased affinity for GTP, while the third results in
inactivation of GTPase function (Nikiforov 2008). These mutations in RAS result in
constitutively activated protein which then activates signaling pathways downstream
(Nikiforov 2008; Nikiforov & Nikiforova 2011). Interestingly, genetic alterations in BRAF
and RAS have been reported to be mutually exclusive in all genomics studies of ATC
sequenced thus far, suggesting differing mechanisms of malignancy arising in these tumour
subsets (Kunstman et al. 2015; Jeon et al. 2016; Landa et al. 2016; Pozdeyev et al. 2018).
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Table 1.3. Genomic alterations in ATC primary tumours presented by four genomics
studies. Four studies using targeted gene panels for the identification of SNVs in ATC.
Each study is indicated followed by the sequencing method, the number of specimens and
the percentage of mutations for the respective gene.

Gene
BRAF
RAS
PIK3CA
EIF1AX
PTEN
TP53
TERT

Landa et al. 2016
MSK-IMPACT
n = 33
15 (45%)
8 (24%)
6 (18%)
3 (9%)
5 (15%)
24 (73%)
24 (73%)
ND , not detected

Number of SNVs
Jeon et al. 2016
Kunstman et al. 2015
OncoPanel V2
Whole exome
n = 11
n = 22
10 (90%)
6 (27%)
1 (9%)
7 (32%)
2 (18%)
2 (9%)
ND
3 (13.5%)
1 (9%)
0
8 (72%)
6 (27%)
0
0

Pozdeyev et al. 2018
MSK-IMPACT, Foundation One
n = 196
41%
27%
14%
ND
11%
65%
65%

14
PIK3CA – Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit
Alpha (PIK3CA) encodes the p110𝛼 catalytic subunit of phosphoinositide 3-kinase
(Leontiadou et al. 2018). Mutations in this gene commonly occur in the helical domain in
E542K or E545K and these alterations activate the PI3K/AKT/mTOR pathway, which
functions as a regulator of cell cycle progression, adhesion and motility, and activates its
oncogenic abilities through aberrant signaling (Lee et al. 2013; Landa et al. 2016). The
TCGA study of PTC shows that only 0.5% of patient samples show genetic alterations in
this gene (Agrawal et al. 2014), while across the various ATC studies, alterations in
PIK3CA are present in 9 – 18% of cases, suggestive of a potential role for alterations in
this gene in driving the progression of disease (Table 1.3) (Kunstman et al. 2015; Jeon et
al. 2016; Landa et al. 2016; Pozdeyev et al. 2018).
EIF1AX – Mutations in the Eukaryotic Translation Initiation Factor 1A X-linked
(EIF1AX) gene, which encode for a key part of the translation preinitiation complex, have
been recently described as a frequently mutated gene across ATC sequencing studies.
These alterations have been shown to be present in 1% of PTCs but are present at a high
mutation frequency of 9 – 13.5% in ATC samples (Table 1.3) (Agrawal et al. 2014;
Kunstman et al. 2015; Landa et al. 2016; Krishnamoorthy et al. 2019). The p.A113_splice
mutation of EIF1AX, which is a unique splice acceptor site found between exons 5 and 6
and one not demonstrated in other tumour types, appears to be specific to thyroid cancer
with a strong concordance of EIF1AX and RAS mutations, unlike in PTC where they are
found to be mutually exclusive (Landa et al. 2016). Interestingly, in PDTC, the presence
of EIF1AX mutations are predictive of worse survival (Landa et al. 2016).

1.3.6.2

Tumour Suppressors

PTEN – Phosphatase and Tensin Homolog (PTEN) is a tumour suppressor gene
and the mutated form of this gene is associated with 9 – 15% of ATC cases (Table 1.3)
(Kunstman et al. 2015; Jeon et al. 2016; Landa et al. 2016; Pozdeyev et al. 2018). Through
epigenetic effects, methylation of PTEN has been implicated in the progression of benign
thyroid adenoma to aggressive ATC (Cerami et al. 2012). PTEN methylation is associated
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with decreased or a complete lack of PTEN expression and has also been found to stimulate
other genetic alterations associated with the PI3K/AKT/mTOR signaling pathway,
including both RAS and PIK3CA (Cerami et al. 2012).
TP53 – Mutations in the tumour suppressor Tumour Protein P53 (TP53) are
commonly associated with 27 – 73% of ATC cases (Table 1.3) (Kunstman et al. 2015;
Jeon et al. 2016; Landa et al. 2016; Pozdeyev et al. 2018). Many of these mutations are
missense mutations, in ATC specifically in the DNA binding domain with an R248W
mutation, leading to a “gain-of-function” phenotype, resulting in the loss of tumour
suppressive functionality and conferring an oncogenic rather than tumour suppressive
function (Landa et al. 2016; Meng et al. 2018; Tanaka et al. 2018). Interestingly, the TCGA
analysis of PTC demonstrates a much lower mutation frequency of 1% in PTC, further
providing evidence of the involvement of TP53 mutational changes in driving the
progression of disease (Agrawal et al. 2014).

1.3.6.3

Promoter Mutations

TERT – The telomerase reverse transcriptase (TERT) gene encodes the reverse
transcriptase component of telomerase, which functions to add telomere repeats to the ends
of the chromosome, therefore enabling cell replication (Landa et al. 2013). Recent genomic
studies have identified a high frequency of TERT promoter mutations in advanced thyroid
cancers including ATC (Table 1.3) (Landa et al. 2016; Pozdeyev et al. 2018). Additionally,
the presence of these mutational changes have been associated with metastatic and
aggressive phenotypes in addition to an overall decrease in patient survival times (Landa
et al. 2016).

1.3.6.4

Gene Fusions

In addition to SNVs, the identification of structural alterations (e.g., CNVs,
translocations and fusions) can aid in our understanding of ATC and its complexity to help
determine why it is more aggressive and less responsive to treatments than other more well-
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differentiated subtypes. Gene fusions in particular are more frequently found in cancers
that are more aggressive and may provide insight into the nature of ATC.
STRN-ALK – Anaplastic lymphoma kinase (ALK) gene fusions have been
particularly associated with aggressive thyroid cancers, whereby rearrangements with ALK
result in tumorigenic activity. One of the ALK rearrangements described involves the
striatin (STRN) gene observed more commonly in thyroid cancers. This STRN-ALK fusion
results in constitutive activity of ALK kinase and induction of thyroid cell proliferation and
tumorigenesis (Kelly et al. 2014).
PAX8-PPARg – Rearrangement of the peroxisome proliferator-activated receptor g
(PPARg) with the PAX8 gene, associated with radiation-induced thyroid cancers, expresses
a fusion protein (PAX8-PPARg) (Placzkowski et al. 2008). This fusion has been found to
accelerate growth, inhibiting normal tumour suppression by PPARg and therefore acting as
an oncogene (Placzkowski et al. 2008).
RET/PTC – Rearrangements of the Rearranged during Transfection (RET) protooncogene are common to thyroid cancers and most commonly include RET-PTC1 and
RET-PTC3, which both result from intrachromosomal paracentric inversions and have a
strong correlation with radiation exposure (Cyniak-Magierska et al. 2011; Nikiforov &
Nikiforova 2011). The RET tyrosine kinase becomes activated by this rearrangement,
leading to constitutively activated MAPK signaling and tumorigenesis in thyroid cells
(Nikiforov & Nikiforova 2011).
NTRK fusions – Chromosomal rearrangements involving neurotrophic tyrosine
receptor kinases (NTRK) can also occur in thyroid cancers and are known as TRK
rearrangements. NTRK1 and NTRK3 fusions have been reported in multiple cancers
including glioblastoma, lung cancer, and in 1-2% of PTC cases (Cerami et al. 2012;
Vaishnavi et al. 2013; Kim et al. 2014). These rearrangements have a strong correlation
with exposure to radiation (Greco et al. 2010; Nikiforov & Nikiforova 2011). Ultimately,
these fusions can involve multiple different partners leading to constitutive kinase
activation (Vaishnavi et al. 2013; Kim et al. 2014).

17

1.3.7

Disease Progression
Theoretically, ATC can arise from follicular-derived thyroid cancer types or can

directly evolve from normal follicular cells. A current model of thyroid carcinoma suggests
that ATC arises from pre-existing WDTC with additional genetic events, which make ATC
much more aggressive (Bin Xu & Ghossein 2016). A proportion of those diagnosed with
ATC have co-existing areas of WDTC and PDTC cell types or prior history of WDTC,
leading to speculation that a significant percentage of ATC cases arise from WDTC or
PDTC. While the TCGA analysis of PTC has identified that the majority of PTCs have a
low frequency of alterations and singular, non-overlapping driver mutations, it still remains
unclear which genetic alterations in particular are acquired and responsible for driving
thyroid cancer progression (Agrawal et al. 2014; Bin Xu & Ghossein 2016).
In recent years, genomic studies of ATC, including our own GATCI study, have
compared sequencing results of both differentiated thyroid cancers (DTC) and ATC to
identify a higher frequency of mutated genes present in ATC, which may ultimately
contribute to the anaplastic transformation (Appendix 1) (Landa et al. 2016; Pozdeyev et
al. 2018). These studies reported genetic alterations in BRAF and RAS in DTC and ATC,
found to occur in a mutually exclusive manner and suggestive of subtype-specific clusters
of ATC associated with particular gene alterations (Landa et al. 2016; Pozdeyev et al.
2018). Furthermore, these sequencing studies also showed a significant increase in the
mutation frequency of TP53 and PIK3CA, with an association between PIK3CA and BRAF,
which has been previously described by Landa et al. (2016) (Landa et al. 2016; Pozdeyev
et al. 2018). Collectively, this data suggests that clusters of mutations (such as the PIK3CA
and BRAF mutations in combination) have the potential to drive progression of disease.
This led to the rationale of the study presented in Chapter 4, which was to introduce a
canonical hotspot PIK3CA mutation (E545K) into a BRAFV600E-PTC cell line in order to
determine whether this cluster of genetic alterations can contribute to the anaplastic
transformation.
Interestingly, the dedifferentiation of cells is also associated with the progression
of disease in ATC and has been shown to result in the loss of specific immunohistochemical
(IHC) markers; including thyroglobulin (Tg), thyroid transcription factor-1 (TTF-1), paired
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box protein Pax 8 (PAX8) and b-catenin (Table 1.4) (Smallridge et al. 2012). The ATA
guidelines for ATC describes the use of IHC markers with fine-needle aspiration or core
biopsy, for identification and diagnosis of ATC. In some cases, ATC possesses similarity
to other malignancies (e.g. large cell lymphoma, medullary carcinoma, metastatic
carcinoma and metastatic melanoma) and can sometimes result in differential diagnosis
(Smallridge et al. 2012). In a subset of cases the presence of WDTC or PDTC tissue coexisting with ATC may demonstrate preserved IHC staining of markers as listed in Table
1.4, which further aides in making a definitive diagnosis when ruling out metastatic disease
and other nonepithelial malignancies (Smallridge et al. 2012; Molinaro et al. 2017).

1.3.8

Targeted Therapies
While the majority of genetic alterations represent inactivating mutations in tumour

suppressor genes and are not considered “actionable” or are nonconsequential passenger
mutations, a subset of activating mutations in oncogenes appear to be druggable and predict
response to targeted molecular agents (The Cancer Genome Atlas Research Network et al.
2013). The overall failure to increase survival rates of those diagnosed with ATC using
conventional treatment strategies has shifted the current efforts towards using targeted
therapy directed against activating mutations.
Studying the genomic profiles of different cancer types has been increasingly useful
in order to direct patients towards treatment driven by the presence of biomarkers to
prescribe targeted therapies. One promising area of study is the utility of targeting receptor
tyrosine kinases (RTKs) using tyrosine kinase inhibitors. RTKs are an important class of
receptors which are found localized to the cell surface where they can transduce
intracellular signaling cascades originating from the extracellular environment into the
cytoplasm and subsequently the nucleus (Choura & Rebaï 2011; Casaletto & McClatchey
2012). Structurally, these receptors are composed of an N-terminus, which is extracellular
and functions as the ligand binding domain, a transmembrane domain, and an intracellular
or catalytic domain. Activation of RTKs occurs with binding of ligands (e.g. cytokines,
hormones or growth factors) to the extracellular domain, which results in homo- or hetero-
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Table 1.4. Immunohistochemical markers used for the diagnosis of ATC. The
dedifferentiation of cells as a result of the increased mutation burden has been used for
diagnostic purposes to characterize changes in epithelial differentiation. This amended
table lists the markers of differentiation used in our future study as described in Chapter 4.
Symbols for thyroid cancer types are indicated as follows: +, positive; -, negative; + / -,
usually positive, often negative; - / +, usually negative, may be positive (Adapted from
Smallridge et al., Thyroid, 2012).
IHC Marker
Tg
TTF-1
PAX8
!-catenin

WDTC
+
+
+

ATC
-/+
+/-

Membranous

Nuclear or -

20
dimerization. This subsequently results in the phosphorylation of the intracellular domains
of the receptors. With phosphorylation, there is recruitment and subsequent
phosphorylation of downstream targets and the activation of signaling cascades (Lemmon
& Schlessinger 2010). Aberrant activation and constitutive activity of these receptors are a
major driving characteristic of human malignancies.
The use of tyrosine kinase inhibitors to target key proteins involved in the
constitutive activation of downstream signaling cascades has become a promising avenue
for treatment of many malignancies including thyroid cancer (Comfere et al. 2013; Hagan
et al. 2013; Bikas et al. 2016; Molinaro et al. 2017; Subbiah et al. 2018). Targeting RTKs
using tyrosine kinase inhibitors can block the enzymatic action of the tyrosine kinases and
can regulate the otherwise aberrantly activated signaling cascade. These inhibitors can
either act by competing for the ATP-binding site of the tyrosine kinase domain of the RTK
or can also function allosterically by binding outside of the allosteric site and inducing a
conformational change in the structure affecting the tyrosine kinase activity (Molinaro et
al. 2017).
In ATC, several kinase inhibitors have been identified as useful agents based on
their response rates. Complete responses have been reported with the use of particular
kinase inhibitors as single agents, specifically

vemurafenib (BRAFV600E inhibitor),

sorafenib (inhibitor of VEGFR1/2/3, PDGFR, MAPK members BRAF and RET, fusion
protein RET/PTC, and c-Kit) and sunitinib (inhibitor of VEGFR1/2/3, PDGFR, KIT, FLT3, CSF-1R and RET) (Grande et al. 2013; Rosove et al. 2013; Ito et al. 2017). In a case
series presented by Harris et al., five patients with confirmed ATC were treated with the
mTOR inhibitor everolimus from 2013 to 2016 (Harris et al. 2019). Of these patients, three
had a partial response of 27.9 months, and two others had stable disease for 3.7 and 5.9
months, respectively (Harris et al. 2019). Genomic analysis identified mutations involving
the PI3K/mTOR pathway in the two partial responders, overall suggesting that everolimus
may have an anti-tumour effect in ATC and may correlate with genomic changes involving
the PI3K/mTOR pathway.
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Furthermore, combinations of drugs have been shown to be highly effective in the
treatment of ATC, with recent evidence suggesting that a combination of tyrosine kinase
inhibitors, which includes the BRAF inhibitor dabrafenib and the MEK inhibitor
trametinib, could be of major importance in the context of ATC for BRAFV600E tumours. A
landmark study by Subbiah et al. showed that in a BRAF-mutant ATC patient cohort, the
combination of these two drugs showed an overall response rate of 69% and was well
tolerated with common adverse events including fatigue (38%), pyrexia (37%) and nausea
(35%) (Subbiah et al. 2018). As of 2018, this combination has been approved by the US
Food and Drug Administration (FDA) as a treatment regimen for metastatic and
nonresectable ATC with BRAFV600E-mutation status (https://www.fda.gov). Together, this
data highlights the importance and efficacy of kinase inhibitors as a treatment strategy in
cancers, however resistance to targeted therapies are almost universally inevitable and
remain a challenge (Groenendijk & Bernards 2014).

1.3.8.1

High-Throughput Screening

Through the combination of genomic characterization and the parallel development
of high-throughput screening, it is now possible to correlate the identified genetic
alterations with drug response, making this technology a primary strategy for early-stage
drug discovery. Using high-throughput screening, large panels of drug compounds can be
tested using this robotic platform to determine the potency in a particular cell line (Fig.
1.3) (Broach & Thorner 2009). This can lead to the identification of ‘hits’, which are
defined as being biologically active agents for a particular cell line and have the potential
to be correlated with known genetic and expression data to determine drug sensitivities
(Barretina et al. 2012; Garnett et al. 2012).
In general, high-throughput screening utilizes cell lines, which are not ideal models
of cancer due to their lack of three-dimensional environment, absence of surrounding
stroma, the absence of an immune system and the genomic evolution in culture, which can
result in variations in cell line strains (Fig. 1.3) (Richmond & Su 2008; Ben-David et al.
2018). However, such models remain an important starting point for use in drug discovery
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Figure 1.3. Schematic of high-throughput screening methodology. Our study utilized
13 anaplastic thyroid cancer (ATC) cell lines for HTS. A Beckman BioMek FX liquid
handler was used to dispense cells into 384-well culture plates at a density of 12,000
cells/ml in a total volume of 50 μl/well. Seeded cells are incubated for 24 hours. Drug
compounds (library of 320 inhibitors) are initially assembled as 1mM stocks in
dimethylsulfoxide (DMSO) and pinned into wells 24 hours post-seeding. Drug testing is
carried out using six different concentrations (0.16 to 4µM final concentration) for each
cell line. Negative controls consisted of wells in the same 384-well culture plate containing
cells that are treated with the DMSO vehicle alone. Wells containing media only were used
as a measure to determine assay background noise. To measure cell viability, alamarBlue
is added to each well after a 48-hour incubation of the cells with the drug compounds.
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which can further be validated in vitro and in vivo using patient-derived xenograft (PDX)
models. PDX models better recapitulate patient tumours and typically preserve the
pathological characteristics, cellular morphology and genetic landscape of the original
patient tumours, making such models highly beneficial preclinical models of disease (Gao
et al. 2015; Gao & Williams 2018). Furthermore, PDX drug responses have been shown to
strongly correlate with drug response of the original patient tumours, further making them
highly valuable tools for drug discovery efforts (Gao et al. 2015). However, due to the
rarity of ATC, most xenograft models are derived from ATC cell lines as opposed to actual
patient tumour tissue (Sewell et al. 2013; Morrison et al. 2015). The use of orthotopic
mouse models is also recognized as being highly valuable, as they have a demonstrated
ability to recapitulate the local invasion and distant metastasis observed in metastatic
thyroid cancers (Antonello & Nucera 2013; Sewell et al. 2013). In the studies described in
this thesis, I have utilized both a PDX model derived from the primary tumour of an ATC
patient, stage T4N1M1 (Chapter 3) in order to test a drug compound identified using highthroughput screening (Appendix 1, Fig. 7) and completed a pilot study using an orthotopic
mouse model to determine its utility in studying disease progression (Chapter 4).

1.3.9

Summary
ATC is rare but a uniformly fatal disease. To date, there is an overall lack of

understanding regarding the genetic drivers of disease progression from the welldifferentiated to the undifferentiated cell type, therefore making it difficult to understand
which genetic changes could be targeted to impede the progression of disease. As such,
specific investigations to identify drivers of disease progression are necessary to
understand the importance of such targets and how they can be acted on through targeted
agents in the context of ATC.
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1.4 Thesis Rationale
As presented in this introductory chapter, ATC is a very rare and poorly understood
disease, particularly in relation to the indolent WDTC subtypes. The genetic landscape of
WDTCs, such as PTC, have been shown to be driven by singular genetic alterations, while
the landscape of ATC is much more complex with a combination of genetic alterations
driving the progression of disease from well-differentiated to an undifferentiated cell type.
Such complex changes have also made it difficult to control ATC using standard
conventional therapies and the use of targeted therapies have only shown limited efficacy
and resistance therefore making it necessary to identify new biomarkers of response using
targeted therapies.

1.5 Overall Goal and Objectives
In this thesis, I begin by focusing on two separate drug studies to identify candidate
therapeutic agents for ATC (Chapters 2 and 3), with compounds I have identified using
high-throughput screening (Appendix 1, Fig. 7). Next, I proceed with exploring the
progression of disease from PTC (well-differentiated) to ATC (undifferentiated) to
determine potential drivers of disease and examine the utility of two types of mouse models
for studying thyroid cancer progression (Chapter 4).
In order to address this goal, the specific objectives of this thesis are:
1. To identify and investigate candidate therapeutics identified using high-throughput
screening for use in the management of anaplastic thyroid cancer (Chapters 2 and
3).
2. To investigate the mechanism(s) driving disease progression from welldifferentiated to anaplastic thyroid cancer using a BRAF-mutant papillary thyroid
cancer cell line with the introduction of an anaplastic-specific genomic alteration
(Chapter 4).
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Chapter 2

2

Lestaurtinib is a potent inhibitor of anaplastic thyroid
cancer cell line models

2.1 Abstract
Anaplastic thyroid cancer (ATC) is a rare and lethal human malignancy with no
known effective therapies in the majority of cases. Despite the use of conventional
treatments such as chemotherapy, radiation and surgical resection, this disease remains
almost universally fatal. In the present study, we identified the JAK2 inhibitor Lestaurtinib
as a potent compound when testing against 13 ATC cell lines. Lestaurtinib demonstrated a
potent antiproliferative effect in vitro at nanomolar concentrations. Furthermore,
Lestaurtinib impeded cell migration and the ability to form colonies from single cells using
scratch-wound and colony formation assays, respectively. Flow cytometry was used for
cell cycle analysis following drug treatment and demonstrated arrest at the G2/M phase of
the cell cycle, indicative of a cytostatic effect. In vivo studies using the chick
chorioallantoic membrane xenograft models demonstrated that treatment with Lestaurtinib
resulted in a significant decrease in endpoint tumour volume and vascularity using power
Doppler ultrasound imaging. Overall, this study provides evidence that Lestaurtinib is a
potent antiproliferative agent with potential antiangiogenic activity that warrants further
investigation as a targeted therapy for ATC.
A version of this chapter has been published:
Pinto N, Prokopec SD, Vizeacoumar F, Searle K, Lowerison M, Ruicci KM, Yoo J, Fung
K, MacNeil D, Lacefield JC, Leong HS, Mymryk JS, Barrett JW, Datti A, Boutros PC and
Nichols AC. 2018 Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line
models. PLoS ONE 13 e0207152–16. (doi:10.1371/journal.pone.0207152)
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2.2 Introduction
Thyroid cancer is the most common endocrine malignancy (Charles et al. 2014).
Well-differentiated thyroid cancers make up the majority of thyroid cancers and have an
excellent prognosis (Agrawal et al. 2014). In contrast, anaplastic thyroid cancer (ATC) is
a rare type of undifferentiated thyroid cancer that makes up approximately 1% of thyroid
cancer cases and is arguably the most lethal human malignancy (Kim et al. 2007; Taccaliti
2012; Gibson et al. 2017). Patients diagnosed with ATC typically present with a rapidly
expanding neck mass resulting in airway and esophageal obstruction, and distant
metastases (Smallridge et al. 2012; Pinto et al. 2014). Despite the aggressive use of
chemotherapy, radiation and surgical resection, the outcomes for patients with ATC remain
dismal, with a mean survival of only 6 months (Smallridge et al. 2012; Ibrahimpasic et al.
2017). While there have been a few studies to date aimed at elucidating the molecular
pathogenesis of this disease (Landa et al. 2013; Kunstman et al. 2015; Landa et al. 2016),
ATC is still very poorly understood.
Presently, there are no effective therapies for patients diagnosed with ATC and thus
the use of targeted agents directed against specific genetic alterations and signaling
pathways remains an attractive cancer treatment strategy. Small-molecule tyrosine kinase
inhibitors represent a molecularly-precise method of cancer treatment that can be used to
target specific signaling pathways and produce an antiproliferative effect (Zhang et al.
2009; Gross et al. 2015). Indeed, kinase inhibitors are undergoing active investigation in
every major cancer type and have been shown to provide meaningful therapeutic responses
in recurrent and metastatic disease, with increased cure rates when administered
concurrently or in the adjuvant setting with surgery or radiation (Gallick et al. 2012; Chen
2013; Jen-Wei et al. 2018). While a small number of targeted agents have been tested in
patients with ATC, there are currently no therapies that have been approved for routine
treatment of this disease (Molinaro et al. 2017).
To begin to fill the gap in our understanding of this disease and how it can be
treated, we screened 13 ATC cell lines and identified Lestaurtinib as a highly potent agent
with nanomolar potency. Efficacy of Lestaurtinib was further validated both in vitro and
in vivo using the chick chorioallantoic membrane (CAM) xenograft model.

34

2.3 Materials and Methods
2.3.1

Cell lines and culture conditions
THJ-11T, -16T, -21T, and -29T cell lines were all obtained from Dr. John Copland

of the Mayo Clinic (Jacksonville, FL, USA). U-Hth7, U-HTh74cl.7, C643, and SW1736
cell lines were obtained from Dr. Nils Erik Heldin (University of Uppsala, Sweden). Cell
lines 8505C, ASH3 and KMH2 were all purchased from the Japanese Collection of
Research of Bioresources Cell Bank (JCRB; Osaka, Japan). Lastly, BHT-101 and CAL62
were both purchased from the DSMZ Cell Bank (Germany, EU).
THJ-11T, -16T, -21T, and -29T cell lines were cultured in RPMI 1640 media
supplemented with 10% FBS (GIBCO; Thermo Fisher Scientific, Carlsbad, CA, USA), 1x
non-essential amino acids (Wisent, St. Bruno, Quebec, Canada), 1 mM sodium pyruvate
(Wisent), penicillin (100 µg/mL) and streptomycin (100 μg/mL) (Invitrogen; Thermo
Fisher Scientific, Carlsbad, CA, USA). U-Hth7, U-HTh74cl.7, C643, SW1736 and 8505C
cell lines were cultured in EMEM media supplemented with 10% FBS (GIBCO), penicillin
(100 µg/mL) and streptomycin (100 μg/mL) (Invitrogen). ASH3 and KMH2 cell lines were
cultured in a 1:1 mixture of DMEM and RPMI 1640, which was supplemented with 10%
heat-inactivated FBS (GIBCO), penicillin (100 µg/mL) and streptomycin (100 μg/mL)
(Invitrogen). BHT-101 and CAL62 cell lines were cultured in DMEM supplemented with
10% heat-inactivated FBS (GIBCO), 1% human serum (Wisent), penicillin (100 µg/mL)
and streptomycin (100 μg/mL) (Invitrogen).

2.3.2

Short tandem repeat (STR) profiling of ATC cell lines
DNA was extracted from cultured cells using the AllPrep DNA/RNA/Protein kit

(Qiagen, Germany, EU), using the instructions provided by the manufacturer. A total of
100 ng of DNA per cell line was analyzed by short tandem repeat (STR) profiling at The
Center for Applied Genomics (TCAG, Toronto, Canada). Cell lines were genotyped with
16 selected markers (including the 8 Combined DNA Index System (CODIS)) core STR
loci, employed by the American Type Culture Collection (ATCC, Manassas, VA, USA)
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and confirmed against published information (Supplemental Table 2.1).

2.3.3

Reagents
The tyrosine kinase inhibitor Lestaurtinib (CEP-701) was purchased from Tocris

(Cephalon Inc., Oakville, ON, Canada). Lestaurtinib was dissolved in dimethyl sulfoxide
(DMSO; Sigma-Aldrich, Oakville, ON, Canada) as a 10-mM stock. Subsequent serial
dilutions were performed for specific concentrations as shown in the Results section.

2.3.4

Drug selection
A Beckman BioMek FX liquid handler was used to dispense cells into 384-well

culture plates (Corning, NY, USA) at a density of 12,000 cells/ml in a total volume of 50
μl/well. Seeded cells were incubated for 24 hours (h) at 37ºC, 5% CO2. Lestaurtinib was
initially prepared as 1mM stocks in 100% DMSO and pinned (200 nL) into wells 24 h postseeding. Drug testing was carried out using six different concentrations ranging between
0.16 and 4 µM (final concentrations) and applied to the 13 cell lines (2 biological
replicates). Negative controls consisted of wells in the same 384-well culture plate
containing cells that were treated with 0.4% DMSO vehicle alone. Wells containing media
only were used as a measure to determine assay background noise. To measure the percent
inhibition of growth, 5 μl/well of AlamarBlue (Invitrogen) was added to each well after a
48 h incubation period of the cells with Lestaurtinib. After the addition of AlamarBlue,
cells were incubated for 4 h at 37°C and then fluorescence intensity was measured in a
PHERAstar microplate reader (BMG LABTECH, Guelph, ON, Canada) equipped with
535nm excitation and 590 nm emission filters. Drug testing was completed in duplicate.
Raw data were loaded into the R statistical environment (v3.2.1). Normalized
absorbance values were obtained by contrasting experimental absorbance values with those
from vehicle control (DMSO-treated) cells. The half-maximal inhibitory concentrations
(IC50 in µM) were calculated using the nplr package (v0.1-4). Similarly, the activity area
(AA) was calculated as the area under the percent (%) inhibition curve using the nplr (v0.1-
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4) package for R. Results were filtered to remove those with poorly fitted models (Rsquared < 0.9). Cell lines were classified as resistant to a compound if absorbance increased
or remained constant over time; likewise, classification as sensitive required an IC50 within
the range examined (0.16-4 µM) with the 85% confidence interval ± 2 µM. Consensus
clustering using the ConsensusClusterPlus.custom (v1.8.1) package for R was used to find
groups of cell lines with similar response patterns (based on activity area).

2.3.5

Growth curves
Cells were seeded at a density of 2,400 cells/well into a 96-well plate and incubated

overnight.

After 24 h, cells were treated with 0.5 and 4.0 µM concentrations of

Lestaurtinib. Cells were incubated with PrestoBlue® (Thermo Fisher Scientific) for 1 h at
37°C and plates were read at 0, 24, 48 and 72 h after the addition of the drug. Fluorescence
readings were completed using a BioTek Synergyä Microplate Reader with 560nm
excitation and 590nm emission wavelengths. Three technical replicates were used for each
concentration tested. A Student’s unpaired, two-tail t-test was used for statistical analysis
using Prism® 7 Graphpad Software, where comparisons were made between treated and
untreated samples for each timepoint. P values < 0.05 were considered to represent
statistically significant differences. Statistical analysis is displayed for the 72 h timepoint
when compared to the control at the same timepoint.

2.3.6

Dose-response curves
Cells (KMH2, CAL62 and THJ-21T) were seeded at a density of 2,400 cells/well

into a 96-well plate and incubated overnight. After a 24 h incubation period, cells were
treated with increasing concentrations of Lestaurtinib (0.06 to 4.0 µM) for 72 h. After 72
h, cells were incubated with PrestoBlue® (Thermo Fisher Scientific) for 1 h at 37°C. The
same procedure was completed using the normal cell line, WI-38, with increasing
concentrations of Lestaurtinib (0.125 to 2.0 µM) for 72 h. For ATC cell lines, two
biological replicates were completed with 3 technical replicates for each concentration. For
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WI-38, one biological replicate was completed with 3 technical replicates for each
concentration. Fluorescence readings were completed using a BioTek Synergyä
Microplate Reader with 560nm excitation and 590nm emission wavelengths. These values
were normalized to the untreated controls and the average viability for each concentration
was calculated. In order to determine the half-maximal inhibitory concentration (IC50), the
normalized relative fluorescence values of the Lestaurtinib-treated samples were calculated
as a percentage of the mean relative fluorescence units of the untreated, control samples.
Drug concentrations were transformed to a logarithmic scale and IC50 values were
calculated using non-linear regression (curve fit). Analysis was completed using Prism® 7
GraphPad Software.

2.3.7

Immunoblotting
Cells were seeded at a density of 200,000 cells/well into 6-well plates and incubated

overnight. For treatments, cells were treated with DMSO-only (vehicle) or Lestaurtinib
concentrations of 0.125, 0.25, 0.5, 1.0, 2.0 and 4.0 µM for 24 h. Staurosporine-treated cells
(5 µM, 3 h) were used as a positive control for apoptosis. Cells were lysed, and a Bradford
assay was performed to determine the protein concentration of the whole cell lysates using
the Bio-rad Protein Assay Dye Reagent (Bio-Rad, Mississauga, ON, Canada). NuPAGE®
Novex® 4-12% Bis-Tris Gel (Thermo Fisher Scientific) was used for protein separation
with 20 µg of total protein loaded per well and run at 200V (1 hour). Novex® Sharp
Standard protein ladder (Thermo Fisher Scientific) was used to determine the mass of
products. A PVDF blotting membrane (GE Healthcare, Mississauga, ON, Canada) was
used for protein transfer at 14V (1 hour). Membranes were blocked using 5% bovine serum
albumin (Sigma-Aldrich). Primary antibodies were prepared according to the manufacturer
and used overnight at 4°C with constant, mild agitation. Endogenous JAK2 (Cat no.
3230P), phospho-JAK2 (p-JAK2; Cat no. 3776S), phospho-STAT5 (p-STAT5; Cat no.
9351S) and α-tubulin (Cat no. 2125S) antibodies were obtained from Cell Signaling
Technology (Whitby, ON, Canada). Endogenous STAT5 (Cat no. sc-835) was obtained
from Santa Cruz Biotechnology (Dallas, TX, USA). Mouse anti-human PARP (Cat no.
556494) was obtained from BD Pharminogen (Mississauga, ON, Canada). Secondary
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antibodies were diluted 1:5000. Detection of target proteins was performed using Luminata
Forte Western HRP substrate (EMD Millipore, Burlington, MA, USA). Detection of αtubulin was used as a loading control.

2.3.8

Colony formation assay
Cells (CAL62) were seeded into 24-well plates at a density of 1,000 cells/well.

After 24 h, cells were treated with 0, .125, .25, .50, 1.0, 2.0 and 4.0 µM concentrations of
Lestaurtinib, with 1 biological replicate, and incubated at 37°C for 7 days with
Lestaurtinib-containing media being replaced every 3 days. Cells were washed with PBS
and fixed with cold 100% methanol for 15 minutes prior to staining with 0.5% crystal violet
in 10% methanol/1x PBS for 10 minutes. Brightfield microscopy was used for
quantification of colonies, which were defined as being >50 cells. A total of 3
representative fields per well were counted for colonies based on the above cell number
parameter. This was completed for each concentration of Lestaurtinib tested and the
number of colonies were totaled for each concentration. A Student’s unpaired, two-tail ttest was used for statistical analysis using Prism® 7 GraphPad Software. Samples were
compared relative to the untreated control and p values < 0.05 were considered to represent
statistically significant differences in colony formation.

2.3.9

Cell motility assay
Cells (CAL62) were seeded into 6-well plates at a density of 150,000 cells/well and

incubated until 90% confluence. After 24 h, cells were washed with PBS and scratched
through the middle in a straight line using a sterile P1000 pipette tip. Immediately after the
scratch, wells were either exposed to media containing the vehicle (DMSO) or media
containing Lestaurtinib at 0.5- or 4.0 µM. The migration of cells from the outer edge of the
scratch towards the center was measured at 0, 4 and 24 h. A total of 10 measurements over
the length of the scratch were taken for each timepoint to produce the mean scratch width
(pixels), for 3 replicates per time point. Means and standard errors were calculated and
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normalized to the 0 h timepoint. A Student’s unpaired, two-tail t-test was used for statistical
analysis using Prism® 7 GraphPad Software and p values < 0.05 were considered
statistically significant.

2.3.10

JAK2 knockout by CRISPR/Cas9

Two cell lines (KMH2 and CAL62) were used for CRISPR/Cas9 gene editing of
JAK2. Cells of each line were seeded at a density of 5 x 104 cells/well in a 24-well dish.
Lentivirus expressing Cas9 was added to cells at a multiplicity of infection (MOI) of 0.3.
When integration had occurred, blasticidin selection was used to kill untransduced cells,
with a concentration that was previously determined with kill curves for each cell line.
Cas9 expression was confirmed by western blot analysis. The Cas9 (+) cell lines were then
transduced with lentivirus carrying a single guide RNA (sgRNA) against JAK2
(NM_004972, targets Exon19; Cat no. VSGH10142-246580412; Dharmacon, Lafayette,
CO, USA), a scrambled non-targeting control (negative control), or a sgRNA against
DNMT3B (positive control). Transduced cells were selected using puromycin (using a
concentration determined by kill curves for each cell line) and confirmed using western
blot analysis probing for endogenous JAK2. Proliferation was compared between the nontargeting CRISPR control and JAK2 knockout lines where cell lines were seeded in 96well plates at a density of 2,400 cells/well. After 72 h, PrestoBlue® was added to wells and
plates were incubated for 1 h prior to fluorescence readings using a BioTek Synergy™ H4
Hybrid Microplate Reader with 560nm excitation and 590nm emission wavelengths.
Relative fluorescence units were normalized to yield percent (%) proliferation compared
to the non-targeting control. Furthermore, we completed dose-response curves where
CAL62 and KMH2:JAK2 knockout (KO) cell lines were seeded into 96-well plates at a
density of 2,400 cells/well. At 24 h post-seeding, Lestaurtinib was added at a range of
increasing concentrations (0.125 – 4 µM). After 72 h, PrestoBlue® was added to wells and
plates were read as mentioned above. A Student’s unpaired, two-tail t-test was used for
statistical analysis using Prism® 7 Graphpad Software and p values < 0.05 were considered
statistically significant differences.
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2.3.11

Live-dead cell assay

Cells (KMH2 and CAL62) were seeded at a density of 100,000 cells/well. After 24
h, cells were either untreated or treated with 0.5 µM or 1 µM Lestaurtinib. Plates were
incubated at 37°C for 24 h. Cells were then washed with PBS and trypsinized; 10 µl of
resuspended cells were combined with Trypan Blue (Sigma-Aldrich; Cat. T8154) at a 1:1
ratio for 10 minutes. Cells were counted using a hemocytometer and Brightfield
microscopy. The ratio of live-dead cells was then calculated for each based on their
exclusion of dye. The number of live cells per mL were calculated and compared to the
untreated control using a Student’s unpaired, two-tail t-test. P values < 0.05 were
considered to be statistically significant.

2.3.12

Cell cycle analysis

To determine the effects of Lestaurtinib on cell cycle distribution, we treated two
ATC cell lines (CAL62 and KMH2) with either DMSO-only or 4 µM Lestaurtinib for 24
h, with 3 biological replicates each. This concentration was chosen from the upper range
of the high-throughput drug screen, and both cell lines were picked due to their sensitivity
as noted from the IC50 analysis. Bromo-deoxyuridine (BrdU; GE Healthcare, Cat. RPN201)
was added to cell media and incubated in culture for 2 hours prior to collection. Cell were
trypsinized, collected and washed 3 times with PBS prior to using 95% freezer-chilled
ethanol to fix cells. Cells were permeabilized using 2N HCl/0.5% Triton X-100, followed
by 0.1 M NaB4O7. Primary (Mouse anti-BrdU primary antibody, 1:50; Lot. 347580, BD
Biosciences) and secondary (FITC-conjugated rabbit anti-mouse secondary antibody, 1:25;
Cat. FI-2000, Vector Laboratories, Burlingame, CA, USA) antibodies were added and
incubated for 30 minutes for each step. Cell pellets were resuspended in propidium iodide
(PI; 10 mg/ml) and RNase A (0.25 mg/ml; Bioshop Canada Inc., Burlington, ON, Canada,
Cat. RNA675) and incubated overnight at 4°C. The following day, cell cycle analysis using
flow cytometry was performed using a Beckman Coulter Inc, CytomicsTM FC500 flow
cytometer with at least 10,000 events that were counted per test. Statistical analysis was
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performed using a Student’s unpaired, two-tail t-test to compare treated and untreated
samples.

2.3.13

Antitumour activity studies in vivo

One million CAL62 cells were combined with Matrigel (Corning, Tewksbury, MA,
USA) at a 1:1 ratio. Chick embryos were used at 9 days post-fertilization. A small circle
of filter paper was placed on an area with small blood vessels of the chorioallantoic
membrane to score the area for the onplant of cells. A total volume of 10 µl, containing the
1:1 ratio of 5 µl 1 million cells: 5 µl Matrigel, was pipetted over top of the scored area.
Once the onplant of cells was complete, embryos were covered and incubated for 2 days at
37°C. Drug treatments were initiated 2 days post-onplant with either vehicle (DMSO)
(n=11) or 4 µM Lestaurtinib (n=19) and applied once daily for a 5-day duration. Tumour
volume was measured at the experimental endpoint using B-mode (anatomical) ultrasound
imaging. Vascularity was measured at endpoint using power Doppler ultrasound imaging,
which estimates fractional vascular volume by displaying the ultrasound power reflected
from moving blood cells in detectable vessels, which are typically larger than 100 µm
diameter.
All ultrasound measurements were performed using a Vevo® 2100 high frequency
imaging system (VisualSonics Inc., Toronto, Canada). B-mode and power Doppler images
were acquired using a 40 MHz linear array (MS-550D, 40 µm axial resolution, 80 µm
lateral resolution). The imaging field of view was set to 10.00 mm (axial) by and 14.08
mm (lateral) with a Doppler color box sized to completely enclose the largest cross-section
of tumour. Three-dimensional volumetric images were acquired using a linear stepper
motor (VisualSonics Inc.) with a step size 0.076 mm and a total step distance 7.98 mm.
Volumetric image reconstruction and analysis was performed using the supplied
software (Vevo 2100 Workstation, VisualSonics Inc.). Estimates of tumour volume were
computed via manual planimetry on reconstructed three-dimensional B-mode images. The
fractional vascular blood volume in the tumour was calculated by summing the number of
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Doppler color voxels, which correspond to regions with detected blood flow, within the
segmented volume and dividing by the total number of voxels in the volume to yield
percent vascularity. This yields the percentage tumour vascularity, which is normalized to
the tumour volume.

2.3.14

Statistical analysis

A Student’s unpaired, two-tail t-test was performed where appropriate using
Prism® 7 Graphpad Software Macintosh Version (by Software MacKiev © 1994-2014
GraphPad Software, Inc). P values < 0.05 were considered statistically significant. P values
are defined as ns p > 0.05, * represents p < 0.05, ** represents p < 0.01, and *** represents
p < 0.001.

2.4 Results
2.4.1

Lestaurtinib inhibits growth of ATC cell lines
We found Lestaurtinib, a JAK2 inhibitor, to be a highly potent agent across our cell

line panel with 11 out 13 cell lines having nanomolar IC50 values. The cell line KMH2 was
the most sensitive; with a mean IC50 between both biological replicates of 0.21 ± 0.06 µM
(Fig. 2.1A, B). CAL62 was the sixth most sensitive, falling into the middle of our cell line
panel, with a mean IC50 of 0.41 ± 0.001 µM (Fig. 2.1A, B). THJ-21T was the most resistant
cell line in our panel, with a mean IC50 of 2.35 ± 0.42 µM (Fig. 2.1A, B). Lestaurtinib
potency was also tested against the normal lung fibroblast cell line, WI-38, to measure how
treatment with this drug would affect a normal cell line. Using a concentration range of
0.125 - 2 µM Lestaurtinib, we could not establish an IC50 for WI-38 because growth was
not inhibited (Fig. 2.1B).
We then sought to determine whether the measured sensitivity of ATC cell lines to
Lestaurtinib could be explained by endogenous levels of JAK2 or its downstream target
STAT5. Using Western blot analysis, we noted that neither the most sensitive lines
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Figure 2.1. Lestaurtinib inhibits growth of ATC cell lines. (A) Lestaurtinib was tested
against 13 ATC cell lines, with 2 biological replicates per cell line. Cells were treated with
Lestaurtinib for 48 h and readings were completed after incubation with AlamarBlue. Mean
IC50 values are shown ± standard deviation, stratified by lowest to highest mean values.
(B) Dose-response curves demonstrating the effect of Lestaurtinib (µM) on cell growth
following 72 h of treatment for KMH2, CAL62, THJ-21T (2 biological replicates) and WI38 (1 biological replicate) cell lines. (C) Western blot showing expression of p-JAK2,
JAK2, p-STAT5 and STAT5 showing protein expression of cells that were either untreated
or treated with increasing concentrations (.125 – 4 µM) of Lestaurtinib, relative to the
Staurosporine (St.) control.
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(KMH2, 8505C and BHT-101) nor the most resistant lines (C643, ASH3 and THJ-21T),
exhibited any correlation between the expression levels of endogenous JAK2 or STAT5
and sensitivity to Lestaurtinib treatment (Supplemental Fig. 2.1). Given the high potency
of Lestaurtinib and its potential as a therapeutic agent in our cell line panel, we selected
both KMH2 and CAL62 cell lines for in vitro and in vivo validation studies.
To investigate whether Lestaurtinib was acting through the JAK2 pathway as
predicted, we treated CAL62 with increasing concentrations of Lestaurtinib for 24 h.
Treatment with Lestaurtinib did not result in a decrease of phospho-JAK2 or endogenous
JAK2; however, the downstream molecule STAT5 demonstrated a concentrationdependent decrease in phosphorylation starting at 0.125 µM, with a complete
disappearance of pSTAT5 expression at 4 µM (Fig. 2.1C). For these reasons, we chose to
use concentrations of 4 µM in our in vivo studies to determine the effects of inhibition of
the JAK2 pathway with complete depletion of pSTAT5 expression.

2.4.2

Lestaurtinib impairs in vitro colony formation and cell
migration of ATC cells
Normal (WI-38) and ATC (CAL62 and KMH2) cells were treated Lestaurtinib for

a 24-hour period. Following 24 h of treatment, a concentration of 0.5 µM Lestaurtinib
resulted in fewer cells with a rounder morphology in both CAL62 and KMH2 lines (Fig.
2.2A). However, the morphology of WI-38 cells treated with 0.5 µM was not altered (Fig.
2.2A).
We next evaluated the effect of Lestaurtinib treatment on cells using a colony
formation assay. Treatment of CAL62 with increasing concentrations of Lestaurtinib
resulted in a significant inhibition of colony formation at all concentrations in the range of
0.125 to 4.0 µM when compared to the untreated control over a 7-day period (Fig. 2.2B).
Previous studies identified a role for the JAK2-STAT pathway in cell migration
(Rawlings 2004; Yang et al. 2012; Teng et al. 2014), thus if Lestaurtinib was acting on the
JAK2-STAT pathway then we sought to determine how Lestaurtinib treatment would

46

Figure 2.2. Lestaurtinib impairs in vitro colony formation and cell migration of ATC
cells. (A) Phase contrast images of WI-38, CAL62 and KMH2 cell lines with and without
Lestaurtinib treatment (0.5 µM; 4X magnification). (B) Clonogenic assay of CAL62 both
untreated and treated with increasing concentrations of Lestaurtinib (0.125 – 4 µM) and
stained with 0.5% crystal violet. Colony formation was quantified by counting colonies
from 3 representative fields, with colonies defined as being >50 cells. (C) Scratch-wound
migration assay of CAL62 cells treated with 0.5 and 4.0 µM Lestaurtinib at 0, 4 and 24 h.
Ten measurements were taken across the width of the scratch and averaged (3 replicates
per cell line) per time point. * represents p < 0.05, ** represents p < 0.01, *** represents p
< 0.001, **** represents p < 0.0001, ns = not significant, unpaired Student’s t-test.
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impact migration of CAL62 cells using a scratch-wound assay. At both 4- and 24 h, there
was a significant difference in normalized scratch width percentage (%), where drugtreated scratches (0.5 and 4.0 µM) remained relatively open compared to the control (Fig.
2.2C).

2.4.3

Lestaurtinib treatment induces an antiproliferative effect with
knockout of JAK2 in ATC cell lines
We used CRISPR/Cas9 technology to knockout JAK2 in CAL62 and KMH2 cells,

which would be expected to make the cells resistant to drug treatment. Complete knockout
(KO) of JAK2 protein expression was achieved in both cell lines (Fig. 2.3A). Furthermore,
we noted that there was a decrease in STAT5 phosphorylation following JAK2 knockout,
recapitulating one of the effects of Lestaurtinib treatment (Fig. 2.3A). We then assessed
cellular proliferation and found that the JAK2-edited CAL62 line exhibited a significant
increase in cellular proliferation after 72 h compared to the non-targeting CRISPR control
(p = 0.0090) (Fig. 2.3B), while the KMH2 line demonstrated a significant decrease in
cellular proliferation at 72 h compared to the non-targeting CRISPR control (p =
0.0014)(Fig. 2.3B). Both JAK2 knockout cell lines were treated with Lestaurtinib over a
6-point concentration range to determine whether Lestaurtinib would impact cellular
proliferation in the absence of JAK2. We observed a significant decrease in cellular
proliferation of CAL62:JAK2 (KO) at the highest concentration (p = 0.0060) (Fig. 2.3C).
Furthermore, we observed a significant decrease in cellular proliferation of KMH2:JAK2
KO at every concentration of Lestaurtinib except the lowest (Fig. 2.3C), suggesting that
the antiproliferative effect of Lestaurtinib could not be explained solely through a JAK2
mechanism.

2.4.4

Lestaurtinib exerts a cytostatic effect on ATC cells in vitro
We utilized a live-dead assay of CAL62 and KMH2 cells to determine the effect of

Lestaurtinib on cell health. The number of cells significantly decreased when treated with
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Figure 2.3. Lestaurtinib treatment induces an antiproliferative effect with knockout
of JAK2 in ATC cell lines. (A) Western blot showing loss of JAK2 expression following
JAK2 knockout in CAL62 and KMH2 cell lines and compared to a non-targeting control.
(B) Cellular proliferation of JAK2 knockout cell lines (CAL62 and KMH2) normalized to
the non-targeting control and measured at 72 h. (C) Dose-response curves of CAL62 and
KMH2 JAK2 knockout cells following 72 h of treatment with Lestaurtinib over a 6-point
dose range (3 replicates per line). * represents p < 0.05, ** represents p < 0.01, ***
represents p < 0.001, **** represents p < 0.0001, ns = not significant, unpaired Student’s
t-test.
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1 µM of Lestaurtinib when compared to the untreated control (p < 0.0001) after 24 h in
KMH2 (Fig. 2.4A). Furthermore, we noted that there was a significant decrease in cell
number with both 0.5 (p < 0.0001) and 1.0 µM (p < 0.0001) after 24 h in CAL62 (Fig.
2.4A). There was significant decrease in cell growth of Lestaurtinib treated KMH2, CAL62
and THJ-21T cell lines at the 72 h for both 0.5 and 4.0 µM treatments (Fig. 2.4B). Western
blot analysis was carried out to determine whether apoptosis was being induced following
Lestaurtinib treatment. At all concentrations, cleaved PARP (c-PARP) was not detectable,
although its presence was detected in cells treated with Staurosporine (St.) as a positive
control (Fig. 2.4C).
As the antiproliferative effects of Lestaurtinib did not appear to result in cell death,
we next evaluated whether Lestaurtinib induced a cytostatic effect on ATC cell lines.
CAL62 and KMH2 cells were treated with a concentration of 4 µM Lestaurtinib for 24 h
and this resulted in a significant decrease in the number of cells in the G1/G0 phase (p =
0.0036) in CAL62 (Fig. 2.4D). An increased number of CAL62 cells in the G2/M phase
were also observed; however, this change was not significant (p = 0.1869) when compared
to the vehicle-treated cells (Fig. 2.4D). Lestaurtinib-treated KMH2 cells showed a
significant increase in the number of cells in the G2/M phase (p < 0.0056), and significant
decreases in the number of cells in the G1/G0 (p < 0.0022) and S (p = 0.0003) phases (Fig.
2.4D), suggesting a decrease in the proportion of proliferating cells.

2.4.5

Lestaurtinib exhibits antiproliferative and antiangiogenic
activity in the in vivo chick CAM membrane model
The chick CAM model was used to examine the anti-tumour effects of Lestaurtinib

in an in vivo model. CAL62 cells were used to establish xenograft tumours in CAM models.
These were treated with either PBS (vehicle) or Lestaurtinib (4 µM) once a day for 5 days,
with drug treatment beginning 2 days post-onplant. Mean endpoint tumour volume of
vehicle-treated embryos (n=11) was 4.05 ± 1.31 mm3, while that of the Lestaurtinib-treated
embryos (n=19) was 1.7 ± 1.02 mm3 (p < 0.0001; Fig. 2.5A). Power Doppler ultrasound
imaging was used to determine the inter-group difference in fractional vascular volume at
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Figure 2.4. Lestaurtinib exerts a cytostatic effect on ATC cells in vitro. (A) Effect of
Lestaurtinib (0.5 µM and 1.0 µM) on cell number following 24 h of treatment (3 replicates
per line) for KMH2 and CAL62 cell lines. (B) Growth curves for KMH2, CAL62 and THJ21T cell lines following treatment with Lestaurtinib at 0, 24, 48 and 72 h, with 3 technical
replicates per timepoint. Statistical analysis is shown for the 72 h timepoint when compared
to the untreated control for the same timepoint. (C) Western blot showing expression of
cleaved PARP (c-PARP) following 24 h of Lestaurtinib doses (0.25 – 4.0 µM) relative to
the apoptosis-inducing Staurosporine (St.) control. (D) CAL2 and KMH2 cells were treated
with Lestaurtinib (4.0 µM) for 24 h (3 replicates per line) prior to BrdU incorporation and
labeling of cells with propidium iodide. A minimum of 10,000 events were counted per
test. Proportions of cells within each phase of the cell cycle is shown ± standard error. *
represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, **** represents p <
0.0001, ns = not significant, unpaired Student’s t-test.
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Figure 2.5. Lestaurtinib exhibits antiproliferative and antiangiogenic activity in the
in vivo chick CAM membrane model. (A) A total of 1 x 106 cells per embryo were
administered over top (onplant) of the chick embryo membrane, 9 days post-fertilization.
Two days post-onplant, embryos were either treated with the vehicle alone or Lestaurtinib
(4 µM), daily for 5 days and sacrificed. Mean endpoint tumour volume was measured using
ultrasound imaging in the vehicle-treated (n=11) and Lestaurtinib-treated (n=19) embryos.
(B) Power Doppler ultrasound imaging measured the intergroup difference in fractional
vascular volume at endpoint to generate mean percent vascularity between groups. *
represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, **** represents p <
0.0001, ns = not significant, unpaired Student’s t-test.
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endpoint. Using this modality, the mean percent vascularity decreased from 23.76 ± 12.95
to 13.99 ± 8.80 % with Lestaurtinib treatment (p = 0.0202; Fig. 2.5B). Together this data
suggests that Lestaurtinib may act as an antiproliferative agent in ATC cell line models,
and its potential as an antiangiogenic agent warrants further investigation.

2.5 Discussion
The aggressive and invasive nature of ATC, paired with the frequency of distant
metastases seen in patients makes this disease very difficult to treat resulting in dismal
patient outcomes (Molinaro et al. 2017). Furthermore, the rarity and rapid progression of
this disease are considerable barriers for clinical trials. Thus, preclinical drug development
is a crucial step to identify new targeted agents and the use of cultured cell lines for this
purpose remains an important aspect of drug discovery due to their ease of manipulation
and ability to test both in vitro and in vivo (Nichols et al. 2014; Pinto et al. 2014).
We identified the tyrosine kinase inhibitor Lestaurtinib as an inhibitor of cellular
growth in ATC cells, with nanomolar IC50 levels across the majority of the 13 ATC cell
lines tested. Lestaurtinib has been previously used in several clinical trials for
hematogenous malignancies, but it has not been explored for potential utility against solid
malignancies such as thyroid cancer (Hexner et al. 2008; Iyer et al. 2010; Diaz et al. 2011;
Vazquez-Ortiz et al. 2014). Furthermore, it has been studied extensively both in vitro and
in vivo, and demonstrates a highly positive safety record and has good oral bioavailability
(Hexner et al. 2008; Iyer et al. 2010).
Lestaurtinib has been reported to be a multi-kinase inhibitor, specifically of the
JAK2 signaling pathway (Hexner et al. 2008); however, many kinase inhibitors have offtarget effects (Zhang & Loughran 2011; Munoz 2017), making their true anti-cancer
mechanism unclear. In this study, we have reported the effects of Lestaurtinib in vitro and
in vivo. Although we found evidence that Lestaurtinib did inhibit JAK2 pathway activation
through a concentration-dependent decrease in downstream STAT5 phosphorylation, we
also found that cells with JAK2 knockout demonstrated a similar or increased sensitivity
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to Lestaurtinib, indicating that the observed antiproliferative effects may be due to offtarget effects via the inhibition of other targets in addition to JAK2. Furthermore, we noted
that the antiproliferative effects of Lestaurtinib were not mediated through apoptosis, but
through cell cycle arrest with the accumulation of drug-treated cells in the G2/M phase of
the cell cycle. Further studies are needed to uncover the true mechanism of action of this
drug in addition to inhibition of the JAK2 pathway.
Xenografts were developed using the chick CAM model to understand the effects
of drug treatment on tumour volume and vascularity using the CAL62 cell line (Deryugina
& Quigley 2008; Ribatti 2014; Xiao et al. 2015). Our in vivo studies demonstrated that
treatment with Lestaurtinib resulted in a significant reduction in tumour volume.
Furthermore, when we controlled for tumour volume, there was a significant decrease in
the percent tumour vascularity when compared to the vehicle control, demonstrating a
potential antiangiogenic effect that warrants further investigation. Together this data
suggests that while Lestaurtinib demonstrates antiproliferative effects in vitro, there is
potential for antiangiogenic effects which contribute to its overall antitumour activity.
In summary, our in vitro and in vivo data suggest that Lestaurtinib may induce its
effects through the inhibition of JAK2 in addition to other off-target effects. Administration
of Lestaurtinib demonstrated an antiangiogenic effect on ATC tumours in vivo, with a
relatively high drug dose used as a proof-of-principle, suggesting that this mechanism of
action may be responsible for the antiproliferative effects observed in our study. Overall,
the data in this study suggests that Lestaurtinib may be an effective and valid therapeutic
agent in the study of ATC, however, this drug warrants further investigation to understand
the full potential as a targeted therapy in ATC.
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2.7 Supplementary Materials

Supplementary Table 2.1. Short tandem repeat profiling of 13 ATC cell lines. Cell
lines were genotyped with 16 selected markers.
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Supplementary Figure 2.1. Western blot analysis of ATC cell lines to determine
endogenous levels of JAK2 and STAT5. Lysates from cell lines that appeared to be
sensitive (KMH2, 8505C and BHT-101) and resistant (C643, ASH3 and THJ-21T) based
on IC50 values were analyzed using Western blot analysis.
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Chapter 3

3

Flavopiridol inhibits anaplastic thyroid cancer models
via CDK inhibition

3.1 Abstract
Anaplastic thyroid cancer (ATC) is a rare, but nearly uniformly fatal disease that is
typically resistant to chemotherapy and radiation. Alternative strategies to target this cancer
at a molecular level are necessary in order to improve dismal outcomes for ATC patients.
We examined the effects of flavopiridol, a CDK inhibitor, in a panel of ATC cell lines.
When cell lines were treated over a ten-point concentration range, CAL62, KMH2 and
BHT-101 cell lines had a sub micromolar half-maximal inhibitory concentration, while no
effect was seen in the non-cancerous cell line IMR-90. Flavopiridol treatment resulted in
decreased levels of the cell cycle proteins CDK9 and MCL1, and induced cell cycle arrest.
Flavopiridol also decreased the in vitro ability of ATC cells to form colonies and impeded
migration using a transwell migration assay. In vivo, flavopiridol decreased tumour weight
and tumour volume over time in a patient-derived xenograft model of ATC. Given the
observed in vitro and in vivo activity, flavopiridol warrants further investigation for
treatment of ATC.
A version of this chapter has been submitted for publication:
Pinto N, Prokopec SD, Ghasemi F, Meens J, Ruicci KM, Khan MI, Mundi N, Patel K, Han
MW, Yoo J, Fung K, MacNeil D, Mymryk JS, Datti A, Barrett JW, Boutros PC, Ailles L
and Nichols AC. 2019 Flavopiridol inhibits anaplastic thyroid cancer models via CDK
inhibition. In preparation for resubmission to Endocrine-Related Cancer.
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3.2 Introduction
Anaplastic thyroid cancer (ATC) is a rare form of undifferentiated thyroid cancer
which progresses rapidly and is almost universally fatal (Nikiforov & Nikiforova 2011;
Bin Xu & Ghossein 2016a; Molinaro et al. 2017). While well-differentiated thyroid cancers
are typically indolent with cure rates in excess of 90% of cases, those diagnosed with ATC
experience a median survival of approximately 6 months following diagnosis (Giuffrida &
Gharib 2000; Akaishi et al. 2011; Guerra et al. 2013; O’Neill & Shaha 2013). Even with
the use of conventional therapies such as surgical resection, chemotherapy and radiation,
improvements in overall patient survival for those diagnosed with ATC have not changed
in the past decade, remaining at a dismal mortality rate of close to 100% (Pinto et al. 2014;
Bin Xu & Ghossein 2016a).
The failure to increase survival rates of those suffering from ATC using the
aforementioned treatment strategies has shifted current efforts to determine which
molecular targets are “actionable” and can be used to halt the otherwise rapid disease
progression. The use of small-molecule kinase inhibitors to target key proteins has become
an attractive strategy across many cancer types including a number of prospective targeted
therapies which have been identified for inhibition of various putative targets in ATC
including sorafenib (VEGFR), axitinib (VEGFR), vemurafenib and dabrafenib (BRAF),
imatinib (PDGFR), and selumetinib (MEK 1 and 2) (Smith & Nucera 2015). Similarly, cell
cycle inhibitors, specifically cyclin-dependent kinase (CDK) inhibitors, are under active
investigation in a number of other cancer types, including breast cancer and non-small cell
lung cancer (Otto & Sicinski 2017; Pernas et al. 2018; Thangavel et al. 2018).
In this study we focus on the small-molecule inhibitor flavopiridol, a reported panCDK inhibitor, which when inhibited results in the inhibition of CDKs, specifically CDK9
resulting down-regulation of MCL1 protein expression and the induction of apoptosis
(Bose & Grant 2013; Boffo et al. 2018). Further, flavopiridol has been described in the
literature to be a potent cell cycle inhibitor with the potential to be used as a radiosensitizer
in some cancer types, including esophageal and ovarian cancer cell lines and in 2014 this
compound was granted orphan drug status by the FDA for the treatment of acute myeloid
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leukemia (AML), thus making this compound highly relevant to ATC (Raju et al. 2003;
Sato et al. 2004; FDA 2014).
In the present study, we focus on the inhibitory action of flavopiridol in ATC. We
observed that flavopiridol is a potent inhibitory compound across our ATC cell lines with
nanomolar inhibitory concentrations. We demonstrate that flavopiridol exhibits efficacy in
ATC models by reducing in vitro cell proliferation, colony formation and migration,
decreasing MCL1 signaling and inducing cell cycle arrest. Finally, we demonstrate that
flavopiridol has significant anti-tumour effects against ATC in vivo using a patient-derived
xenograft model of ATC.

3.3 Materials and Methods
3.3.1

Cell lines and culture conditions
The ATC cell line KMH2 was purchased from the Japanese collection of Research

of Bioresources Cell Bank (JCRB; Osaka, Japan). BHT-101 and CAL62 cell lines were
both purchased from the DSMZ Cell Bank (DSMZ Cell Bank, Germany, EU). All cell lines
were cultured in DMEM supplemented with 10% heat inactivated FBS (GIBCO; Thermo
Fisher Scientific, Carlsbad, CA, USA), penicillin (100 µg/mL) and streptomycin (100
µg/mL) (Invitrogen; Thermo Fisher Scientific, Carlsbad, CA, USA). Cell lines were
routinely confirmed for authenticity using Short tandem repeat (STR) profiling. The lung
fibroblast cell line IMR-90 was purchased from ATCC (ATCC, Manassas, VA, USA) and
the media used for culture was EMEM supplemented with 10% FBS (GIBCO), penicillin
(100 µg/mL) and streptomycin (100 µg/mL) (Invitrogen).

3.3.2

Drug treatment
Flavopiridol was purchased from Selleckchem (Burlington, ON, Canada; Cat no.

S1230). The drug was dissolved in dimethyl sulfoxide (DMSO; Sigma-Aldrich, Oakville,
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ON, Canada) and prepared as a 10mM stock solution. Subsequently, serial dilutions were
performed for the initial drug testing (final concentrations of 0.0075-4µM).
The normal lung fibroblast cell line (IMR-90) and ATC cell lines (KMH2, BHT101 and CAL62) were seeded into 96-well plates at a density of 2,400 cells per well and
incubated at 37°C and 5% CO2. After 24hrs, cells were treated with an extended dose range
of flavopiridol concentrations from 0.06 to 32µM. After 72hrs, plates were read by
incubating cells with PrestoBlue (Thermo Fisher Scientific) for 1hr at 37°C. After
incubation with PrestoBlue (Thermo Fisher Scientific), fluorescence readings were
completed using a BioTek Synergy Microplate Reader with 560nm excitation and 590nm
emission wavelengths. To generate dose-response curves, raw fluorescence data was
loaded into Prism 7 GraphPad Software, where the values were then normalized to the
untreated control samples. To determine the IC50, the normalized relative fluorescence
units (RFU) of the flavopiridol-treated samples were calculated as a percentage of the mean
RFU of the untreated samples. Drug concentrations were then transformed to a logarithmic
scale and IC50 values were calculated using non-linear regression (curve fit).

3.3.3

Immunoblotting
Cells were seeded at a density of 200,000 cells/well in 6-well plates and incubated

overnight. After 24hrs, cells were treated with flavopiridol and incubated for either 24 or
48hrs. Cells were lysed, and a Bradford assay was performed to determine the protein
concentration of the whole cell lysates using the Bio-rad Protein Assay Dye Reagent (BioRad, Mississauga, ON, Canada). NuPAGE® Novex® 4-12% Bis-Tris Gel (Thermo Fisher
Scientific) was used for protein separation with 20 µg of total protein loaded per well and
run at 200V (1 hour). Novex® Sharp Standard protein ladder was used to determine the
mass of products. A PVDF blotting membrane (GE Healthcare, Mississauga, ON, Canada)
was used for protein transfer at 14V (1 hour). Membranes were blocked using 5% bovine
serum albumin (Sigma-Aldrich, Oakville, ON, Canada). Primary antibodies were prepared
according to the manufacturer and incubated overnight at 4°C with constant, mild agitation.
Antibodies used included CDK9 (Cat no. 2316), phospho CDK9 (Thr186) (Cat no. 2549),
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MCL1 (Cat no. 39224) and a-tubulin (Cat no. 2125) obtained from Cell Signaling
Technology (Whitby, ON, Canada). PARP (Cat no. 556494) was obtained from BD
Pharminogen (Mississauga, ON, Canada). Secondary antibodies were diluted 1:5000.
Detection of target proteins was performed using Luminata Forte Western HRP substrate
(EMD Millipore, Burlington, MA, USA). α-tubulin was used as a loading control.

3.3.4

Clonogenic assay
CAL62 and BHT-101 cells were seeded into 6-well plates at a density of 1,000 cells

per well. After 24hrs, cells were treated with 60 and 125nM flavopiridol and incubated at
37°C for 7 days based on colony formation of the control-treated wells. Cells were washed
with PBS and fixed with 100% chilled methanol for 15 minutes. Following fixation, cells
were stained with 0.5% crystal violet in 10% methanol/1x PBS for 10 minutes. Brightfield
microscopy was used to quantify colony formation, with a colony defined as being > 50
cells. For quantification, three representative fields per well were counted for the number
of colonies and this was completed for both the control and the varying concentrations of
flavopiridol tested.

3.3.5

Cell migration assay
Cell migration for CAL62, BHT-101 and KMH2 cell lines was assessed using a 24-

well cell transwell migration plate and fluorometric analysis (Cat no. CBA-100; Cell
Biolabs Inc, San Diego, CA, USA). Initial cell suspensions (5x104 cells per well) were
placed into the upper chambers containing 0, 60 and 125 nM concentrations of flavopiridol
in serum-free media, with two biological replicates. Cells were incubated at 37°C in order
to allow migratory cells to migrate through the polycarbonate membrane to the bottom of
the chamber. Cells that stayed in the upper chamber were considered to be non-migratory.
Migratory cells were then dissociated from the membrane of the chamber using the Cell
Detachment Buffer provided in the cell migration plate kit. Cells which migrated through
were lysed and quantified using CyQuant GR Fluorescent Dye provided in the same kit.
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Fluorescence readings were completed using a BioTek Synergy Microplate Reader and
representative images were collected using brightfield microscopy.

3.3.6

Cell cycle analysis
KMH2, CAL62 and BHT-101 cells were treated with either DMSO-only or 125nM

flavopiridol for 24hrs, with 3 biological replicates each. Bromo-deoxyuridine (BrdU; Cat
no. RPN201, GE Healthcare) was added to cell media and incubated in culture for 2hrs
prior to collection. Cell were trypsinized, collected and washed 3 times with PBS prior to
using 95% freezer-chilled ethanol to fix cells. Cells were permeabilized using 2N
HCl/0.5% Triton X-100, followed by 0.1 M NaB4O7. Primary (mouse anti-BrdU primary
antibody, 1:50; BD Biosciences lot. 347580) and secondary (FITC-conjugated rabbit antimouse secondary antibody, 1:25; Cat no. FI-2000, Vector Laboratories, Burlingame, CA,
USA) antibodies were added and incubated for 30 minutes for each step. Cell pellets were
resuspended in propidium iodide (PI; 10 mg/ml) and RNase A (0.25 mg/ml; Cat no.
RNA675, Bioshop Canada Inc., Burlington, ON, Canada) and incubated overnight at 4°C.
The following day, cell cycle analysis using flow cytometry was performed (Beckman
Coulter Inc, Cytomics FC500).

3.3.7

RNA interference
KMH2 and CAL62 cells were seeded into 6-well plates at a confluency of ~40% at

transfection. Lipofectamine® RNAiMAX Reagent (Cat no. 13778030, Thermo Fisher
Scientific) was used for transfection purposes. ON-TARGETplus CDK9 siRNA (Cat no.
L-003243- 00-0002, Dharmacon, Lafayette, CO, USA) and scrambled negative siRNA
transfection control (siCT) (Cat no. 4390843, Thermo Fisher Scientific) were used for
transfections in Opti-MEM at a concentration of 10 µM. Media was replaced after 24hrs.
Cells were incubated for 72hrs and proliferation was measured every 24hrs by the addition
of PrestoBlue and measuring the resulting fluorescence values, which were then
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normalized. Immunoblotting was used to determine levels of knockdown for each cell line
relative to the siCT.

3.3.8

Study approval
A fresh surgical ATC specimen was received from the consenting patient with

diagnosed ATC who underwent surgery at the London Health Sciences Centre under a
Research Ethics Board approved protocol (REB# 108920; Appendix 2). Mice in the in
vivo study were handled in accordance with the AUP 1542 approved by the University
Health Network Animal Care Committee and the CCAC regulations (Appendix 3).

3.3.9

Establishment of a patient-derived xenograft model
A fresh tumour sample was obtained from the tumour tissue of a 70-year old female

with confirmed ATC (tumour (T) category 4, lymph node (N) category 1 and with distant
metastasis to the lung (M) category 1 – T4N1M1) who underwent surgery at the London
Health Sciences Centre. The ATC sample was received 15 minutes after open biopsy and
kept at 4°C in PBS until engraftment 24hrs post biopsy. The tumour specimen was then
divided into ~1mm3 pieces and implanted subcutaneously into the flank region of
NOD/SCID/IL2R2g-/- (NSG) male mice. Once tumours reached 1 - 1.5cm in size, mice
were sacrificed, and tumours were dissected from the flank, dissociated in culture medium
containing collagenase/hyaluronidase and DNASE 1 and passaged subcutaneously into five
mice per treatment (minimum 100,000 cells/mouse) in 1:1 Matrigel/PBS to generate
patient-derived xenograft (PDX) models. Once tumours were palpable, measurements with
calipers began.
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3.3.10

PDX drug treatment and specimen collection

Five xenografts were established per treatment and randomized to either
flavopiridol (7.5mg/kg/day) by intraperitoneal injection or a vehicle control (water). Mice
were treated for a period of 17 days (five days on, two days break in between) with the
treatment beginning at 14 days post injection until controls reached endpoint at day 35.
Control-arm mice were maintained until tumours reached a maximum size of 1.5 cm in
diameter or an alternative humane endpoint was reached as stated in the animal protocol.
Animals were observed daily for their overall health. Mice were evaluated for tumour size
and weight every 2 – 4 days. Individual tumour volumes were calculated using the formula:
[length x (width)2] x 0.52. When mice were sacrificed, tumours were dissected from flanks
and stored in formalin for formalin-fixed paraffin embedding (FFPE) and
immunohistochemistry (IHC). Hematoxylin and eosin (H&E) staining was carried out in
standard fashion at the Department of Pathology & Laboratory Medicine and the Molecular
Pathology Core Facility at Western University. Slides were scanned using an Aperio
ScanScope slide scanner.

3.3.11

Statistical analysis

A Student’s unpaired, two-tail t-test was performed where appropriate using
Prism® 7 Graphpad Software Macintosh Version (by Software MacKiev © 1994-2014
GraphPad Software, Inc). P values < 0.05 were considered statistically significant. P values
are defined as ns p > 0.05, * represents p < 0.05, ** represents p < 0.01, and *** represents
p < 0.001.

3.4 Results
3.4.1

Flavopiridol inhibits cell growth in ATC cell lines
Three ATC cell lines were treated over a ten-point concentration range between

0.0075 and 4µM flavopiridol for 48 hours, in biological duplicates. Of these cell lines, all
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three had an IC50 value below 1µM when calculated as an average of duplicates (Fig. 3.1A).
Three of these cell lines were selected for further in vitro studies, based on their IC50 values
– KMH2 (0.13 + 0.002 µM), BHT-101 (0.12 + 0.007 µM) and CAL62 (0.10 + 0.02 µM)
(Fig. 3.1A).
To evaluate whether flavopiridol had the potential to cause damage to normal
tissues, such as those adjacent to malignant tissue, we used the lung fibroblast cell line
IMR-90 as a normal control. When treated with a concentration range from 0.06 to 32µM,
the IMR-90 cell line did not appear to reach an IC50 (Fig. 3.1B). Brightfield microscopy
images were collected for KMH2, BHT-101 and CAL62 cell lines following treatment with
flavopiridol (125nM) for 24hrs. Fewer cells with a rounder morphology were observed to
be present for KMH2 and CAL62 cell lines (Fig. 3.1C).
To assess whether treatment of ATC cell lines with increasing concentrations of
flavopiridol affected the steady state protein levels or phosphorylation status of its reported
target (CDK9), immunoblotting was carried out. Treatment with flavopiridol for 24 hours
in CAL62 BHT-101 cells resulted in a decrease in phosphorylation of CDK9 (pCDK9).
We also assessed the changes in the anti-apoptotic regulator MCL1 as previous studies
have demonstrated a depletion of the anti-apoptotic protein MCL1 in response to
flavopiridol drug treatment (Yeh et al. 2018). A corresponding reduction of MCL1
expression was also observed (Fig. 3.1D).

3.4.2

Flavopiridol reduces colony formation and cell migration of
ATC cell lines
As flavopiridol has been reported to be cytostatic (Rixe & Fojo 2007), we next

assessed the clonogenic capabilities of CAL62 and BHT-101 cells, which are both
moderately sensitive to flavopiridol, when treated with 60 and 125nM concentrations of
flavopiridol with concentrations based on IC50 values for cell lines. For both cell lines,
flavopiridol treatment reduced clonogenic capabilities with a concentration of 125nM
compared to the untreated control, (p = 0.005 and p = 0.004 for BHT-101 and CAL62,
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Figure 3.1. Flavopiridol inhibits cell growth in ATC cell lines (A) Flavopiridol was
tested against 3 ATC cell lines, with 2 biological replicates per cell line. Cells were treated
with flavopiridol for 48hrs and plate readings were completed after incubation with Presto
Blue. Mean IC50 values are shown ± standard deviation. (B) Dose-response curve
demonstrating the sensitivity of the lung fibroblast cell line, IMR-90, over 10
concentrations (0.06 to 32µM) of flavopiridol with 2 biological replicates. (C) Brightfield
microscopy images of KMH2, BHT-101 and CAL62 cell lines with and without 125nM
flavopiridol treatment for 24hrs. Cells were seeded at a density of 150,000 cells per well
and treated with flavopiridol after 24hrs. Images were collected after 24hrs of drug
treatment. Scale bar represents 150 µm. (D) Immunoblot of CAL62 and BHT-101 cells
treated with flavopiridol for 24hrs. Cells were collected after drug treatment and whole cell
lysates were prepared with 20 µg total protein loaded per well.
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respectively) and this effect was not significant at a concentration of 60nM (p = 0.09 and
p = 0.06 for BHT-101 and CAL62, respectively) (Fig. 3.2A).
Flavopiridol has also been reported to inhibit cell migration by altering cell
adhesion leading to suppression of migration (Zocchi et al. 2018). Cell migration was
quantified using a transwell migration assay and fluorometric analysis, where CAL62,
BHT-101 and KMH2 cells were seeded into serum free media containing 60 or 125 nM
flavopiridol. When CAL62 cells were treated with 60 nM, there was a significant decrease
in cell migration as quantified by fluorometric analysis (OD540) with untreated being 0.78
+ 0.01 versus 0.65 + 0.03 (p = 0.04) (Fig. 3.2B). When treated with 125 nM flavopiridol,
migration decreased with an OD540 of 0.48 + 0.003 (p = 0.0007). For BHT-101, there was
a significant decrease in migration with an untreated OD540 of 0.95 + 0.07 versus 0.55 +
0.003 (p = 0.01) in the 125 nM flavopiridol treated cells (Fig. 3.2B). For the KMH2 cell
line, migration significantly decreased with flavopiridol treatment at a concentration of 60
nM from 0.83 + 0.05 untreated 0.64 + 0.02 (p = 0.04) (Fig. 3.2B).

3.4.3

Flavopiridol induces cell cycle arrest and apoptosis in vitro
We next used flow cytometry to assess the changes in cell cycle upon exposure to

flavopiridol (125nM) for 24hrs. Flavopiridol has previously been described as a cytostatic
agent, with the potential to induce apoptosis at higher concentrations (Shapiro et al. 1999).
The proportion of KMH2 cells in the control group in the G1/G0 phase were 64.4 + 1.7%,
however, with flavopiridol treatment, cells appeared to accumulate (84.2 + 4.8%) in G1/G0
(p = 0.03) (Fig. 3.3A). For CAL62 cells treated with 125nM flavopiridol, 35.9 + 1.9% of
cells were arrested in the G2/M phase compared to 19.6 + 1.0% in the vehicle-control group
(p = 0.01) (Fig. 3.3A). Likewise, BHT-101 cells also demonstrated cell cycle arrest in the
G2/M phase of the cell with 96.0 + 1.2% of cells were arrested in the G2/M phase compared
to 18.3 + 1.5% in the vehicle-control group (p < 0.0001) (Fig. 3.3A).
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Figure 3.2. Flavopiridol reduces colony formation and cell migration of ATC cell
lines. (A) Clonogenic assays comparing untreated and treated (60 and 125nM flavopiridol)
ATC cell lines after 7 days. Colonies were counted and graphed for 3 representative fields
from each well. The number of colonies were compared to the untreated control. (B) Cell
migration was quantified using fluorometric analysis. Cells were seeded into the top
chamber containing serum-free media at a density of 5x104 cells per chamber with either
0, 60 or 125 nM flavopiridol. Each chamber was then placed into a well containing media
with serum. Cells which migrated through to serum-containing media after 24 hours were
quantified using fluorometric detection as described using the standard protocol provided.
Fluorescence readings were completed using a microplate reader. * represents p < 0.05, **
represents p < 0.01, *** represents p < 0.001, ns = not significant, unpaired Student’s, twotail t-test.
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Figure 3.3. Flavopiridol treatment results in cell cycle arrest in vitro. (A) KMH2,
CAL62 and BHT-101 cells were exposed to the vehicle control or flavopiridol (125nM)
for 24hrs, with 3 biological replicates per cell line, prior to BrdU incorporation and labeling
with propidium iodide. A minimum of 10,000 events was counted and the proportion of
cells present in each phase of the cell cycle + standard deviation is shown.
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3.4.4

siRNA knockdown of CDK9 impairs ATC cell proliferation
Many kinase inhibitors are characterized as having off-target effects, making it

unclear what their true anti-cancer mechanism is (Zhang & Loughran 2011; Munoz 2017).
KMH2 and CAL62 cell lines were used for CDK9 siRNA knockdown (siCDK9) and level
of knockdown relative to the scrambled control (siCT) was quantified using
immunoblotting for both cell lines (Fig. 3.4A). To determine the involvement of CDK9 as
a target in ATC, siRNA-mediated knockdown was used to investigate the effect of target
knockdown on cellular proliferation. Knockdown of CDK9 in the KMH2 cell line
demonstrated a significant decrease in cell proliferation when measured at 72hrs (p = 0.01);
however, knockdown of CDK9 in CAL62 did not significantly affect cell proliferation (p
= 0.34) (Fig. 3.4B). We then sought to determine whether knockdown of CDK9 as a target
would result in an increase in resistance with a higher IC50 value of the siCDK9 cell line
relative to the siCT cell line. Overall, for the KMH2 cell line the siCT IC50 went from 0.100
µM to 0.096 µM with siCDK9 knockdown (Fig. 3.4C). Likewise, for the CAL62 cell line,
knockdown of CDK9 did not appear to make the cell line more resistant, with the IC50 in
the siCT going from 0.137 µM to 0.127 µM in the siCDK9 cell line (Fig. 3.4C).

3.4.5

Flavopiridol inhibits tumour growth in a PDX model of ATC
A primary tumour from a 70-year old female patient was used to develop PDX

models. The patient was diagnosed with ATC – tumour (T) category 4, lymph node (N)
category 1 and with distant metastasis to the lung (M category 1; Fig. 3.5A). The PDX
model was generated through implantation of 1mm3 tumour pieces into the hindflanks of
NOD/SCID/IL2R-/- (NSG) male mice as previously described. Once established, tumours
were passaged into 10 mice to provide 5 mice per treatment group. Mice were administered
a dose of flavopiridol (7.5 mg/kg/day) or vehicle control once daily for 5 consecutive days
with 2 days break in between for a total of 17 days (beginning at 14 days post-injection of
cells), until controls reached endpoint at day 35 post-injection. Tumour volume was
measured between groups over this same time period and at 27, 31 and 35-days post-
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Figure 3.4. siRNA knockdown of CDK9 impairs ATC cell proliferation. (A)
Immunoblot (20 µg total protein) of CDK9 expression in KMH2 and CAL62 cell lines
showing the siCT relative to the siCDK9 knockdown. (B) Changes in cell proliferation
with siRNA-mediated knockdown with Lipofectamine® RNAiMAX Reagent of CDK9
(siCDK9; 10 µM) relative to the scrambled control (siCT; 10 µM) in KMH2 and CAL62
cells. * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, ns = not
significant, unpaired Student’s, two-tail t-test. (C) Dose-response curves of KMH2 and
CAL62 cell lines comparing the siCT and siCDK9 cell lines treated with flavopiridol (0.06
– 4.00 µM) with their respective IC50 values.
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Figure. 3.5. Flavopiridol inhibits tumour growth in a PDX model of ATC. (A)
Characterization of patient specimen obtained for development of PDX model for
flavopiridol drug testing. Primary tumour was obtained from a 70-year old female with
diagnosed ATC stage T4N1M1. Five xenografts (per treatment) were generated and
randomized to either daily flavopiridol (7.5 mg/kg/day) by intraperitoneal injection or a
vehicle control (water). (B) Mice were treated with flavopiridol for a period of 17 days
(five days on, two days break in between) with the treatment beginning at 14 days post
injection until controls reached endpoint at day 35. (C) Mice were evaluated for tumour
weight (g) comparing the vehicle control group to the flavopiridol treated group at
endpoint. * represents p < 0.05, ** represents p < 0.01, *** represents p < 0.001, ns = not
significant, unpaired Student’s, two-tail t-test. (D) Representative IHC sections of the
primary tumour, vehicle and flavopiridol-treated specimens demonstrating H&E staining
in the PDX model of ATC.
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treatment there was a significant difference in tumour volume (mm3) for flavopiridoltreated PDX models when compared to the vehicle control (p = 0.002, p = 0.02 and p =
0.01, respectively) (Fig. 3.5B). Furthermore, when we assessed tumour weight at the end
of our study, we found that the vehicle control group had a mean tumour weight of 0.94 +
0.13 g and mice treated with flavopiridol showed a mean tumour weight of 0.46 + 0.17 g
(p = 0.02) (Fig. 3.5C). After completion of the study, tumours were excised from the mouse
models for FFPE and IHC studies. H&E slides showed consistent tumour cellularity across
the vehicle and flavopiridol-treated samples, with no visible differences in pathology (Fig.
3.5D).

3.5 Discussion
While rare, ATC is arguable the most lethal human cancer. Patients suffering from
ATC have little to no hope, particularly in the face of unresectable or metastatic disease
(Nikiforov & Nikiforova 2011; Bin Xu & Ghossein 2016b; Molinaro et al. 2017). This
disease often presents with dramatic symptoms and conventional therapies are typically
futile, with survival measured in months and sometimes weeks (Perri 2011; Sugitani et al.
2012). However, recent studies have focused on the utilization of small-molecule inhibitors
as a means of targeting specific genomic alterations to improve patient outcomes. In
particular, significant clinical responses of ATC patients to inhibitors such as vemurafenib,
sunitinib, and more recently combinations of therapies including dabrafenib and trametinib
have been approved for treatment for those with metastatic and nonresectable ATC with
BRAFV600E mutation status (Grande et al. 2013; Rosove et al. 2013; Subbiah et al. 2018).
Inhibition of the cell cycle using small molecule cell cycle inhibitors to
downregulate cell survival genes is a promising avenue for controlling the progression of
disease. In our study, we found that treatment with flavopiridol, a pan-CDK inhibitor with
the highest potency demonstrated against CDK9 (Boffo et al. 2018), demonstrated growth
inhibition as measured by decreased cell proliferation and also impeded colony formation
and cell migration. CDK9 specifically plays a critical role in the control of gene
transcription, allowing for transcriptional elongation and expression of genes including
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MCL1, which increases the survival of cancer cells (Boffo et al. 2018). The use of
flavopiridol as a CDK9 inhibitor demonstrated a reduction in expression of MCL1 in our
study, which is otherwise an apoptosis regulator, therefore affecting the survival of these
cells. Furthermore, previous studies have linked high MCL1 expression with acute myeloid
leukemia (AML) development in a murine model of disease (Boffo et al. 2018). Such
studies have also demonstrated relapse of disease with deletion of MCL1 and reduced cell
death in AML-afflicted mice (Bose & Grant 2013; Boffo et al. 2018).
We then attempted to uncover the mechanism responsible for the potency of
flavopiridol across our ATC cell line panel. In CAL62 and BHT-101 cell lines, treatment
of cells with 125 nM resulted in cell cycle arrest in the G2/M phase; while treatment of
KMH2 resulted in cell cycle arrest in the G0/G1 phase of the cell cycle. Interestingly,
flavopiridol has been demonstrated to be both cytostatic and cytotoxic in prostate,
esophageal, lung and head and neck carcinoma cell lines (Shapiro et al. 1999). Most
notably, cytotoxicity was most characteristically observed after prolonged exposure (48 –
72 hours) with as high of a dose as 500 nM and was often preceded by cell cycle arrest
(Shapiro et al. 1999).
We then used siRNA knockdown of CDK9 to determine the specificity of
flavopiridol and importance of CDK9 as a target in ATC. While we achieved knockdown
in KMH2 and CAL62 cell lines as demonstrated by immunoblot, only KMH2 demonstrated
a significant decrease in cell proliferation compared to the scrambled control. We then
treated control and knockdown cell lines with flavopiridol to determine whether there
would be a rightward shift in the dose-response curve indicative of a higher IC50 (more
resistant). Interestingly, we found that cell lines did not become more resistant. This
suggests that there is possibly a lack of selectivity for CDK9 specifically (Shapiro et al.
1999), and more targeted approaches warrant further investigation to improve future
clinical efficacy.
In this study, we were also able to establish a PDX model from primary tumour of
a patient with stage T4N1M1 disease. The use of PDX models using patient specimens are
a highly valuable entity for preclinical drug development because such PDX drug
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responses have been shown to strongly correlate with drug response of the original tumour,
making them highly useful for drug discovery efforts such as our own (Gao et al. 2015).
We examined changes in tumour volume over time for all models treated with flavopiridol
relative to the vehicle-treated arm. Overall, we found that at the time of sacrifice the
difference in tumour volume between the vehicle control and treated arms were 1588.91 +
290.69 mm3 versus 571.01 + 109.87 mm3, respectively. Likewise, tumour weight at
endpoint also demonstrated a significant decrease with flavopiridol treated having a tumour
weight of 0.46 + 0.17 g versus 0.94 + 0.13 g in the vehicle arm. When we looked at the
overall effect on PDX tissue architecture relative to the patient tumour reference tissue, we
found that H&E staining suggested a similar tissue architecture and consistent tumour
cellularity. Overall our PDX studies suggest that flavopiridol acts as an anti-tumour agent
in vivo, but warrants future studies, which may center on determining the potential
immunohistochemical changes between the vehicle and treated arms. Markers of interest
include Ki67 (proliferation) and E-cadherin (cell-cell adhesion), as well as changes in
PARP cleavage (indicative of apoptosis induction).
Collectively, our findings identify flavopiridol as a potent small molecule inhibitor
that delays progression of disease in both cell line studies and a PDX model of disease.
While flavopiridol demonstrated an effect both in vitro at nanomolar concentrations and in
vivo, it is evident that CDK9 inhibition alone is not the only mechanism contributing to
this effect and therefore, further work needs to be done to understand the effects of this
promising agent. Given the results from this study and the urgent need for therapeutic
options for patients facing ATC, further investigations are necessary to improve our
understanding of the clinical validity of this drug as an option for patients to delay disease
progression and improve overall patient outcomes.
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Chapter 4

4

Introduction of PIK3CAE545K into a papillary thyroid
cancer BRAFV600E cell line leads to disease progression

4.1 Abstract
Anaplastic thyroid cancer (ATC) is a rare, aggressive form of undifferentiated
thyroid cancer, which exhibits rapid progression and is almost universally fatal. ATC is
thought to arise from pre-existing well-differentiated thyroid cancer, most frequently
papillary thyroid cancer (PTC), due to acquisition of additional mutations. While PIK3CA
mutations are rare in PTC (0.5%), they are more common in ATC (18%) and tend to cooccur with BRAF mutations. This provided the rationale for our study, which was to
identify the potential role of PIK3CA mutations in the progression of disease from welldifferentiated to undifferentiated thyroid cancer. In our study, we transfected PIK3CAE545K
into the LAM1 cell line, which carries a BRAFV600E mutation. Overall, we found that the
transfected cell line (LAM1:PIK3CAE545K) proliferated faster and had a significantly
increased propensity to form colonies and migrate through a transwell membrane system
in vitro. We did not observe an increase in resistance of LAM1:PIK3CAE545K to
radiotherapy or etoposide chemotherapy compared to the parental line in vitro. Both the
parental and transfected lines were implanted into hind flanks of athymic nude mice as a
pilot study for the assessment of disease progression in vivo. While we found that tumour
weights and volumes tended to be higher in the LAM1:PIK3CAE545K group, these results
were not significant and emphasize a need for future studies with a larger sample size.
Collectively, this study provides evidence of a potential role for PIK3CAE545K in driving
disease progression from a well-differentiated to an undifferentiated thyroid cancer but
warrants further investigation.
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4.2 Introduction
Well-differentiated subtypes of thyroid cancer (papillary thyroid cancer, PTC;
follicular thyroid cancer; FTC) have a favorable prognosis when treated. In contrast,
anaplastic thyroid cancer (ATC) is a rare form of undifferentiated thyroid cancer which
progresses rapidly and has a mortality rate of almost 100% (Pinto et al. 2014; Bin Xu &
Ghossein 2016). Anaplastic thyroid cancer patients treated with surgery, radiation and
chemotherapy experience a median survival of approximately six months following
diagnosis, with some patients dying within days of diagnosis (Giuffrida & Gharib 2000;
Akaishi et al. 2011; Guerra et al. 2013; O’Neill & Shaha 2013). Arguably, ATC represents
the most lethal human malignancy.
One current model of thyroid carcinoma suggests that ATC arises from pre-existing
well-differentiated thyroid cancer (WDTC) following accumulation of additional genetic
events and producing a much more aggressive cancer (Xu & Ghossein 2016). In some
cases, patients diagnosed with ATC also have co-existing or a prior history of WDTC,
providing further evidence of its derivation from pre-existing thyroid cancer lesions. The
Cancer Genome Atlas (TCGA) Project has characterized the well-differentiated subtype
PTC as having a low frequency of genetic alterations, with singular, non-overlapping
driving mutations (Agrawal et al. 2014); however, the genetic basis of ATC is still very
poorly understood. Only in the past few years has there been progress in studying larger
numbers of tumour samples with cancer-related gene panels (Kunstman et al. 2015; Landa
et al. 2016; Pozdeyev et al. 2018).
Of these studies, Landa et al. (2016) identified a clustering of mutations in ATC
tumours, specifically those involving BRAFV600E and the PIK3CA canonical hotspot
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mutation E545K (Landa et al. 2016). While BRAFV600E has been demonstrated to be
present in a large proportion of PTC (59.7% ) and ATC (45%) patient tumours, mutational
changes in PIK3CA are only present in 0.5% of PTC patient samples and at a much higher
frequency of 18% in ATC (Agrawal et al. 2014; Landa et al. 2016). Interestingly, the
BRAF and PIK3CA mutations tended to co-occur in the ATC tumours, leading us to
hypothesize that the introduction of a PIK3CA mutation into a BRAF mutant PTC model
would lead to increased aggressiveness and dedifferentiation.

4.3 Materials and Methods
4.3.1

Cell lines and culture conditions
The LAM1 cell line, which is a confirmed BRAFV600E PTC cell line, was kindly

provided by Dr. Laura Marlow (Mayo Clinic, Jacksonville, Florida) (Copland et al. 2006).
The LAM1 cell line was cultured in DMEM/F12 media supplemented with 10% heat
inactivated FBS (GIBCO; Thermo Fisher Scientific, Carlsbad, CA, USA), penicillin
(100µg/mL) and streptomycin (100µg/mL) (Invitrogen; Thermo Fisher Scientific,
Carlsbad, CA, USA). The CAL62 cell line was purchased from DSMZ Cell Bank and
profiled using short tandem repeat (STR) profiling. The CAL62 cell line was cultured in
DMEM supplemented with 10% heat-inactivated FBS (GIBCO), 1% human serum
(Wisent, St. Bruno, Quebec, Canada), penicillin (100 µg/mL) and streptomycin (100
μg/mL) (Invitrogen).

4.3.2

Transfection of PIK3CAE545K into the LAM1 cell line
An expression vector containing mutant PIK3CA (PIK3CA-Exon9-E545K) (Cat

no. 16642; Addgene, Watertown, MA, USA) was used for transfection into the LAM1
parental PTC BRAFV600E cell line for stable PIK3CAE545K mutant over-expression studies
(with the mutant cell line denoted as LAM1:PIK3CAE545K). The parental cell line was
transfected using Lipofectamine 3000 Reagent (Cat no. L3000001, Thermo Fisher
Scientific) according to the standard protocol using 5µg of plasmid DNA. Cells were
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incubated overnight, and transfection media was replaced the following day with normal
cell line media. The following day, neomycin (G418) was added for selection at a
concentration of 300µg/mL to kill untransfected cells. The concentration of neomycin used
was predetermined for the LAM1 cell line using a standard kill curve.

4.3.3

Immunoblotting
Immunoblotting as completed as described with 20 µg protein loaded per well

(Pinto et al. 2018). Primary antibodies were prepared according to the manufacturer and
incubated overnight at 4°C with constant, mild agitation. PI3 kinase (p110a) (Cat no. 4249)
and a-tubulin (Cat no. 2125) antibodies were obtained from Cell Signaling Technology
(Whitby, ON, Canada). Membranes were incubated with peroxidase-conjugated anti-rabbit
secondary antibodies diluted 1:5000 for 1 hour at room temperature. Detection of target
proteins was performed using Luminata Forte Western HRP substrate (EMD Millipore,
Burlington, MA, USA). α-tubulin was used as a loading control.

4.3.4

Growth curves
Cells were seeded at a density of 2,400 cells per well into 96-well plates. Plates

were then read using PrestoBlue (Thermo Fisher Scientific) at 0, 24, 48 and 72 hours.
Fluorescence readings were completed using a BioTek Synergy Microplate Reader with
560nm excitation and 590nm emission wavelengths. An unpaired Student’s two-tailed ttest was used for statistical analysis, where comparisons were made between treated and
untreated samples for each time point. P values < 0.05 were considered to represent
statistically significant differences. Statistical analysis is displayed for the 72-hour time
point when compared to the control at the same time point.
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4.3.5

Dose-response curves
Cell lines were seeded into 96-well plates at a density of 2,400 cells per well and

incubated overnight at 37°C and 5% CO2. After 24 hours, cells were treated with Etoposide
(Cat no E1383; Sigma-Aldrich, Oakville, ON, Canada) using a concentration range of
0.125 to 32µM. After 72 hours, plates were read by incubating cells with PrestoBlue for 1
hour at 37°C and fluorescence readings were completed using a BioTek Synergy
Microplate Reader with 560nm excitation and 590nm emission wavelengths. To generate
dose-response curves, raw fluorescence data was loaded into Prism 7 GraphPad Software,
where the values were then normalized to the control samples and the average viability for
each concentration tested was calculated. In order to determine the half-maximal inhibitory
concentration (IC50), the normalized relative fluorescence units (RFU) of the etoposidetreated samples were calculated as a percentage of the mean RFU of the untreated samples.
Drug concentrations were then transformed to a logarithmic scale and IC50 values were
calculated using non-linear regression (curve fit).

4.3.6

Clonogenic assay and radiation response
LAM1 and LAM1:PIK3CAE545K cells were seeded into six-well tissue culture plate

at a density of 1,000 cells per well. Cells were incubated at 37°C for 10 days based on
colony formation of the parental cells with cell media changed every three days. Cells were
washed with PBS and fixed with 100% chilled methanol for 15 minutes. Following
methanol fixation, cells were stained with 0.5% crystal violet in 10% methanol/1x PBS for
a total of 10 minutes. Brightfield microscopy was used to visualize colony formation, with
a colony defined as being > 50 cells. Three representative fields per well were quantified
for the number of colonies. Mutant cells were compared to the parental control and p values
< 0.05 were considered to represent statistically significant differences in colony
formation.
LAM1 and LAM1:PIK3CAE545K cells were seeded at a density of 250 (0 Gy), 500
(1 Gy), 1000 (2 Gy) and 2000 (4 Gy) cells per well in six-well plates, with respective doses
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of radiation applied after 24 hours (N=3). Cells were incubated at 37°C for a one-week
period with cell media changed every three days. Cells were washed with PBS and fixed
with 100% chilled methanol for 15 minutes. Following fixation, cells were stained with
0.5% crystal violet in 10% methanol/1x PBS for 10 minutes. Stained colonies were
visualized using brightfield microscopy and quantified for colony numbers as described
above. The plating efficiency (PE) of cells that were untreated was also calculated. The
survival fraction was calculated and defined as the number of colonies that arose following
radiation treatment, and expressed in terms of PE (Franken et al. 2006).

4.3.7

Cell migration assay
Cell migration for LAM1 and LAM1:PIK3CAE545K cell lines were quantified using

a 24-well cell migration plate and fluorometric analysis (Cat no. CBA-100; Cell Biolabs
Inc, San Diego, CA, USA). The initial cell suspension was placed into the upper chamber
containing serum free-media at a density of 5x104 cells per chamber, with three biological
replicates. Cells were incubated at 37°C in order to allow migratory cells to pass through
the polycarbonate membrane through to the bottom of the chamber. Cells that stayed in the
upper chamber were considered to be non-migratory. Migratory cells were then dissociated
from the membrane of the chamber using the Cell Detachment Buffer provided in the cell
migration plate kit. Cells which migrated through were lysed and quantified using CyQuant
GR Fluorescent Dye provided in the same kit. Fluorescence readings were completed using
a BioTek Synergy Microplate Reader and representative images were collected using
brightfield microscopy.

4.3.8

Pilot study 1: an orthotopic mouse model of ATC
Athymic nude mice (Charles River Laboratories, Wilmington, MA, USA) were

maintained and handled in accordance with the University of Western Ontario animal use
protocol (AUP) 2015-045 (Appendix 3). The ATC cell line CAL62 was used for the
generation of orthotopic mouse models. CAL62 cells were grown with standard media,
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excluding antibiotic, and treated with Plasmocin (Invivogen) for two weeks prior to use in
mouse models. A total of 5x105 cells per mouse were prepared and injected into the thyroid
gland for each mouse (n = 5). Weight (g) measurements were taken once per week for a
total of nine weeks until mice were sacrificed. Thyroid glands were dissected and stored in
formalin for formalin-fixed paraffin embedding (FFPE) and immunohistochemistry (IHC)
with hematoxylin and eosin (H&E) staining.

4.3.9

Pilot study 2: a hind flank mouse model of thyroid cancer
disease progression
Mice were maintained and handled in accordance with the AUP 2015-045. We used

the cell line LAM1 and LAM1:PIK3CAE545K for the generation of cell line xenograft hind
flank models of disease (n = 5 per group). Both cell lines were cultured in DMEM/F12
media supplemented with 10% HI FBS and excluding penicillin and streptomycin. Cells
were treated with Plasmocin for two weeks prior to use in mouse models. A total of 1x106
cells were injected into the hind flank of each athymic nude mouse. Mice were weighed
twice weekly and tumour dimensions (length and width) were measured once weekly using
digital calipers after tumours were palpable. Individual tumour volumes were calculated
using the formula: [length x (width)2] x 0.52 (Ruicci et al. 2018). Mice were sacrificed at
14 weeks post-injection and tumours were dissected from flanks and stored in formalin for
FFPE preparation and future IHC studies.

4.3.10

Statistical analysis

A Student’s unpaired, two-tail t-test was performed where appropriate using
Prism® 7 Graphpad Software Macintosh Version (by Software MacKiev © 1994-2014
GraphPad Software, Inc). P values < 0.05 were considered statistically significant. P values
are defined as ns p > 0.05, * represents p < 0.05, ** represents p < 0.01, *** represents p
< 0.001 and **** represents p < 0.0001.
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4.4 Results
Transfection of PIK3CAE545K into LAM1 cells promotes
increased cellular proliferation, colony formation and cell
migration

4.4.1

In an attempt to study the progression of a thyroid cancer from a well-differentiated
to an undifferentiated cell state, we used the PTC cell line LAM1, which is a BRAFV600E
cell line (Copland et al. 2006). The LAM1 cell line was transfected with a plasmid
containing the PIK3CAE545K and immunoblotting confirmed the over-expression of
PIK3CA in the altered cell line (Fig. 4.1A). Images of the parental and transfected cell line
were collected 24 hours after plating using brightfield microscopy. Cells demonstrated a
morphology that appeared to be less elongated than the parental cell line, but still similar
in overall cell morphology (Fig. 4.1B). Furthermore, cellular proliferation at both 48 and
72 hours showed that LAM1:PIK3CAE545K had a significant increase in cellular
proliferation as measured using normalized relative fluorescence units (RFU) (p < 0.0001)
(Fig. 4.1C).
We then tested the ability of cells to form colonies and found that
LAM1:PIK3CAE545K demonstrated a significant increase in the number of colonies formed
after a two-week period with an average number of colonies of 7.33 + 0.58 in the parental
(LAM1) versus 11.00 + 1.00 in the mutant cell line (p = 0.005) (Fig. 4.2A). Furthermore,
when we investigated how cell migration was affected with the addition of PIK3CAE545K,
using a transwell system and fluorometric analysis, we found that cells transfected and
stably expressing PIK3CAE545K demonstrated a significant increase in their capacity to
migrate when compared to the parental cell line (p = 0.004) (Fig. 4.2B). Together this data
suggests that the addition of PIK3CAE545K in combination with the BRAFV600E in the
parental PTC cell line increases cellular proliferation, colony formation, and cell migration
in vitro.
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Figure 4.1. Introducing mutations into a BRAF-mutant PTC cell line leads to an
increase in cell proliferation. (A) Immunoblot analysis of the LAM1 cell line containing
the BRAFV600E-mutant alone and the LAM1 cell line with the PIK3CAE545K added. Cells
were collected and whole cell lysates were prepared with 20 µg total protein loaded per
well. α-tubulin was used as a loading control. (B) Brightfield microscopy images were
collected 24 hours after plating of the parental LAM1 cell line and the LAM1:PIK3CAE545K
cell lines. Cells were seeded at a density of 150,000 cells per well. (C) Cells were seeded
at a density of 2,400 cells per well and incubated for 24 hours. Cellular proliferation was
measured with the addition of PrestoBlue to cells, which were then incubated for one hour
prior to plate readings. Changes in cellular proliferation were measured at baseline, 24, 48
and 72 hours for both LAM1 and LAM1:PIK3CAE545K cell lines.
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Figure 4.2. The PIK3CAE545K mutation in a BRAF-mutant PTC cell line promotes
colony formation and cell migration, in vitro. (A) Clonogenic assay of LAM1 parental
and mutant cells seeded into six-well tissue culture plates at a density of 1,000 cells per
well. After 10 days, cells were fixed and stained with 0.5% crystal violet. Brightfield
microscopy was used to quantify colony formation, with a colony define as being > 50
cells. For quantification, three representative fields per well were counted for the number
of colonies and this was completed for both the parental and mutant cell lines. (B) Cell
migration was quantified using fluorometric analysis. Cells were seeded into the top
chamber containing serum-free media at a density of 5x104 cells per chamber and each
chamber was then placed in a well containing media with serum. Cells which migrated
through to serum-containing media after 24 hours were quantified using fluorometric
detection as described using the standard protocol provided. Fluorescence readings were
completed using a microplate reader and representative images were collected using
brightfield microscopy.
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4.4.2

PIK3CAE545K did not alter cell line resistance in response to
etoposide or radiation
ATC is typically characterized as nonresponsive to conventional therapies when

compared to other well-differentiated thyroid cancer subtypes (Smallridge et al. 2012;
Molinaro et al. 2017). We next chose to investigate potential changes in response between
LAM1 and LAM1:PIK3CAE545K in order to determine whether the addition of PIK3CAE545K
to the BRAFV600E background resulted in a cell line more resistant to clinically-relevant
therapy regimens. We first tested our cell lines with the chemotherapeutic drug etoposide
in order to determine whether the two cell lines demonstrated differential responses. We
found that there was no significant difference between the responses of the parental cell
line versus the LAM1:PIK3CAE545K cell line. The parental cell line had an IC50 of 0.99 µM
and the PIK3CAE545K mutant cell line demonstrated an IC50 value of 1.02 µM (Fig. 4.3A).
We then irradiated the cell lines with 1, 2 and 4 Gy to compare the overall response
between both cell lines, as ATC is considered to be radioresistant compared to the response
observed with PTC (Giuffrida & Gharib 2000; Smallridge et al. 2012). At a radiation dose
of 2 Gy, we found that there was a significant decrease in the survival fraction in the LAM1:
PIK3CAE545K cell line (p = 0.02), suggesting that cells are even less resistant than the
parental cell line at a radiation dose of 2 Gy (Fig. 4.3B). Collectively, this data suggests
that the overall response to conventional therapeutics, which includes treatment with the
chemotherapeutic agent etoposide and radiation, does not appear to change with the
addition of PIK3CAE545K in a BRAFV600E PTC cell line when tested in vitro.

4.4.3

Pilot study 1: an orthotopic mouse model of ATC
We used an orthotopic mouse model as a pilot study in order to determine whether

we could recapitulate disease progression and metastatic behaviour as observed clinically.
Mice were weighed twice per week and sacrificed when they began to demonstrate a rapid
decline in weight (g) between weeks 8 and 9 (Fig. 4.4A). During this time period, mice
also appeared pale in colour, lethargic and less responsive than observed prior to week 8.
We were surprised that tumours were not palpable in the neck region when mice were alive;
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Figure 4.3. The LAM1:PIK3CA-mutant cell line does not exhibit increased resistance
in response to conventional therapies in vitro. (A) LAM1 parental and mutant cells were
seeded into 96-well plates at a density of 2,400 cells per well. After 24 hours cells were
treated with an extended dose range of etoposide concentrations from 0.125 to 32µM and
plate readings were completed after 72 hours and incubation with PrestoBlue. Doseresponse curves were generated using Prism 7 GraphPad Software and IC50 values were
calculated for each cell line. (B) The LAM1 parental cell line and the LAM1: PIK3CAE545K
mutant cell line were seeded at a density of 250 (0 Gy), 500 (1 Gy), 1000 (2 Gy) and 2000
(4 Gy) cells per well, with respective doses of radiation shown in parenthesis applied after
24 hours. Cells were incubated for a one-week period with cell media changed every three
days. Following this incubation period, cells were fixed and stained with 0.5% crystal
violet. Brightfield microscopy was used to visualize colony formation and colonies were
quantified, with a colony defined as being > 50 cells. Quantification was completed by
calculating the plating efficiency for each control cell line and the respective survival
fraction as described by Franken et al. 2006).
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Figure 4.4. Pilot study 1: an orthotopic mouse model of ATC. (A) A total of five
athymic nude mice were used for the generation of an orthotopic mouse model to study
thyroid cancer disease progression. A total of 5 x 105 cells (CAL62) per mouse were
injected into the thyroid gland, posterior to the strap muscles. Mice were sacrificed at nine
weeks post-injection when body weight (g) began to rapidly decline. (B) Thyroid tumours
were not palpable until mice were sacrificed, and the neck region was dissected nine weeks
post-injection of the CAL62 cells. (C) Nine-weeks post-injection, mice were sacrificed,
and thyroid glands and organs of interest were FFPE for H&E staining. (D) FFPE thyroid
glands were characterized to observe the invasiveness of ATC in thyroid tissue and the
effect of adjacent structures of the neck including the trachea and esophagus. (E) FFPE
organs including the spleen, lungs and liver were characterized to determine whether there
was any evident metastases or commonality to locations as is frequently observed in the
clinical manifestation of ATC.
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however, when mice were sacrificed, tumour tissue was observed growing around the
thyroid region of the neck resulting in airway and esophageal obstruction (Fig. 4.4B). To
collect tumour specimens, the thyroid gland, including the tumour-encased trachea and
esophagus, was dissected in addition to the mouse lungs, liver and spleen and prepared for
FFPE and subsequently stained using H&E (Fig. 4.4C). H&E sectioning of the mouse
thyroid gland demonstrated infiltration of the CAL62-derived tumour into the thyroid and
adjacent organs in our orthotopic mouse model (Fig. 4.4D). Moreover, there did not appear
to be ATC infiltration and metastases to other distant organs as noted in the H&E sections
of the spleen, lungs and liver tissue (Fig. 4.4E). Overall, while we found this model useful
to study ATC and its manifestation locally in the neck region, we chose to move forward
with a hind flank model in order to more accurately palpate and measure tumour growth
over time.

4.4.4

Pilot study 2: the role of PIK3CAE545K in driving disease
progression in a hind flank model of disease
We then completed a pilot study using both the LAM1 and LAM1:PIK3CAE545K

cell lines in order to determine whether there were any changes in tumour growth over
time, tumour volume, and distant metastasis. In both groups, two mice did not appear to
develop tumours at all over the duration of our 14-week study (mouse ID 5-N and 1-L in
the LAM1 group and mouse ID 5-N and 2-R in the LAM1:PIK3CAE545K group) (Table
4.1). Within the LAM1 group, two mice grew tumours on both flanks (3-B and 4-2L), while
mouse 2-R only grew a tumour on the right flank (Table 4.1). Likewise, in the
LAM1:PIK3CAE545K group, only mouse 3-B grew a tumour on both flanks, while mouse
1-L and 4-2L grew single tumours on the left flank (Table 4.1). Tumours were dissected,
weights were recorded in milligrams (mg) and stored in formalin for FFPE block
preparation and future IHC studies. Representative images were taken for dissected
tumours from both LAM1 and LAM1:PIK3CAE545K groups (scale provided in millimeters;
mm) (Fig. 4.5A). Mouse lungs were also dissected for FFPE preparation from one mouse
from each group with the largest tumour burden (data not shown).
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Table 4.1. Pilot study 2: a hind flank model of disease progression. LAM1 and
LAM1:PIK3CAE545K cell lines were used for the generation of cell line xenograft hind flank
models of disease (n = 5 per group). A total of 1x106 cells were injected into the hind flank
of each athymic nude mouse. Mice were weighed twice per week and tumour dimensions
(length and width) were measured once weekly when tumours were palpable using digital
calipers. Tumour weights (mg) were measured and collected after dissection.
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Of interest in the LAM1:PIK3CAE545K group, mouse 1-L had both the largest
tumour volume and also an enlarged lymph node located on the upper left side on the
ventral surface of the mouse (Fig. 4.5A). When we measured tumour weights of the
dissected specimens, we found that there were no significant differences between groups
(p = 0.66), although the average tumour weight in the LAM1:PIK3CAE545K group was
higher at 784.00 + 387.72 mg versus 609.00 + 674.41 mg in the parental group (Fig. 4.5B).
Similarly, we found that the mean tumour volume was higher in the LAM1:PIK3CAE545K
group at 1202.14 + 544.50 mm3 versus the parental group, which was 573.49 + 575.46
mm3, however this trend was not significant (p = 0.16) (Fig. 4.5C). Collectively, the data
presented in this pilot study suggests that tumours in the LAM1:PIK3CAE545K group appear
to trend towards a larger tumour weight and volume, although sample size should be
expanded in the future in order to power for this study appropriately.

4.5 Discussion
While well-differentiated thyroid cancer subtypes are the most prevalent and have
a favourable prognosis when treated with conventional systemic therapies, the
undifferentiated subtype ATC is rare and arguably the most lethal human cancer. Patients
diagnosed with ATC have little to no hope for cure, particularly in the face of unresectable
or metastatic disease (Nikiforov & Nikiforova 2011; Bin Xu & Ghossein 2016; Molinaro
et al. 2017). By the time of presentation, this disease often exhibits dramatic symptoms and
conventional therapies are typically futile with survival times measured in months and
sometimes weeks (Perri 2011; Sugitani et al. 2012). Little is known about disease
development and progression of ATC, however a current model of thyroid cancer suggests
that ATC arises from pre-existing WDTC, with addition genetic events and an increased
mutation burden, resulting in a more aggressive thyroid cancer subtype (Bin Xu &
Ghossein 2016).
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Figure 4.5. Pilot study 2: A hind flank mouse model of disease progression. (A)
Mice were sacrificed at 14 weeks post-injection and tumours were dissected from
flanks and stored in formalin for FFPE preparation and IHC. (B) Dissected tumours
were weighed (mg) for each specimen and compared between cell line groups. (C)
Individual tumour volumes of dissected specimens were calculated using the formula:
[length x (width)2] x 0.52 and compared between cell line groups.
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In our study, we introduced the activating mutation PIK3CAE545K, which has been
demonstrated to be present in ATC at a higher proportion (18%) and rare in PTC (0.5%),
in order to understand whether this genetic change may in part, contribute to the
progression of disease (Landa et al. 2016; Leontiadou et al. 2018). A previous study of
ATC by Landa et al. (2016) has identified the co-occurrence of BRAFV600E and
PIK3CAE545K mutations in a proportion of ATC tumour specimens (Landa et al. 2016),
which led to the rationale of our study to determine whether the PIK3CAE545K mutation in
combination with the BRAFV600E contributes to the progression of disease from PTC to
ATC. The canonical hotspot PIK3CAE545K mutation is described in the literature as being
an activating mutation resulting in constitutive oncogenic activity (Meyer et al. 2013).
Overall, we found that with the addition of the PIK3CAE545K mutation, the LAM1 cell line
demonstrated a significant increase in cellular proliferation and an increase in both colony
formation and cell migration in comparison to the parental cell line. The demonstrated
increase in migratory behaviour appears to mimic the clinical manifestation as
approximately 50% of ATC cases present with distant metastases and approximately 25%
of patients develop metastases over the course of the disease, which overall provides
further evidence for a role of PIK3CAE545K in the progression of disease in our cell line
model.
The PIK3CAE545K mutation has been demonstrated to confer resistance to both
cisplatin and cisplatin plus radiation in cervical cancer cell lines, which are heterozygous
for the mutation in comparison to cells expressing wild-type PIK3CA or those with
PIK3CA depleted (Arjumand et al. 2016). This is of interest to our study as ATC is
characterized as being nonresponsive to standard therapeutics and so we sought to
determine whether the PIK3CAE545K mutation had any related role in our
LAM1:PIK3CAE545K cell line. Overall, when we tested our cell lines against a standard
chemotherapeutic agent (etoposide) and radiation therapy, we found that there was no
significant difference in the overall response to both agents when used separately compared
to the parental cell line. Together this data suggests that while overall resistance of the
mutant cell line did not change in vitro, the PIK3CAE545K mutation in combination with the
BRAFV600E may not confer resistance to standard treatments in ATC.
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We then completed a pilot in vivo study to determine whether an orthotopic model
of disease would be feasible in order to study the progression of disease. Like other
orthotopic studies with ATC cell lines, we found that our model had a demonstrated ability
to recapitulate local invasion as observed in aggressive thyroid cancers (Antonello &
Nucera 2013; Sewell et al. 2013); however, the inability to measure tumour volume over
time resulted in us moving forward with a hind flank model instead of the orthotopic model
to study disease progression. Our initial hind flank model included a sample size of n = 5
per group, with the two groups being LAM1 and LAM1:PIK3CAE545K. Between both
groups, the average tumour size and weight was higher in the LAM1:PIK3CAE545K line,
however this difference was not statistically significant. In the future, a study including a
larger sample size is necessary in order to draw conclusions regarding progression
attributed to the addition of the PIK3CAE545K mutation.
Future studies will focus on the IHC of FFPE tumour specimens dissected from the
in vivo hind flank study in order to determine whether there are any cellular changes,
characteristic of cell dedifferentiation as observed in ATC. Specifically, the
dedifferentiation of cells associated with the progression of disease in ATC has been shown
to result in the loss of IHC markers and this aids in the diagnosis of ATC in order to
characterize changes in epithelial differentiation (Smallridge et al. 2012). The American
Thyroid Association guidelines for ATC describes the use of IHC markers with fine needleaspiration or core biopsy, for identification and diagnosis of ATC. The preservation of IHC
markers or epithelial and thyroid differentiation including thyroglobulin (Tg), thyroid
transcription factor-1 (TTF-1), paired box protein Pax 8 (PAX8) and B-catenin, are
routinely used for diagnosis of ATC as the poorly/undifferentiated nature of ATC possesses
similarity to other malignancies (e.g. large cell lymphoma, medullary carcinoma,
metastatic carcinoma and metastatic melanoma) and can usually result in differential
diagnosis (Smallridge et al. 2012). In some cases, the presence of well differentiated or
poorly differentiated thyroid cancer co-existing with ATC may demonstrate preserved IHC
staining of markers as previously mentioned, which further aids in making a definitive
diagnosis while ruling out metastatic disease and other nonepithelial malignancies
(Smallridge et al. 2012; Molinaro et al. 2017).

102
ATC is a rare type of thyroid cancer and is very poorly understood to date. By
studying which genes are involved with driving more indolent forms of thyroid cancer
towards an aggressive state, we can better understand how the emergence of such genetic
changes driving disease progression can be targeted in order to strategize and make the
most beneficial recommendations regarding a patients’ personalized treatment plan.
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Chapter 5

5

Overall Discussion

5.1 Overview
The genomic characterization of PTC has revealed a simple mutational landscape
comprised of a low mutation burden with the vast majority of tumours containing single
canonical driver mutations (e.g. BRAFV600E, NRASG12V or a kinase gene fusion) (Agrawal
et al. 2014). In contrast, recent studies, including our own genomics study presented in
Appendix 1, have demonstrated a markedly more complex genomic landscape of ATC
containing multiple oncogene mutations and alterations in tumour suppressor genes
(Kunstman et al. 2015; Jeon et al. 2016; Landa et al. 2016; Pozdeyev et al. 2018). These
studies have identified genes present at a higher mutation frequency in ATC, suggesting
that these genomic changes may have contributed to driving the progression of disease.
ATCs are frequently treatment refractory and almost universally fatal. The aggressive
nature and rapid growth of ATC tumours into surrounding vital structures, with frequent
distant metastases, and the characteristic chemo- and radio-resistance make ATC a difficult
disease to treat. Combinations of kinase inhibitors, specifically combined BRAF and MEK
inhibitors, have demonstrated exciting patient responses (Subbiah et al. 2018), however
the identification of additional highly active kinase inhibitors are needed for this disease.
The use of high-throughput screening to identify candidate therapeutics is an active area of
research involving large panels of small molecule inhibitors as an initial step for drug
discovery. With the identification of drug ‘hits’, promising compounds can then be
validated in vitro and in vivo using preclinical models prior to moving into clinical
development.
My research has focused on utilizing high-throughput screening for early stage drug
discovery (Appendix 1, Fig. 7B) and investigating two separate candidate therapeutic
agents (Chapters 2 and 3). In Chapter 4, I undertook a proof-of-principle study to
investigate the progression of lethal undifferentiated thyroid cancer from the PTC state to
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ATC. In particular, I introduced a canonical PIK3CA mutation (E545K) into a BRAFmutant cell line to experimentally test the progression of disease (Chapter 4). Taken
together the overall goal of my research has been to expand our understanding of disease
progression of thyroid cancer to the ATC disease state and identify candidate therapeutics
in order to better understand which patient populations may be at risk for developing ATC
and improve patient outcomes.

5.2 Summary of Findings
I began this investigation by interrogating a panel of 13 ATC cell lines with 320
kinase inhibitors using high-throughput screening (Appendix 1, Fig. 7B). For each
compound tested, a total of six concentrations were used in order to generate half-maximal
inhibitory concentrations. Another measure of activity (or specificity), the activity area, for
each cell line/compound combination was also determined. The high-throughput screening
of the kinase inhibiting compounds identified eight drug compounds that were capable of
limiting cell growth in at least 10 out of the 13 cell lines. I chose to study the inhibitory
action of two of these “hits”: lestaurtinib (JAK2 inhibitor) and flavopiridol (CDK
inhibitor), both with activity previously unexplored in thyroid cancers. Overall the use of
high-throughput screening demonstrated its usefulness for early-stage drug discovery and
identification of candidate therapeutic agents, however, follow-up studies and preclinical
models were necessary in order to validate the findings observed.
In the first data chapter (Chapter 2), I studied the JAK2 kinase inhibitor lestaurtinib
in order to determine the efficacy of this drug in vitro and in vivo. In the high-throughput
screen completed with 320 kinase inhibitors and 13 ATC cell lines, I identified lestaurtinib
as being highly potent across the cell line panel (Appendix 1, Fig. 7B), with significant
anti-proliferative effects at nanomolar concentrations. When testing the effect of
lestaurtinib on otherwise aggressive ATC cell lines, I found that lestaurtinib impeded cell
migration using scratch-wound assays and the ability to form colonies from single cells in
colony formation assays. Lestaurtinib demonstrated a cytostatic effect across the cell line
panel and cells treated with this drug accumulated in the G2/M phase of the cell cycle. I
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then examined the effect of lestaurtinib in a chick chorioallantoic membrane xenograft
model with the tumours grown using the ATC cell line CAL62 and determined that
treatment with lestaurtinib resulted in both a significant decrease in tumour volume and
tumour vascularity. Overall, lestaurtinib demonstrated significant anti-proliferative effects
and potential anti-angiogenic activity that warrants further investigation as a targeted
therapy for ATC.
In the second data chapter (Chapter 3), I studied the effects of the cell cycle
inhibitor flavopiridol, which was also identified as being an anti-proliferative agent in the
initial high-throughput screen (Appendix 1, Fig. 7B). Screening of the ATC cell line panel
with the library of kinase inhibitors demonstrated that the majority of cell lines had a
nanomolar half-maximal inhibitory concentration, which was not observed in the noncancerous cell line IMR-90. Further, treatment of cells with flavopiridol resulted in
decreased levels of the cell cycle proteins, specifically phosphorylated CDK9 and MCL1,
induced cell cycle arrest and impeded the ability of cells to form colonies and migrate in
vitro. A single primary tumour from a patient diagnosed with ATC was used to generate a
PDX model to test flavopiridol in comparison to the vehicle control. Overall, treatment
with flavopiridol resulted in a decreased in tumour weight and volume when observed up
to 35 days. Collectively, this data suggests that cell cycle inhibition via flavopiridol may
be a promising avenue for treatment of ATC and warrants further investigation to
understand its full potential.
Finally, Chapter 4 focused on understanding the progression of disease from PTC
(well-differentiated) to ATC (undifferentiated) to determine whether over-expression of
the canonical hotspot E545K mutation of PIK3CA influences disease progression. In this
study, I introduced PIK3CAE545K, which has been demonstrated to be present at a much
higher mutation frequency in ATC than in PTC, into a PTC (BRAFV600E) cell line in order
to understand whether this genetic change may be partly responsible for the progression of
disease. Stable PIK3CAE545K over-expression studies were completed using the PTC cell
line LAM1 (BRAFV600E) (Copland et al. 2006). Overall, LAM1 cells overexpressing
PIK3CAE545K had an increased proliferation rate, tendency to form colonies and migratory
capacity when compared to the parental cells. Furthermore, ATC is characterized as being
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mostly inoperable and resistant to conventional therapies such as chemotherapy and
radiation, and so I sought to investigate whether the LAM1 cells transfected with
PIK3CAE545K would be more resistant to conventional therapeutic strategies including the
chemotherapeutic agent etoposide and the response to radiation exposure. When treated
with etoposide, there was no significant difference in the susceptibility of cells to etoposide
suggesting that the PIK3CAE545K mutation did not actually alter the sensitivity of cells to
this chemotherapeutic agent. With respect to radiation response, cells overexpressing
PIK3CAE545K did not demonstrate an increased resistance to radiation as seen with the
overall decrease in survival fraction at 2 Gy. Lastly, I tested an orthotopic model of disease
using the ATC cell line CAL62 as a pilot study to determine whether such a model would
aid in studying the clinical manifestation of disease as observed in ATC patients. Overall,
I found that this model was beneficial for studying the infiltration of disease proximal to
the thyroid gland, however, monitoring changes in tumour growth over time proved to be
challenging. Tumours were not palpable in the neck region and the mice in this study
exhibited an abrupt loss of weight between weeks 8 and 9 and a decline in overall health.
I then used a hind flank model as a pilot study to study disease progression between the
two cell lines. Overall, this study showed that tumours with the PIK3CAE545K mutation
tended to have higher volumes, however this trend was not significant.

5.3 High-Throughput Screening for Early Stage Drug
Discovery
The use of conventional therapies (e.g. surgery, chemotherapy and radiation) in
treating ATC has not significantly improved patient outcomes and to date, there are no
long-term effective therapeutic options available for those diagnosed (Saini et al. 2018).
While a multimodal approach to treatment is recommended and can provide local control
in a small cohort of patients, these treatments are ineffective in those with advanced,
metastatic disease (Smallridge et al. 2012; Molinaro et al. 2017). In recent years, the focus
of using tyrosine kinase inhibitors to inhibit otherwise aberrant pathway activation has been
helpful in blocking enzymatic action of tyrosine kinases and is being evaluated for potential
treatments in many different cancer types including thyroid cancers (Molinaro et al. 2017;
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Subbiah et al. 2018; Harris et al. 2019). The identification of targeted therapies with the
goal of correlating genomic features can be accelerated greatly using high-throughput
screening technologies (Broach & Thorner 2009).
Using high-throughput screening, I was able to screen 320 drugs at six doses for all
13 ATC cell lines, with two biological replicates. The efficacy of these inhibitors was
determined by calculating the activity area (Barretina et al. 2012), with inhibition being
defined as a threshold of activity area that was greater than 0.5. Two inhibitors (NVPBEZ235 and Staurosporine) inhibited growth across all 13 cell lines, with an activity area
of greater than 0.6 (Appendix 1, Fig. 7B). Staurosporine is regarded to be a positive control
of apoptosis acting as a potent, non-selective inhibitor (Gani & Engh 2010). Further, NVPBEZ235, which was found to be highly inhibitory across our cell line panel, is a dual
PI3K/mTOR inhibitor that has previously been shown to have a synergistic effect with
cisplatin in head and neck squamous cell carcinoma (Hsu et al. 2018). In ATC this may be
particularly effective, specifically in the context of our thyroid cancer progression studies,
which demonstrate that the addition of a PIK3CA mutation to PTC cells of a BRAF-mutant
background become more aggressive relative to the parental cell line (Chapter 4).
Furthermore, six other compounds inhibited growth in at least 10 cell lines
(Appendix 1, Fig. 7B). These inhibitors included lestaurtinib (JAK2 and FLT3 inhibitor),
alvocidib (flavopiridol; pan-CDK inhibitor), PI-103 and PIK-75 (both are PI3K inhibitors),
A-443654 (Akt inhibitor) and JNJ-10198406 (Appendix 1, Fig. 7B). In Chapter 2, I
focused on the study of lestaurtinib as a JAK2 inhibitor, which has been previously untested
in ATC. JAK kinases function through an association with cytokine receptors, resulting in
JAK kinase phosphorylation and activation, subsequent phosphorylation of cytokine
receptors, followed by the phosphorylation of STAT proteins downstream (Levine et al.
2007). In recent years, JAK2 mutations have been described where Pozdeyev et al. showed
that in their cohort of ATC specimens, there was a significantly higher percentage of
genomic alterations of JAK2 compared to differentiated thyroid cancer (p = 0.03)
(Pozdeyev et al. 2018). Furthermore, Khan et al. completed a comprehensive genomic
profiling of 90 ATC specimens, which showed the emergence of JAK2 mutational changes,
which were found to correlate with patient age, where patients over the age of 70 showed
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an increase in the frequency of JAK2 mutations (Khan et al. 2019). To date, targeting JAK2
in ATC has not been characterized leading us to conclude that this may be a promising
therapeutic approach in the future for correlating drug response with mutation status.
In Chapter 3, I focused on the study of flavopiridol which functions as a pan-CDK
inhibitor, with an especially high potency as a CDK9 inhibitor (Boffo et al. 2018). CDK9
is involved with regulation of gene transcription elongation and messenger RNA (mRNA)
maturation, in addition to other physiological processes (e.g. differentiation and apoptosis)
and dysregulation of this pathway has been implicated in a number of hematologic
malignancies and solid tumours (Boffo et al. 2018). In the context of ATC, flavopiridol is
of particular importance and warrants further investigation, specifically because it
demonstrates a high potency in our ATC cell lines and previous studies in esophageal and
ovarian cancer cell lines have identified flavopiridol as a radiosensitizer (Raju et al. 2003;
Sato et al. 2004). Collectively, this suggests that flavopiridol may be particularly beneficial
in the context of ATC as a combination therapy, as ATC is otherwise characterized as being
radioresistant (Smallridge et al. 2012; Molinaro et al. 2017).
Ideally, being able to complete follow-up drug testing of candidate therapeutics
identified using high-throughput screening is highly beneficial in a preclinical patientderived xenograft model. Unfortunately, because ATC is infrequently operable, the
collection of tumour tissue from patients is not always possible. This is why ATC cell line
models are most commonly used as preclinical models of disease. While cell line
xenografts are useful tools for drug testing, they may not always recapitulate the drug
response as demonstrated by the original patient tumour. This could possibly be attributed
to the effects from serial passaging in culture and an increase in mutational burden acquired
over time. In our drug study of flavopiridol, we obtained ATC patient specimen and noted
a similar potent in vitro response to drug treatment. Ongoing IHC studies are focusing on
the characterization of markers associated with proliferation and apoptosis induction in
order to determine how these traits are affected in vivo, and whether they compare to the
observed in vitro response.
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Ultimately, high-throughput screening in the context of drug discovery in ATC has
demonstrated its practicality in identifying potent agents that may be further validated in
vitro and using preclinical models of disease in vivo (Broach & Thorner 2009).
Collectively, the benefits of high-throughput screening include having the ability to
complete large-scale screens of drug compounds, which may be known to be active across
other disease-types but may remain relatively unknown for diseases such as ATC. This
technology is especially useful for an aggressive and rare disease like ATC where there are
otherwise no other effective therapies and the identification of new therapies can
potentially prolong longevity and improve patient outcomes.

5.4 Identification of Genetic Alterations Involved in the
Progression of Disease
Evidence suggests that some cases of ATC may be derived from WDTC with the
accumulation of genetic changes resulting in an overall increase in mutation burden
(Kondo et al. 2006; Bin Xu & Ghossein 2016). In some cases, those diagnosed with ATC
also have simultaneous areas of WDTC, which suggests its derivation from pre-existing
thyroid cancer lesions (Smallridge et al. 2012). A current model of thyroid cancer suggests
that ATC arises from indolent and pre-existing WDTC, with additional genetic events and
an increased mutation burden, resulting in a more aggressive thyroid cancer subtype (Bin
Xu & Ghossein 2016).
The rationale of our study presented in Chapter 4 was to use a BRAF-mutant PTC
cell line (well differentiated; LAM1) and introduce a PIK3CA (E545K) mutation, which
has been demonstrated in the literature to be present at a high mutational frequency in ATC
in comparison to PTC (Landa et al. 2016; Pozdeyev et al. 2018). In our study, we found
that the addition of PIK3CAE545K in a BRAF-mutant PTC cell line resulted in an overall
increase in characteristics associated with disease progression. This included an increase
in cell proliferation, colony formation and cell migration when compared to the parental
PTC cell line. Furthermore, ATC is also characteristically known to be nonresponsive to
conventional therapies, and so we sought to determine whether cells with the additional
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PIK3CA mutation would demonstrate a resistant response upon exposure to a
chemotherapeutic agent (etoposide) or radiation therapy when compared to the parental
BRAF-mutant cell line. With both modalities of treatment (separately), there was no
significant difference in the response rate between both cell lines. Future studies may focus
on the use of a preclinical mouse model of disease and understanding how tumour
progression and growth is affected (in response to treatment) with the addition of the
PIK3CA mutation.
While the pilot study presented in Chapter 4 did not test this, I used a preclinical
mouse model to determine how tumour growth and metastases differed between these two
groups. Overall, I found that tumours over-expressing PIK3CAE545K tended to have a higher
volume, but this trend was not significant. Of interest, each group only had an n=5 and
tumours only grew in three mice per group. With this in mind, future studies warrant larger
group sizes in order to draw conclusions with the appropriate statistical power.
By understanding the importance of which genes are involved with driving more
indolent forms of thyroid cancer towards an aggressive state, we can better understand how
the emergence of such genetic changes driving disease progression can be targeted. This
can help us to understand how this disease can be targeted in order to strategize and make
the most beneficial recommendations regarding a patient’s personalized treatment plan.
Furthermore, understanding which mutations are involved with the progression of disease
can prove to be a highly useful tool in understanding which patient populations may be at
risk for developing ATC in the future. If we know that ATC is initially derived from PTC,
the knowledge of which mutations are driving disease progression can direct treatment of
those diagnosed with PTC towards more frequent surveillance to combat the accelerated
progression of disease as observed in ATC.

5.5 Limitations
The data presented throughout this thesis describes the practicality of highthroughput screening for drug discovery in ATC and the resulting identification of
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candidate therapeutic agents. Furthermore, this work includes the investigation of genomic
changes that may in part contribute to the aggressive progression of disease, namely
PIK3CA. While the results presented in this thesis represent significant contributions to the
field of ATC research, there still remains a major limitation which exists in that ATC is
such a rare and aggressive disease. Overall, this limits the access to clinical samples,
making it difficult to comprehensively study the genomic changes underlying this disease
and the response to candidate therapeutic agents using patient-derived samples.
One of the limitations of this study in particular includes the use of the chick
chorioallantoic membrane model as an ex vivo model for drug testing. Overall, this model
possesses many benefits, including its accessibility to vasculature to study angiogenesis,
the rapid tumour growth that can allow for screening of pharmacological agents in a
shortened timeframe, and overall cost-effectiveness in comparison to a mouse model
(Gabrielli & Accili 2010; Nowak-Sliwinska et al. 2014). However, relative to an in vivo
mouse model, many limitations for this model do exist including the simplicity and lack of
anatomical similarity to higher order models of disease (Nowak-Sliwinska et al. 2014).
Likewise, for studies which extend after 15 days, there can be the presence of non-specific
inflammatory reactions resulting in angiogenic responses making it difficult to actually
determine the cause of the increase in vascularity (Ribatti 2014). In general, the chick
chorioallantoic membrane model is also highly sensitive to environmental changes,
including oxygen levels, pH and osmolarity, potentially rendering this model highly
sensitive to outside influences and prone to premature death (Ribatti 2014).
Another limitation is regarding the in vivo pilot study completed in Chapter 4. For
the study described in Chapter 4, I used the parental and PIK3CA-mutant cell lines and
injected 1x106 cells per flank in athymic nude mice with an n=5 per group. Only three mice
per group grew tumours. Overall, I found that the tumour volume average was higher in
the PIK3CA-mutant group versus the parental group, however this trend was not
significant. As a pilot study, I found these results to be informative and provided us with
the knowledge that the cell lines were in fact tumorigenic. Likewise, because this study
was completed as a pilot study and not adequately powered with an n=5 per group (with
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only three mice per group growing tumours), future studies will warrant an increase in the
number of mice per group in order to draw valid conclusions.
While high-throughput screening is beneficial for a variety of reasons as previously
described, it also possesses limitations in that the initial drug discovery step is completed
with the use of cell lines. Cancer cell lines are the backbone of cancer research; however,
they are known to acquire genetic alterations over time with serial passaging in culture
resulting in unknown functional consequences. A recent study demonstrated that 27
versions (‘strains’) of the estrogen receptor (ER)-positive breast cancer cell line MCF7
showed differential responses when cell viability was measured following the treatment
with 321 drugs at a single concentration. The differential responses observed were linked
directly to the genetic variation of the 27 strains of the same cell line and not the
reproducibility of the assay (Ben-David et al. 2018). Therefore, the variability of cell lines
observed in culture represents a significant limitation and this is precisely why follow-up
studies are necessary in vitro and using patient-derived specimens.

5.6 Concluding Remarks
Overall, the research presented in this thesis builds on and increases the current
state of knowledge regarding how ATC can be targeted, and which patients may be at risk
to develop ATC to treat patients more effectively. In the future, the work presented in this
thesis has the potential to play a key role in a larger area of knowledge relating to how we
can improve our understanding of disease progression and effective treatments in order to
improve patient outcomes associated with human cancers.
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The genomic and evolutionary landscapes of anaplastic
thyroid cancer

6.1 Abstract
Anaplastic thyroid cancer is arguably the most lethal human malignancy, yet the
molecular origins of its aggressivity are unknown. We generated copy number and pointmutation profiles of 312 regions of thyroid cancer, including 170 anaplastic thyroid cancers
(157 patient tumours and 13 cell lines), 26 differentiated thyroid cancers that co-occurred
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with anaplastic components, and 112 papillary thyroid cancers. We show that anaplastic
thyroid cancers have a higher density of mutations than differentiated thyroid cancers, with
multiple cancer driver genes mutated. These mutational profiles reflect a set of distinct
tumour subtypes and correspond to specific trinucleotide mutational signatures. Anaplastic
thyroid cancers shared a genomic origin with co-occurring differentiated cancers, but with
characteristic driver mutations enriched in anaplastic components. Taken together,
anaplastic thyroid cancers can share a common genomic origin with differentiated thyroid
cancers, but are distinguished by elevated genomic instability, divergent mutational
processes and characteristic driver mutations.

6.2 Introduction
Human malignancies range widely in their lethality. Some tumour types, like
differentiated thyroid cancer (DTC) and prostatic adenocarcinomas, are typically indolent
with long life-histories and managed with minimally-invasive therapies or even
surveillance protocols1,2. Others, like pancreatic adenocarcinomas, progress rapidly after
initial diagnosis and are refractory to most therapeutic interventions3. This variability
between tumour types is mirrored within tumour types, leading to the development of
molecular prognostic markers that predict tumour aggressivity from transcriptomic or
proteomic features4-6.
At one extreme end of the spectrum of tumour lethality lies anaplastic thyroid
cancer (ATC). It is arguably the most lethal human tumour type, with a median survival of
~12 weeks: some patients succumb to their disease within days of diagnosis7,8. ATC often
presents dramatically, with rapid onset of airway and oesophageal obstruction due to
explosively growing neck masses7,8. Primary ATCs are frequently surgically inoperable
due to encasement of nerves, blood vessels and the airway. Radio- and chemo-resistance
occur frequently, and distant metastases are near-ubiquitous7,9. ATC is a major clinical
dilemma and a model for understanding lethal, treatment-resistant cancer.
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The aggressiveness of ATC is particularly intriguing because of its life-history:
~80% of ATCs occur in the context of a prior history or a distinct co-existing region of
differentiated thyroid cancer (DTC). Thus, the most lethal human malignancy frequently
arises in the context of one a highly indolent tumour10-14. This suggests that at least a subset
of ATC develops via dedifferentiation of DTCs: either well- or poorly-differentiated.
Despite these observations, there has been little molecular confirmation of progression
from a well to poorly differentiated tumour, nor testing of the mutational field effect
surrounding lethal ATC. Several studies have sequenced small numbers of ATCs with
limited genome coverage, highlighting frequent TP53 mutations and a subset of tumours
with multiple oncogene driver mutations15-21. However, the genomic landscape of ATC
remains largely unknown, and the molecular characteristics of their evolutionary
relationship to DTC remain elusive.
To fill these gaps in our understanding of ATC pathobiology, we established a 14site consortium called the Global Anaplastic Thyroid Cancer Initiative (GATCI). We report
the mutational landscape of 312 thyroid cancers, including 170 ATCs (156 derived from
primary patient tumours, 1 recurrent ATC and 13 previously established ATC cell lines)
and 26 co-occurring regions of DTC within ATCs. As a control DTC with excellent clinical
outcome, we analyzed 115 papillary thyroid cancers, including 2 with multiple PTC
regions and 1 with a metastasis. These data reveal distinct genomic subtypes of ATC, with
elevated mutational density and signatures. ATCs harbour a distinct set of driver mutations
from DTCs, including multiple recurrent tumour suppressor hits. ATC arising in the
context of DTCs share a common genomic origin, with additional specific driver mutations
recurrently altered in the anaplastic components.

6.3 Results
6.3.1

Cohort summary
A total of 312 tumour regions from 283 patients were collected, including 156

primary anaplastic thyroid carcinomas and 112 papillary thyroid cancers (PTCs;
Supplementary Figure 6.1). These tumour samples (and in most cases, a blood reference

123
sample) were characterized for copy number aberrations (CNAs), whole-exome
sequencing (WES), deep targeted-panel sequencing and RNA-sequencing (RNA-Seq;
Figure 6.1a, Supplementary Table 6.1). ATCs were sequenced to a depth of 123 ± 14x,
and reference samples to 116 ± 13x (median ± standard-deviation, SD). In contrast to the
strong female preponderance of PTC (F:M 2.93:122, 1.53:1 for the current PTC cohort),
our ATC cohort was balanced by sex (F:M 1.11:1), consistent with previous reports17. The
median age at diagnosis was 70 years for ATCs and 50 years for PTC. Most ATC patients
presented with locally advanced disease: 87% with T4b disease and 70% with nodal
involvement. Distant metastases were common (43%), and median survival was 126 days
from diagnosis. PTCs were equally distributed across tumour stage (T1-4), and all tumours
were surgically resected, with a median follow-up of 10.9 years. All tumours were
subjected to expert consensus pathology review and manually macro-dissected to
maximize tumour cellularity (Supplementary Table 6.1).

6.3.2

Anaplastic thyroid cancers are rich in copy number
aberrations
We began by evaluating the somatic copy number aberration (SCNA) landscape of

ATCs and co-existing DTCs. PTC typically has a quiescent mutational profile, with a low
background mutation rate and fewer SCNAs relative to other tumour types22. In contrast,
ATCs have been suggested to be highly mutated, particularly in SCNAs17,23. We identified
120 ± 44 distinct CNAs in each ATC (mean ± SD; median = 83.5), with an average size of
6.21 ± 1.33 Mbp (mean ± SD; median = 4.95 Mbp). In contrast, DTCs that co-occur with
ATC harboured fewer SCNAs (32 ± 15 per tumour), but these tended to be larger (14.4 ±
11.5 Mbp; median= 3.47 Mbp). PTCs tended to have a large number of small SCNAs, with
an average of 144 ± 52 events of size 0.89 ± 0.26 Mbp. Some of these differences may
reflect variation in genomic technology, tumour purity and ploidy: ATC generally had
higher average ploidy (median 2.4 vs. 2.0 for DTC components), with lower tumour
cellularity (median 56% vs. 83% for DTC components).
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Figure 6.1. Summary of CNAs. (a) Overlap of tumours (well, poorly, undifferentiated;
metastatic patient tumours and 13 ATC cell lines) processed by CNA arrays, WES and
IonTorrent targeted sequencing after quality assessment. (b) Copy number aberrations
(CNAs); consensus clustering was used to identify the optimal method and designation for
sample groupings. Each row represents the CNA profile for a single undifferentiated
tumour along the genome (chromosome 1 on the left to chromosome Y on the right),
ordered by PGA within each subtype. (c) Average CNA profiles and (d) distribution of
PGA for samples from each ATC subtype, co-occurring DTC and PTC, showing a
significant difference between groups (one-way ANOVA, p < 0.01). GISTIC was used to
identify recurrent CNAs within (e) ATC or f) co-occurring DTC. Copy number losses of
CDKN2A were more frequent in ATC than co-occurring well/poorly differentiated samples
(DTC).
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The SCNA landscape of PTCs was mostly quiet profiles with a small subset of
patients harbouring amplification of 1q and deletion of 22q (Supplementary Figure 6.2a),
consistent with previous reports22. These events occurred at similar frequencies in both
ATCs (Figure 6.1b-c) and the co-occurring DTC components of ATCs (Supplementary
Figure 6.2b). ATC showed many additional recurrent chromosome-scale events, including
loss of chromosome 13 (39% of tumours), gain of chromosome 7 (26% of tumours) and
gain of chromosome 20 (35% of tumours). These large-scale changes reflect five distinct
patterns of CNA, which we term Subtypes A-E (Figure 6.1b-c). Each subtype is defined
by characteristic genomic abnormalities, such as wide-scale amplifications with occasional
arm-level deletions for Subtype A (11% of ATCs) and large-scale deletions with cases of
uniparental polysomy, similar to Hürthle cell thyroid cancers (HTC)24,25, for Subtype B
(29%). Subtype C (20%) is dominated by gains of chromosomes 7 and 20 (similar to
HTC24,25) and 1q amplifications (similar to PTC22), while Subtype D (15.5%) demonstrates
many focal regions of CNA. Subtype E (24.5%) shows a quiet copy number profile,
characterized by few CNAs, analogous to profiles observed in breast, prostate and head
and neck cancers26-28.
These subtypes can be distinguished by the proportion of the genome with a CNA
(PGA27), with Subtype A tumours having ~51% of their tumour copy-number altered while
only ~1.2% of the genome of subtype E tumours are copy-number altered (Figure 6.1d).
These subtypes were also associated with distinctive profiles of SCNA number, CN gains
and average CN length, but not with CN losses, estimated tumour cellularity or ploidy
(Supplementary Figure 6.2d-j). Subgroups were not detectable when examining either
CN gains or losses separately (data not shown), suggesting they reflect composite profiles
of DNA mutation rather than single mutational processes.
To identify specific SCNAs that may drive ATC aggression, we identified recurrent
mutations using GISTIC29. PTCs harboured recurrent amplifications on chromosome 17
affecting numerous genes (q < 0.01), many of which were recurrently deleted in ATC
(Supplementary Figure 6.2k). In addition to CDKN2A loss17,30 in 42% of ATCs, we
identified multiple candidate driver events (Figure 6.1e, q < 0.01). Particularly prominent
were loss of a 62 kbp region on 22q containing GSTT2 and GSTTP1, loss of regions on
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chromosome 13 involving FGF9, MYCBP2 and FLT3 and a 429 kbp gain on chromosome
3p containing VGLL3. Loss of GSTTP1 and CDKN2A (7/22 and 5/22 respectively) were
also identified as driver events in the co-occurring DTCs (Figure 6.1f), but not in PTCs
(6/111 for each). Loss of BRCA2 was recurrent in ATCs (33.6%), rare in DTCs (13.6%)
and uncommon in PTCs (4.5%). These data are consistent with a model where ATCs and
DTCs evolve from a common precursor, and that specific mutations within that common
precursor increase the risk of ATC evolving.
To validate the functional consequences of these recurrent SCNAs, RNA
abundance was quantified via RNA-seq of 23 matched ATCs (Supplementary Table 6.2).
Despite somewhat limited statistical power, three recurrent CNAs were validated to
influence mRNA abundance: MYCBP2, SPATA13 and OMG (Wilcoxon rank sum test, p <
0.01; Supplementary Figure 6.2l-n).
Finally, we contrasted the above findings to 13 ATC-derived cell lines. The SCNA
profiles of ATC cell lines were highly perturbed, with a median ploidy of 2.9, and elevated
CN count (mean of 343 ± 92 events) of similar-sized events size (6.0 ± 2.5 Mbp) relative
to ATC. As a result, they harboured elevated PGA (median: 54%) and are not
representative of the full diversity of ATC subtypes (Supplementary Figure 6.2c).

6.3.3

Landscape of point mutations in ATC
To identify single nucleotide driver variations (SNVs), WES was performed on 289

thyroid tumours: 173 ATC-associated samples (including primary/recurrent ATCs, cooccurring DTCs and cell lines) and 115 PTC-associated samples. Reads were aligned and
somatic SNV-detection performed using a validated pipeline6,31. . After stringent qualitycontrol, seven ATCs were excluded, leaving 282 tumours (Supplementary Figure 6.6;
Figure 6.1a). Recognizing that ATCs can have low tumour cellularity, we validated 1,140
candidate mutations by deep targeted-sequencing on an orthogonal platform, the
IonTorrent (median: 512x coverage), validating our SNV detection to have a median F1 of
0.914 (Supplementary Figure 6.3).
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On average, ATCs had 3.8 ± 1.2 SNVs/Mbp of DNA sequenced, while cooccurring DTC components had a statistically indistinguishable 4.4 ± 2.8 SNVs/Mbp.
These SNVs consisted predominantly of C>T or G>A substitutions (Figure 6.2a, top). In
ATC, we identified 92 genes mutated in ≥5% of tumours, and 16 statistically significant
driver genes were identified using SeqSig6 (FDR < 0.01). These included a series of likely
driver mutations: TP53, BRAF, NRAS and PIK3CA (Figure 6.2a, Supplementary Figure
6.4). Four genes (i.e. SYNE1, USH2A, HMCN1 and DNAH9) are relatively long and may
represent passenger mutations. Using the same matched RNA-Seq, we confirmed the
expected association between non-synonymous SNVs in TP53 and elevated mRNA
abundance (Wilcoxon rank sum test p = 0.0067, Figure 6.2b). Unfortunately, recurrence
of SNVs was minimal in this small subset, making it under-powered to detect associations
for other, less frequently mutated, driver genes.Other mutations previously described in
ATC were detected at low frequency – EIF1AX mutations were detected in 5 tumours,
including three with the p.X113 splice-site mutation that appears to be exclusive to thyroid
cancers17 and two missense mutations (G9R). These tended to co-occur with RAS
mutations, consistent with previous reports (Supplementary Figure 6.5a-b)17. BRAF
V600E and RAS mutations were mutually exclusive, while BRAF V600E and PIK3CA
mutations co-occurred as expected15,17 (hypergeometric test p=0.0052). Promoter
mutations in TERT could not be detected using this technology.
It has been suggested that ATC evolve from pre-existing DTCs11-13,32,33. Therefore,
we next sought to uncover the relationship between these tumours by comparing the
mutational characteristics of ATC with co-occurring regions of DTC. We identified
marked differences in the frequency of specific driver gene mutations between ATCs, cooccurring DTCs and PTCs. The mutation frequency of TP53 correlated directly with
disease progression, increasing in frequency from 0.9% of PTC to 26.3% of co-occurring
DTC and 36.4% of ATC (Figure 6.2c, Supplementary Table 6.3). Several other genes
showed this trend, including PIK3CA, ATR and ATM (Figure 6.2c, Supplementary
Figure 6.4). BRCA2 mutations were more common in co-occurring regions of DTC than
ATC, and none were detected in our PTC cohort. Notably, BRAF was the only gene that
showed an inverse profile, being more common in differentiated thyroid cancers: it was
mutated in 50.0% of PTC, 52.6% of co-occurring DTC and 20.5% of ATCs.
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To assess germline variants in known cancer pre-disposition genes, we analyzed
matched reference tissue (typically blood) from ATCs34. We found 10 genes with
heterozygous germline SNVs in at least 2 patients (2.4% of ATCs), with a maximum
recurrence of 4 patients (5%) for RECQL4 (Supplementary Table 6.4). This included a
number of DNA repair genes such as BRCA2 and FANCF. Given the lack of strong
recurrence however, much larger cohorts will be required to understand the germline
correlates, if any, of ATC.
Finally, we examined whether the SNV profile of 13 available ATC-derived cell
lines was reflective of primary tumours, to give insight into their utility as model-systems.
We confirmed the identity of these lines by short tandem repeat profiling (Supplementary
Table 6.5)35. Unsurprisingly, the rate of point mutations in cell lines was significantly
elevated (average = 91 ± 202 SNVs/Mbp; p = 0.0001; Wilcoxon u-test). As a positive
control, four cell-lines (8505c, BHT-101, SW1736 and THJ-21T) carry the BRAF V600E
variant36,37; this mutation was confirmed in 3 cases, with the fourth having poor coverage
in this region (Figure 6.2d). Mutations were identified in 12/14 genes recurrently mutated
in primary ATC (exceptions: DYNC1H1 and NEURL4; Figure 6.2d).

6.3.4

The mutational processes of ATC
Non-negative matrix factorization (NMF) was used to generate signatures based on

the distribution of trinucleotide sequences at variant positions in ATCs38 (Figure 6.3a).
Using Euclidean distance and the Hungarian method for linear sum assignments, NMFderived signatures for this cohort were associated with COSMIC signatures. Thyroid
cancers have been reported to harbour activation of COSMIC signatures 1, 2, 5 and 1338,39.
Our analysis recapitulated similar relationships for ATC. In addition, ATCs exhibited
COSMIC signature 6 and a novel signature characterized by a large fraction of G[T>G]G
mutations not observed within the COSMIC signature set. As this feature is strongly
detected in only three tumours (Figure 6.3b), it may embody unknown sequencing
artefacts or an as-yet-undescribed mutational process. None of these mutational signatures
were associated with sex, age or overall survival (Student’s t-test, FDR > 0.1). COSMIC 5
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Figure 6.2. Summary of somatic SNVs. (a) Point mutations were used to determine the
mutation rate (SNVs per million bp of DNA covered) for each tumour sample. These were
categorized according to base change with an observed bias for G>A or C>T mutations
across the cohort. Recurrence analysis identified 14 genes with mutations in at least 11
primary ATCs that were predicted to be significant and potential driver events; for each
gene, the mutational profile for patient tumours (ATC, co-occurring DTC or, metastasis)
and FDR-adjusted p-values are shown [n = 153 tumours]. (b) Non-synonymous variants in
TP53 were associated with significantly elevated mRNA abundance by RNA-Seq
(Wilcoxon rank sum test, p = 0.0067). (c) Gene-wise mutation frequencies were contrasted
between datasets (GATCI-ATC, GATCI- DTC, GATCI-PTC, and TCGA-PTC) to identify
candidate drivers of tumour progression. Genes with a statistically significant difference
(proportion-test) between ATC and TCGA-PTC were selected and further filtered to show
only known driver genes. FDR-adjusted p-values from proportion-tests across the three
tumour types (PTC (combined), co-occurring DTC, ATC) are shown. Results for pairwise
comparisons are available in Supplementary Table 3. (d) Type and distribution of
mutations in the above genes as observed within the 13 ATC-derived cell lines, along with
the proportion of these that contained a mutation.
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Figure 6.3. Mutational processes in ATC. (a) NMF identified five trinucleotide
signatures within ATC, four matching known COSMIC signatures and one novel signature.
a) Within each signature, the percent of mutations within the cohort presenting each base
change (broken down by trinucleotide context); (b) for each patient, the proportion of
SNVs that contribute to each signature. There are no associations between these signatures
and covariates shown (Spearman’s correlation p-value < 0.1). (c-d) This was repeated for
112 PTCs independently to identify 2 signatures; again, no significant associations were
found with patient age or sex.
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describes a diverse range of point mutations consisting of low frequency pyrimidine
transition mutations, and COSMIC signature 13 is attributed to AID/APOBEC activity38,
suggesting specific mutational aetiologies for ATCs.
NMF was repeated separately for PTCs (Figure 6.3c-d) and identified two
prominent signatures that likely represent composite COSMIC signatures caused by the
sparseness of SNVs: COSMIC signatures 2 and 13 (both related to AID/APOBEC activity)
and COSMIC 6 (MMR deficiency). Again, these were not associated with patient sex or
age (Student’s t-test, FDR > 0.1). Co-occurring DTCs were mapped to these ATC and PTC
derived signatures; 11/17 cases demonstrated similar characteristics to their ATC
counterparts. Three of the remaining DTCs more closely resembled COSMIC 13 (ATC
classified as COSMIC 5); the remaining 3 resembled COSMIC 6 (ATC classified as
COSMIC 1), suggesting a divergent evolution or multiple distinct subclones.
To understand better the mutational processes at play in ATC, we next examined
our genomic features for patterns (key CNA- or SNV- containing genes along with CNA
and SNV metrics, including trinucleotide signatures). As both datasets provided metrics
for grouping samples, we first compared our trinucleotide signatures with CNA subtypes
(one-way ANOVA; Supplementary Figure 6.5c). We found no associations between
these grouping metrics (p > 0.05), suggesting that the processes that drive CNA
diversification may be relatively independent from those driving SNV mutational trends.
To further consider this, we compared a combination of mutation-density, mutationsignature and driver-gene features (Figure 6.4a). Several associations were detected,
including an expected strong correlation between SNVs mutation density (SNVs/Mbp
sequenced) and the COSMIC 1 signature (Spearman’s rho = 0.43, q = 0.0002), suggesting
interplay between these features that can be uncovered in future larger ATC cohorts.
To assess the clinical relevance of these ATC somatic mutational features, we
systematized clinical annotations (Supplementary Table 6.1). We first assessed the
impact of clinical factors on overall survival; treatment with radiotherapy (FDR = 3.4 x 107

), surgery (FDR = 0.0005) and patient age (FDR = 0.06) were all associated with survival.

As radiotherapy status was unavailable for nearly half of the dataset, patient age and
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surgery (Figure 6.4b) were included as covariates for downstream survival analyses.
Tumours with lower PGA more often presented with distant metastases (Wilcoxon rank
sum test: FDR = 0.034; median PGA for patients with and without distant metastases =
8.6% and 11.6% respectively). Surprisingly, PGA was not associated with overall survival
(median dichotomized; HR = 0.93 [95%CI, 0.59-1.47], p = 0.77, adjusted for patient age
and surgery), in contrast to several other tumour types27,40,41. Furthermore, overall patient
survival was not associated with any recurrent CNAs (all FDR > 0.1; Supplementary
Table 6.6). By contrast, CNA subtypes showed distinctive clinical hallmarks: subtype A
was enriched for older patients with better overall survival, subtype B was depleted for
patients with nodal involvement as well as moderate enrichment for patient death, subtype
C was enriched for younger patients, subtype D was enriched for male patients with
metastatic disease and subtype E showed no associations with clinical variables
(Supplementary Figure 6.5d). However, these CNA subtypes do not comprise a robust
prognostic biomarker, since the current sample-sizes do not provide sufficient statistical
power (Supplementary Figure 6.5e). None of the genes with point mutations in at least
five patients were associated with overall survival (all FDR > 0.1, Supplementary Table
6.7), however overall SNV mutational density was: patients with an elevated mutation rate
had an increased survival time (optimal threshold = 0.61 SNVs/Mbp, tumours with
matched normal only; HR = 0.28, [95%CI, 0.12-0.67], p = 0.0041 adjusted for patient age
at diagnosis and surgery; Figure 6.4c). Thus, the mutational features of ATC are associated
with distinct clinical characteristics.
Next, we contrasted the overall mutation burden of thyroid cancers with 32 tumour
types
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https://doi.org/10.1101/163907). PTCs are some of the most genetically quiescent adult
tumours known, both in their PGA (Figure 6.5a) and SNVs/Mbp (Figure 6.5b). While
ATCs had elevated PGA and SNVs/Mbp density, they were not amongst the most mutated
tumour types, nor did they show atypically high inter-tumour variability in mutation burden
relative to other cancer types. Co-occurring DTC components macro-dissected from ATCs
demonstrated consistently higher PGA and SNV rate than non-ATC associated DTCs.
Thus the small subset of DTC that dedifferentiate to form ATC have a higher mutational
burden prior to morphologic evidence of anaplastic dedifferentiation, perhaps because they
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exist in a mutagenic field that increases genomic complexity. However, overall mutation
burden does not appear to be a key driver of ATC lethality and aggressiveness as it is in
other tumour types27,41

6.3.5

Thyroid cancer evolution and progression
Given the poor concordance of SNV and CNA somatic aberrations (Figure 6.4a),

we next evaluated whether the two mutational types play different roles in distinguishing
ATCs from DTCs. For CNAs, we compared our ATC samples to PTC samples from this
study and the TCGA22. We identified genes preferentially deleted in ATC (χ2 proportiontest, FDR < 0.01), including tumour suppressors like CDKN2A, BRCA2 and RB1
(Supplementary Table 6.8). A broad region on chromosome 20q harbouring 328 genes
was preferentially amplified in ATC relative to both cohorts of PTCs (proportion-test, FDR
< 0.01). This region harbours several known driver genes such as ARFGEF2, CHD6 and
GNAS, all of which are ubiquitously expressed in thyroid tissue42.
For SNVs, findings were compared between the current study and 5 previous
studies of ATC, PTC and HTC17,21,22,24,25; TP53 mutations were consistently more common
in ATC and HTC than PTC (χ2 proportion-test, FDR < 0.01), while BRAF mutations were
more common in PTC (Figure 6.2c, Supplementary Table 6.3). When comparing
recurrence frequency of common point mutations, NRAS Q61R/K was observed at similar
frequencies in both the TCGA PTC and current ATC cohorts, while BRAF V600E
presented at significantly different frequencies.
Since these specific mutational events distinguish ATC from DTC, we sought to
determine their precise evolutionary relationships. We selected three ATCs that contained
components of well-differentiated thyroid cancer, along with one primary ATC and a
paired cervical metastasis. We performed high-coverage (median ~512x) sequencing of
both components from these tumours, to allow precise estimates of variant allele
frequencies (VAF). These were used to classify individual SNVs as occurring clonally or
subclonally (Figure 6.6).
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Since these specific mutational events distinguish ATC from DTC, we sought to
determine their precise evolutionary relationships. We selected three ATCs that contained
components of well-differentiated thyroid cancer, along with one primary ATC and a
paired cervical metastasis. We performed high-coverage (median ~512x) sequencing of
both components from these tumours, to allow precise estimates of variant allele
frequencies (VAF). These were used to classify individual SNVs as occurring clonally or
subclonally (Figure 6.6). After removal of known germline variants, mutations fell into
four groups: clonal SNVs observed at a high VAF in both components, SNVs clonal in one
component and not observed in the other and SNVs present in both components, but
subclonal in at least one.
In ANPT0012 (Figure 6.6, top left panel), PCNXL4 and CRB2 harbour clonal
somatic SNVs in both the ATC (y-axis) and co-occurring PTC (x-axis). The PTC
component also harbours a BRAF mutation that may be clonal, and that is present
subclonally in the ATC component. The ATC component has also gained mutations in
TP53 and PIK3CA in one or more subclones. The presence of shared clonal mutations
between the two components are strongly suggestive of a common precursor cell, with the
ATC emerging from a low-frequency BRAF-wildtype subclone in the PTC field and
gaining additional oncogenic mutations.
A similar story emerges for each tumour, with generally concordant trends. For
example, BRAF mutations were identified in all cases, and typically in a subclonal
population. Indeed for ANPT0021 (Figure 6.6, bottom left panel), the primary ATC
exhibits a clonal or high-prevalence subclonal BRAF mutation (y-axis, VAF ~0.4) while
its cervical metastasis has near-zero prevalence of this mutation, suggesting either loss of
this allele or that it derived from another subclone present at low-frequency in the primary
tumour. To generalize these observations, we analyzed nine additional patients using WES
data with stringent filtering criteria (see Methods). While having reduced precision VAF
estimates due to the lower coverage, these tumours yielded similar findings
(Supplementary Figure 6.6a).
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Figure 6.4. Mutational overlap and clinical utility. (a) χ2, Spearman’s correlation,
Wilcox or Kruskal-Wallis tests were used to assess overlap across genomic features in
ATC (recurrently altered genes by SNV or CNAs, SNVs/Mbp, PGA, trinucleotide
signatures, CNA metrics); shading indicates Bonferroni-adjusted p-value. (b) Patient age
and surgical resection of the tumour were associated with overall patient survival (log-rank
test). (c) SNV mutational density (SNVs/Mbp) was associated with patient survival such
that a higher mutation rate was associated with prolonged survival, following adjustment
for patient age and surgery in tumours with matched reference material (Cox proportional
hazards test).
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Figure 6.5. Comparison with the PCAWG dataset. (a) Metrics of mutation density for
ATC, co-occurring DTC and PTC were compared with 32 additional tumour types
available in the PCAWG dataset: a) total PGA and (b) SNVs/Mbp. Light purple indicates
the PCAWG thyroid carcinoma cohort (primarily PTC) and similar GATCI PTC cohort;
co-occurring DTC samples are shown in medium purple while ATC are in dark purple.
PGA for the GATCI PTC samples is similar to that of the PCAWG thyroid carcinoma
cohort. SNVs/Mbp for the GATCI PTC cohort was unavailable. ATC shows higher PGA
than either co-occurring DTC or PTC, and a lower rate of point mutations than co-occurring
DTC.
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Figure 6.6. Tumour progression and patient survival. Deep sequencing was used to
validate a subset of variants identified by WES. Four patients had data from multiple
tumour components; variant allele frequencies were compared to assess tumour evolution,
after removal of suspected germline variants.
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We further examined SNV overlap across 16 cases that contained both ATC and
well or poorly differentiated components analysed by WES and identified shared somatic
mutations in all cases. Similar results were observed from CNAs analysis, with common
mutations present in all cases (Supplementary Table 6.10). Thus, ATC and co-occurring
DTCs arise from a common precursor cell of origin in all cases tested (Supplementary
Table 6.9). Patients with regions of co-occurring DTC were not restricted to a specific
CNA subtype, and no consistent trends in PGA, total number of CNAs, or other
characteristics were observed (Supplementary Figure 6.6b). These results suggest that
most or all ATCs arising in the context of DTC arise from a (preferentially BRAF-wildtype)
subclone of that DTC, acquiring characteristic additional oncogenic drivers

6.3.6

Functional validation of recurrent somatic mutations
To identify candidate targetable mutations in ATC, we next evaluated our primary

tumour RNA-Seq data for recurrent fusion genes (Supplementary Table 6.11). We
identified 84 distinct fusion genes across the 24 primary tumours sequenced, covering 144
total partner genes. None of these fusions have been previously observed in COSMIC. The
typical ATC harboured 3 ± 3 distinct fusion genes (median ± standard-deviation), with
25% of samples containing at least 6 distinct fusions (max = 11 fusions in two samples).
Only five fusion genes were recurrent (i.e. present in two or more patients), with
LINC01133:SAMHD1 fusions in four patients and MDM4:TRA and KDSR:ANAPC7
fusions each observed in three. The latter was also identified in two of 13 ATC-derived
cell lines by RNA sequencing (Supplementary Table 6.11), but none were associated with
specific somatic SNVs or SCNAs in this cohort or altered mRNA abundance.
Given the lack of targetable fusion genes in ATC, we next considered kinase
inhibition, an effective treatment for some thyroid cancers43,44. First, we performed an
siRNA screen to evaluate whether specific kinases are essential for growth in 12 ATCderived cell lines (Supplementary Table 6.12). Effectiveness of an siRNA to impair cell
growth was defined as a mean growth < 0.8. Of 714 kinases examined, inhibition of 170
resulted in reduced growth of at least one cell line with six of these (PLK1, CKM, MAP4K3,

140
PRKDC, PRPF4B and C9orf96) proving effective inhibitors of growth in at least 4 cell
lines (Figure 6.7a, Supplementary Figure 6.7a-c). None of the tested kinases proved
essential for all cell lines. Six cell lines were rarely affected by kinase knockdown (reduced
growth for two or fewer kinases), while one cell line (C643) proved quite sensitive to kinase
inhibition (reduced growth on knockdown of 122 kinases). Knockdown of PLK1 produced
the largest effects, with a mean growth reduction of 30-35% in three cell lines. This
inhibition was not associated with variant status (SNVs, CNAs or fusions) of these genes
(p > 0.1).
Next, high-throughput drug screening was performed to assess the ability of 320
kinase inhibitors to reduce cell growth within the 13 cell lines (Supplementary Table
6.13). The inhibitory efficacy for each compound was calculated using activity area45,
using a threshold of activity area > 0.5 to define inhibition. Growth was successfully
inhibited by a median of 25 ± 15 (minimum = 12) compounds across the cell lines. Three
compounds had no impact on growth in any cell line, with 85 compounds proving effective
in at least one cell line. Two compounds (NVP-BEZ235 and Staurosporine) were effective
inhibitors of cell growth in all 13 cell lines (activity area > 0.6 for all cell lines), while an
additional 6 compounds were effective in at least 10 cell lines (Figure 6.7b,
Supplementary Figure 6.7d-f). Effectiveness of these compounds was compared to
mutation status for genes identified in the above sections. Activity area for these
compounds was not associated with the presence of non-synonymous variants (Wilcoxon
u-test FDR > 0.1) or CNA (Spearman’s correlation, FDR > 0.1) in any known driver gene.
Finally, we contrasted the results of the drug screening with the siRNA screen.
Here, a significant negative correlation indicates effective inhibition by both the given
compound and siRNA target gene. In particular, TX-1918 and MK-1775 were effective
inhibitors in 7/13 and 5/13 cell lines tested (activity area > 0.4) and were significantly
correlated with knockdown of ADRBK2 (beta-adrenergic receptor kinase 2) and CSNK2B
(casein kinase 2 beta) respectively (Figure 6.7c-d). These associations could not be
explained by SNV or CNA status. MK-1775 is a selective inhibitor of WEE1, however no
statistical associations were observed between activity area and SNV or CNA status, or
RNA abundance of this gene.
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6.4 Discussion
ATC is rare, with undifferentiated pathological features, and is likely the most
lethal human malignancy known. On the other hand, the vast majority of thyroid cancers
are well-differentiated papillary and follicular types with extremely favourable prognoses
(>90% survival at 10 years)46-49. It is intriguing that the same organ can harbour both the
most aggressive tumour known and many of the most indolent, manageable ones, including
papillary, follicular and Hürthle cell thyroid cancers (HTC). The genomic landscape of
PTC has been reported by The Cancer Genome Atlas (TCGA) and demonstrates a low
mutational burden and a simple genomic landscape. Most tumours contain either single
activating mutations in an oncogene (BRAF or RAS family genes) or a receptor tyrosine
kinase gene fusion22. This genomic simplicity has been speculated to partially explain the
indolent nature of the disease. Similarly, the genomic profile of HTC has recently been
examined, with key features involving whole chromosome duplication events (particularly
chromosome 7) and uniparental disomy, with few recurrent point mutations24,25. In
contrast, the genomic landscape of ATC is highly complex, with significant inter-patient
heterogeneity; individual tumours carry mutations in multiple oncogenes and tumour
suppressors, and an overall elevated rate of copy number changes.
ATC frequently occurs in patients with a previous history of DTC or contains coexisting areas of DTC11-13, leading to speculation that some ATC evolves via
dedifferentiation from DTC. However, evidence has been limited to analysis of a small
number of genes, particularly BRAF32,33. Through WES and CNA profiling of the DTC and
ATC components from 21 tumours, we conclusively demonstrated that both components
share a common genetic origin. High coverage validation of a subset of cases allowed us
to further classify mutations as clonal (common to both ATC and DTC components) or
subclonal variants that are exclusive to ATC. Many ATC driver mutations are subclonal.
A set of SNVs and CNAs are more frequently altered in ATC (Supplementary Tables
6.3,8), a subset of which are likely critical to thyroid cancer progression. Functional studies
are necessary to determine which mutations lead to the dedifferentiation and increased
aggression of well-differentiated thyroid cancer models.
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Figure 6.7. Functional screens reveal potential drug targets. (a) Screening of 714
kinases in 12 ATC-derived cell lines revealed 6 genes for which siRNA-targeted
knockdown had significant inhibitory effects on cell growth. (b) High-throughput drug
screening of 320 kinase inhibiting compounds uncovered 8 molecules capable of limiting
cell growth in at least 10/13 cell lines tested. Comparison of siRNA and drug-screening
results revealed a significant correlation between (c) TX-1918, a non-selective kinase
inhibitor, and siRNA targeting of ADRBK2. (d) A similar correlation was detected between
MK-1775 and siRNA targeting of CSNK2B.
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Taken together, these data suggest a model where both ATC and DTC arise from a
non-malignant mutational field effect, where a set of cells have accumulated a series of
SNVs through some combination of environmentally-driven and replication-associated
mutational processes. Some of these cells then accumulate the characteristic somatic
mutations of DTCs and give rise to curable tumours. A subset of these cells accumulates
further mutations, particularly SCNAs, and then eventually subclonal driver pointmutations in genes like PIK3CA and TP53. This model suggests that their evolutionary
trajectories may lead to the differential aggressivity of these related tumour types, and to
the expansive subclonal architecture of ATC. This model implies that ATC emerges from
precursors within its co-occurring DTCs by significantly increasing genomic diversity, and
potentially evolves further as the disease colonizes new metastatic sites. Studies of the
epigenome and whole-genome landscape will be needed to further help outline this
subclonal structure, as well as uncover the role of non-coding mutations, such as TERT
promoter variants within these cancer types, and to better understand the contribution of
such events to tumour evolution during metastasis and treatment.

6.5 Methods
6.5.1

Sample collection and handling
Research Ethics Board approval was obtained at all site locations. Tumours from

patients previously diagnosed as ATC were reviewed by at least one study pathologist at
each site. Samples meeting the American Thyroid Association diagnostic criteria for
anaplastic thyroid cancer9 were selected for study including both fresh frozen and formalin
fixed paraffin embedded (FFPE) samples (Supplementary Table 6.1). FFPE tumours and
matched normal tissue (when available) were retrieved. Well-differentiated and/or poorly
differentiated components were macro-dissected when present separately from the
undifferentiated ATC components using 1 mm punches. Fresh tumour was prospectively
collected at four institutions with matched blood collected in the majority of cases. DNA
was extracted using Qiagen kits.
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PTC samples (n = 112, Supplementary Table 6.1) were selected from the tissue bank at
MD Anderson based on age and tumour status (organ confined, regional involvement, or
regional and distant metastasis) with either good or poor prognosis. No matched blood was
available. DNA was isolated and processed as described previously50,51.

6.5.2

Detection of Copy Number Aberrations
Affymetrix OncoScan FFPE assays were used to evaluate a total of 157 samples

(including 99 ATCs, 24 samples from co-occurring well (20) or poorly (4) differentiated
regions, 1 co-occurring cervical ATC metastasis, 20 normal thyroid samples and 13 ATCderived cell lines) for copy number aberrations (CNAs). Analysis was performed using
.OSCHP files generated by OncoScan Console 1.1 using either build 33 of the NetAffx
annotation (FFPE samples) or a custom reference consisting of 119 normal blood samples
from male patients with prostate cancer, 2 normal blood samples from females with
anaplastic thyroid cancer and 10 female HapMap cell line samples (fresh frozen samples
and cell lines). BioDiscovery’s Nexus Express Software was used to call copy number
aberrations using the SNP-FASST2 algorithm with default parameters, with manual recentering performed as required. Nine samples (six normal tissues, one ATC and two welldifferentiated tumour components) were removed due to poor quality and the remaining
data evaluated for recurrence. Cellularity and ploidy of tumour samples was assessed using
ASCAT (v2.5) package in R. LRR and BAF values were obtained from the.OSCHP files.
Tumour ploidy and aberrant cell fraction estimates for each sample were obtained using
either predicted germline SNPs or by leveraging matched normal arrays where available.
PTC samples (112 tumours), along with an additional 13 ATCs, were processed
using Illumina Human Omni2.5-8 or OmniExpress12v1-1 beadchips, as described
previously50,51. Briefly, DNA was denatured, amplified, enzymatically fragmented and
hybridized for 16-24 hours at 48°C. Beadchips were imaged using the Illumina iScan
system. For improved CNV analysis, B allele frequencies (BAF) were calculated and log2
R ratios (LRR) were extracted after re-clustering the raw data using GenomeStudio cluster
algorithms. BAF and LRR were then loaded into Nexus to identify somatic DNA copy
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number aberrations. UCSC’s command-line liftover tool (v359) was used to transfer
resulting CNAs to GRCh38 coordinates. CNAs from both platforms were combined, and
UCSC’s command-line liftOver tool (v359) was used to convert segment positions to hg38
coordinates (using the hg19-to-hg38 chain file downloaded from UCSC). Gene level copy
number aberrations for each patient were identified by overlapping CN segments with
Ensembl annotation (Ensembl release 84). Percentage of genome altered (PGA) was
calculated for each sample by dividing the number of base-pairs involved in a copy number
change by the total length of the genome. GISTIC2.0 (v2.0.22)29 was used to study the
recurrence of gene level CNAs. For each sample, a profile was created that segmented each
chromosome into regions with neutral, CN loss, and CN gain events. The average copy
number intensity for each segment was obtained from the SNP array analysis.
Chromosome-level events were defined as a gain or loss of 25% of the chromosome for
each sample.
Subtype discovery was performed on CNA calls for 110 ATCs using consensus
clustering to determine the optimal number of clusters and class membership for each
sample by stability evidence. Specifically, the ConsensusClusterPlus.custom (v1.8.1)
package for R was used to evaluate a wide variety of clustering methods for distributing
samples into k clusters (where k is every value from 2 to 10) using 1000 sub-samplings of
80% of the cohort. The method which produced the most stable groups used hierarchical
clustering using a Euclidean distance similarity metric with modified Ward’s minimum
variance method (ward.D) and 5 clusters. Subtypes and CNA metrics are shown in Figure
6.1 and Supplementary Figure 6.2.
Data visualization was performed in the R statistical environment (≥ v3.2.3). Venn
diagrams were created using the VennDiagram package (v1.6.17) and all other data
visualizations were generated using the BPG (v5.8.8) (bioRxiv 156067; doi:
https://doi.org/10.1101/156067), lattice (v0.20-35) and latticeExtra (v0.6-28) packages.
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6.5.3

Whole-exome sequencing (WES)
Tumour samples (and matched normal tissue where available) from 139 patients

(including 139 ATCs with 20 co-occurring regions of well or poorly differentiated tissue,
1 cervical ATC metastasis and 13 ATC-derived cell lines; total = 173 tumours) obtained
from eight centres were sequenced at one of six sequencing facilities (Supplementary
Table 6.1). Raw FASTQ files were provided for a subset of samples while the remainder
were provided in BAM format. In the latter case, read extraction was performed using the
SamToFastq component of Picard tools (v1.121) to produce FASTQ files. Data were
aligned to the GRCh38 human reference genome, including available ALT and decoy
alleles using BWA-mem (v0.7.15)52. The reference files were downloaded from NCBI
(GCA_000001405.15; release date 2013/12/17). Duplicate reads were marked using Picard
tools (v1.121). As the exome capture kit regions were provided in hg19 coordinates,
USCS’s web-based liftover tool (https://genome.ucsc.edu/cgi-bin/hgliftover) was used to
convert regions to GRCh38 positions. The Genome Analysis Toolkit (GATK v3.5.0)53 was
used for local realignment and base quality recalibration, with regions limited to those
targeted by the applicable exome capture kit (Supplementary Table 6.1). As hg38 has not
yet been widely adopted, a beta-version of the hg38bundle containing known variants was
downloaded from the Broad (ftp://ftp.broadinstitute.org/bundle/hg38/hg38bundle/).
GATK’s HaplotypeCaller (v3.5.0) was used to identify germline SNPs and indels
using default parameters, however with --output_mode EMIT_VARIANTS_ONLY -emitRefConfidence

GVCF

--standard_min_confidence_threshold_for_calling

50.

GenotypeGVCFs and SelectVariants tools were used to format variant calls, followed by
VariantFiltration with the following criteria: (QD < 10.0 || FS > 60.0 || MQ < 40.0 || DP <
50 || SOR > 4.0 || ReadPosRankSum < -8.0 || MQRankSum < -12.5), (MQ0 >= 4 && ((MQ0
/ (1.0 * DP)) > 0.1). Variants were annotated using SnpEff (v4.3)54 and filtered to keep any
position with coverage in the 1000 genome project that had a population allele frequency
<1%. These were then filtered to keep variants in clinVar and to remove synonymous
variants. Finally, for patients with multiple tumour components, germline variants present
in a single component were labelled false positives and removed. Remaining variants were
searched against a list of relevant cancer predisposition genes34 and checked for recurrence.
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Coverage was estimated across target regions using BEDTools (v2.18.2)
(Supplementary Figure 6.3a). For tumour/normal pairs, ContEst (v1.0.24530)55 was used
to estimate cross-sample contamination, using the above generated germline SNPs. As the
necessary population allele frequencies were not yet available using GRCh38 coordinates,
allele frequencies were obtained from HapMap (hg19) and added to the GRCh38 HapMap
file, with variants matched across builds using rsID. Seven samples demonstrated
contamination >3% and were removed from downstream analysis (Supplementary Figure
6.3b).
For samples with matched normal tissue, somatic SNVs were predicted using
SomaticSniper (v1.0.5.0)56, as described previously6. A panel of normals (PoN) consisting
of the 83 normal thyroid samples was generated using MuTect’s (v1.1.7) artifact detection
mode; variants detected in two or more normal samples were included in the PoN. For
unmatched samples, SNVs were identified using MuTect (v1.1.7)57 with PoN, with dbSNP
(build 150) and COSMIC (v74) filters; COMSIC variants present in five or more samples
within the PON were discarded. To combine samples processed at different sequencing
facilities, predicted somatic variants were filtered to regions appearing in all exome capture
kits used (Supplementary Table 6.1). Overlapping regions across kits were identified
using bedtools:multiIntersectBed (v2.24.0), resulting in coverage of roughly 26 Mbp.
Recurrence analysis was performed using RecSNV (v2.1.5). Briefly, all variants were
annotated using Annovar (v2016Feb01) with comprehensive filtering performed to remove
known germline variants using previously described datasets6; any variant present in
COSMIC (v82) was retained, regardless of presence in other datasets. Significance of
recurrent non-synonymous mutations was assessed using SeqSig (v3.7.8)6, using a required
mutation threshold of 6 samples across the cohort per gene, individual sample weights of log10(x) + log10(1-x) [where x is the background mutation rate per sample], with p-values
calculated using the exact distribution, followed by FDR correction for multiple testing.
Genes containing variants in multiple samples were carried forward.
PTC samples (116 tumours with matched normal) were processed separately, as
described previously50,51. Briefly, DNA was prepared and processed by WES at the Human
Genome Sequencing Center (HGSC) at Baylor College of Medicine (BCM). Reads were
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aligned to GRCh37 by BWA52, duplicate reads were marked by Picard tools and BAMs
realigned/recalibrated by GATK53. Somatic SNVs were identified using Atlas-SNP;
filtering was applied to ensure variants had a minimum of 4 high-quality support reads and
a minimum VAF of 0.08. For comparison to the above ATC cohort, the resulting SNVs
were transferred to GRCh38 coordinates using UCSC’s command-line liftover tool (v359).

6.5.4

Targeted Panel Sequencing
A total of 1,140 variants were selected for validation based on recurrence within

the initial dataset of 30 ATCs. Primer design generated an AmpliSeq-custom panel for
1125 of these variants (995 target regions). A subset of samples were used for targeted
validation by IonTorrent sequencing including 30 ATCs (13 with matched normal, 3 with
matched co-occurring DTCs and 1 cervical ATC metastatic tumour), 13 ATC-derived cell
lines and an additional 7 ATCs without WES data. DNA for each sample was shipped to
GeneDX for sequencing. Raw FASTQ files were provided and reads were aligned to
GRCh38, as described above however without marking of duplicate reads. Targeted
sequences were converted from hg19 to GRCh38 coordinates using liftOver (UCSC). Read
lengths were extracted from FASTQ files and visualized against target region length
(Supplementary Figure 6.3c). Coverage was estimated across target regions using
BEDTools58 (v2.18.2) (Supplementary Figure 6.3d).
Base counts at target positions were assessed and used to calculate variant allele
frequencies (Supplementary Figure 6.3e). Validation was performed as described
previously59. Briefly, variant positions were used, along with either the GATK-processed
WES BAMs or the IonTorrent BAMs to generate a modified pileup file indicating the base
counts at each SNV position. For T/N pairs, metrics including a χ2 test of the base-count
distribution between tumour and normal at each position followed by Bonferroni
adjustment of the p-values (padj < 0.25; Supplementary Figure 6.3f left panel), Euclidean
distance between variant allele frequencies (> 0.15; Supplementary Figure 6.3f right
panel), z-score of the sample coverage across target positions (< 2 standard deviations
from the mean for tumour and normal separately), and ternary allele proportion for normal
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samples to quantify potential false positive variants (< 0.05) were used to classify variants
as somatic or non-somatic. For tumour only samples, similar metrics were used, however
comparing AmpliSeq and WES values to classify read-counts as similar or different
between the platforms. Accuracy, sensitivity and specificity were assessed for each sample
(Supplementary Figure 6.3g). Variants identified as false-positives using this method
were excluded from WES analyses.

6.5.5

RNA Sequencing
Total RNA was isolated from 13 ATC cell lines and 8 tumour samples using Qiagen

AllPrep DNA/RNA kits and shipped to The Center for Applied Genomics (Hospital for
Sick Children, Toronto, ON) for sample processing using random primers and sequenced
using the manufacturer’s protocols. Specifically, sequences were generated using pairedend, strand-specific methods. Data were provided in BAM format; FASTQ files were regenerated using picard (v1.141) CleanSam and samtools (v1.4) fastq functions. A second
set of 16 patient tumours were processed as described previously51. Briefly, frozen tissue
was thawed in RNAlater™-ICE Frozen Tissue Transition Solution (ThermoFisher
Scientific) to enable easy extraction of high-quality RNA. Total RNA was prepared using
TRIzol reagent (Life Technologies) according to the manufacturer’s instructions. Poly-A+
Illumina RNA-Seq libraries were prepared and paired-end sequencing performed using the
Illumina HiSeq 2000 and HiSeq 2500 platforms at the Human Genome Sequencing Centre
(Baylor College of Medicine, Houston, TX).
For mRNA abundance, top ,level DNA sequences and gene annotations (GTF) were
downloaded from ensemble.org (release 88) and used to generate reference files needed
for RSEM (v1.3.0)60, using the STAR (v2.3.3a)61 alignment tool; transcripts per million
(TPM) values are available in Supplementary Table 6.2. Fusion detection was performed
using fusioncatcher (v0.99.7c)62. Detected fusions are shown in Supplementary Table
6.11.
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6.5.6

High-Throughput Drug Screening
High-throughput drug screens were performed at the Simple Modular Assay

Robotic Technology (SMART) facility at the Samuel Lunenfeld Research Institute
(Toronto, Canada) in order to evaluate the potency of the kinase panel. The Beckman
BioMek FX and High-Throughput Screening Robotics platform were used for cell seeding
into 384-well culture plates (Corning, NY, USA) at a density of 12,000 cells/ml in a total
volume of 50 μL/well. Seeded cells were incubated for 24 hours at 37ºC and 5% CO2.
Drugs were added 24 hours post-seeding into 384-well culture plates using a 320-drug
kinase inhibitor library, where the drugs were solubilized in 100% dimethyl sulfoxide
(DMSO) and then diluted to six different concentrations (0.16 – 4 µM). These compounds
were then applied to the 13 cell lines. Negative controls consisted of wells in the same 384well culture plate containing cells that were treated with 0.1% DMSO vehicle alone. Wells
containing media only were used to measure background noise. To measure cell viability,
5 μL/well of alamarBlue (Invitrogen) was added to each well after a 48 hours incubation
of the cells with the chemical compounds. Following the addition of alamarBlue, cells were
incubated for 4 hours at 37°C and then fluorescence intensity was measured using the
Pherastar mexiicroplate reader (BMG LABTECH) using an excitation filter (535 nm) and
an emission filter (590 nm). The full drug screen was completed in duplicate.
Raw data were loaded into the R statistical environment (v3.2.1). Normalized
absorbance values were obtained by contrasting experimental absorbance values with those
from vehicle control (DMSO-treated) cells. The half-maximal inhibitory concentrations
(IC50 in µM) were calculated using the nplr package (v0.1-4). Similarly, the activity area
(AA) was calculated as the area under the percent (%) inhibition curve using the nplr (v0.14) package for R. Results were filtered to remove those with poorly fitted models (R2 <
0.9).

6.5.7

High-Throughput siRNA Screening
High-throughput siRNA screens were performed using the same methods outlined

above. Seeded cells were incubated for 24 hours at 37ºC and 5% CO2. Lipofectamine
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RNAiMAX transfection reagent (ThermoFisher Scientific) was prepared according to
standard protocols with Opti-MEM (ThermoFisher Scientific) in 96-well plates. Each
siRNA was added to the RNAiMAX/Opti-MEM mixture (further referred to as the siRNA
complex) at a final concentration of 25 nmol using the robotic platform and incubated for
25 minutes prior to seeding plates containing cells. Negative siRNA controls consisted of
wells in the same 384-well culture plate containing cells treated with the RNAiMAX/OptiMEM mixture alone while wells containing media only were used to evaluate assay
background noise. Changes in cell growth were measured by adding 5 μl/well of
alamarBlue (Invitrogen) to each well, 48 hours after treatment with the siRNA complex.
After the addition of alamarBlue, cells were incubated for 4 hours at 37°C and then
fluorescence intensity was measured in a PHERAstar microplate reader (BMG
LABTECH) equipped with 535nm excitation, and 590 nm emission filters.

6.5.8

Statistical Analysis
Non-negative matrix factorization (NMF) was used to assess the contribution of

various trinucleotide signatures within our ATC and PTC cohorts separately. NMF was
performed in R (v3.4.1) using the NMF package (v0.20.6) using counts of abnormal
trinucleotides from undifferentiated tumours. Rank estimation metrics, combined with
visual inspection of consensus clustering maps, suggested the presence of 5 trinucleotide
signatures for ATC (Supplementary Figure 6.5f), and 2 signatures for PTC
(Supplementary Figure 6.5g). Signatures were mapped to previously described
trinucleotide signatures from COSMIC (downloaded from COSMIC on 2017-12-08) using
the consensus of Euclidean distance, Pearson’s or Spearman’s correlation, followed by the
Hungarian method for linear sum assignment63 using the clue (v0.3-54) package for R.
Spearman’s correlation did not identify any associations between these 5 signatures and
clinical covariates or CNA clusters.
Gene-wise mutation frequencies from the current dataset were compared to
previous studies of thyroid cancer, including a set of 22 ATCs by WES published by
Kunstman et al.15, 84 PDTCs and 33 ATCs by targeted-sequencing published by Landa et
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al.17, 182 PDTCs and 134 ATCs by targeted-sequencing published by Pozdeyev et al.21, 2
independent studies of 32 and 56 HTCs respectively by WES published by Gopal et al. and
Ganly et al. and 496 PTCs from TCGA (MAF downloaded from GDC on 2017-11-02)22
(Supplementary Table 6.3). Variants were filtered to keep only those with predicted
functional relevance with an additional coverage threshold applied to the TCGA MAF
(minimum 10 reads in both tumour and matched normal). SNV data were collapsed to
gene-level and proportion tests used to evaluate differences between studies (ATC or cooccurring DTC (GATCI) vs. TCGA-PTC), followed by FDR adjustment for multiple
testing.
Similar comparisons were made for CNAs, again using TCGA-PTC data (masked
copy number segment data downloaded from GDC on 2018-01-29). TCGA data were
converted to ternary CN values and annotated with overlapping genes to produce a gene
by sample matrix (primary tumour samples only). Proportion tests were again used to
assess differences in population frequencies for each gains/losses separately, with FDRadjustment (Supplementary Table 6.8).
Well or poorly-differentiated co-occurring tumour components were obtained from
24 patients and a single patient provided both an ATC and metastatic tumour obtained from
the cervical region. For CNA analysis, data were available for 20 co-occurring DTC tumour
components as well as ATC. Hypergeometric tests were used to evaluate the CNA overlap
across regions within each patient [P(actual overlap ≥ expected overlap)] (Supplementary
Table 6.10). Similar analyses were performed for SNV overlap (16 patients with multiple
components; Supplementary Table 6.9).
Clinical variables were assessed for associations with each other using χ2
independence tests to assess co-linearity, and with overall survival to identify which should
be used as covariates in downstream models. Age, nodal metastases and treatment methods
(surgery, radiotherapy and chemotherapy) were all individually associated with survival
(FDR < 0.1). Treatment methods showed considerable overlap, as did nodal and distant
metastases (FDR < 0.1). Therefore, covariates including age, nodal metastases and surgery
were used for survival analyses. Overall survival was evaluated using either CNA or SNV
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features. For copy number status, of 961 genes identified by GISTIC, 723 were CN altered
in 10% of the cohort with available survival data (n = 83) and were collapsed to 187
genomic regions. Regions were collapsed to binary status where reasonable, such that the
CN type with 4 or fewer cases was merged with neutral. Associations with survival were
evaluated using either log-rank (for ternary CN status) or Cox proportional hazards
regression model with linear adjustments for covariates described above (binary CN
status). Binary cases which failed the assumptions for the Cox model were repeated using
log-rank tests. FDR-adjustment of the p-values was applied for multiple testing correction
(Supplementary Table 6.6). For point mutations, 101 patients had available survival data.
Feature reduction was performed to remove low frequency variants (≥ 5 patients); this
reduced the feature set from 14,543 genes to 514 recurrently altered genes. Associations
with survival were using a Cox proportional hazards regression model with linear
adjustments using covariates described above, or log-rank test where the Cox model failed
its assumptions. FDR-adjustment of the p-values was applied for multiple testing
correction (Supplementary Table 6.7).
In addition to gene-wise features, clinical and survival associations were also
evaluated using PGA or SNVs/Mbp. Associations with clinical variables were performed
using Wilcoxon rank sum tests. For survival analyses, PGA and SNVs/Mbp were median
dichotomized and a Cox proportional hazards regression model with linear adjustments
using covariates described above was performed. For SNV mutational density, only data
from samples with a matched normal were used.
Finally, mutational features were combined and examined for overlaps.
Specifically, pairwise comparisons were made between all combinations of CNA features
(key GISTIC genes, numbers of CNAs/gains/losses, average CNA length, PGA and CNA
subtypes) and SNV features (top recurrently mutated genes, SNVs/Mbp and trinucleotide
signatures using either a χ2 test, Spearman’s correlation or non-parametric Wilcox or
Kruskal-Wallis rank sum test with FDR adjustment of the p-values (Figure 6.4a,
Supplementary Figure 6.5c). Similar comparisons were made between RNA abundance
(TPM) and CNA/SNV/fusion status using Wilcox rank sum tests.
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6.5.9

Data Availability
All WES and SNP array data is available in EGA (accessions

EGAD00001003235 and EGAD00010001579).
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6.7 Supplementary Materials

Supplementary Figure 6.1. Sample summary. a) Breakdown of samples processed by
CNA arrays, WES, IonTorrent targeted sequencing, RNA sequencing, high-throughput
drug screening of kinase inhibitors and siRNA knockdown of kinase panels, before and
after removal of poor quality or contaminated samples. A subset of tumours provided both
an undifferentiated (ATC) and co-occurring differentiated component, metastatic (Met)
tumour or matched reference sample. b) Breakdown of tumours with multiple components:
of the 25 co-occurring DTC components available, 21 were processed alongside a paired
ATC region (numbers in brackets indicate remaining pairs after QC); one case of both a
well-differentiated and poorly differentiated tumour component (no ATC); one case of cooccurring DTC alone; one case of ATC processed by WES only, with paired co-occurring
DTC processed by OncoScan only. c) Four patients with PTC had multi-regional
interrogation: in three cases, two regions of the primary, and in the fourth the primary
tumour and a lymph node metastasis were analyzed.
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Supplementary Figure 6.2. CNA profile of thyroid cancers. CN profile for a) 112 PTCs,
b) 22 co-existing DTC components collected from 21 ATC patient tumours with a single
cervical ATC metastasis; PTC and co-occurring DTC demonstrate similar recurrent
alterations (amplification of 1q and deletion of 22q). c) 13 ATC-derived cell lines
demonstrated considerable alterations to copy-number, likely attributable to aneuploidy. d)
ATC samples evaluated on CNA arrays to generate a number of metrics for each patient,
including CNA count (gains/losses), PGA, ploidy and purity estimates. Samples are
ordered by PGA within each subtype. Distribution of e) total number of CNAs, f) aberrant
cell fraction (purity), g) estimated ploidy, h) number of gains or i) losses, and j) average
CNA length for patients within each subtype; p-values indicate results of one-way ANOVA
tests. k) GISTIC was used to identify recurrent CNAs within PTC; this identified
considerable amplifications of chromosome 17 as being significant and recurrent, as well
as deletions on chromosome 22. While these CN aberrations were more abundant in ATC,
they were not statistically significant following GISTIC analysis. RNA-sequencing of 23
primary ATC tumours was used to evaluate mRNA abundance of genes identified by
GISTIC as being significantly affected by copy number deletions. Wilcoxon rank sum tests
were used to contrast mRNA abundance (TPM) between tumours with a CN deletion to
those with neutral/gain, followed by FDR adjustment of the p-values. Three genes were
found to have significantly different mRNA abundance between groups: l) MYCBP2 (part
of GISTIC segment labeled KLF5 in Figure 6.2e), m) SPATA13 (part of the BRCA2
GISTIC segment) and n) OMG (part of GISTIC segment labeled NF1).
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Supplementary Figure 6.3. WES quality metrics and IonTorrent validation. a) Percent
of target bases from the exome-capture kit used that demonstrated 50x (tumour) or 30x
(normal) coverage. b) ContEst was used to assess cross-sample contamination (T/N pairs
only); both sample-level (top) and lane-level (bottom) estimates were obtained where
possible. Samples with a contamination estimate >3% were excluded from downstream
analyses (n = 7 samples removed). In both cases, samples are ordered from highest to
lowest (based on the ATC component), with additional components to the immediate right
of these for each patient. For example, in b) ANPT0165P has low contamination such that
it near the middle, while a poorly-differentiated component from the same patient
(ANPT0165PI, immediately to the right of ANPT0165P) demonstrated high contamination
by ContEst and was removed from downstream analyses. c) Distribution of read length
(grey) for each sample or target region length (orange). d) Percent of target bases from the
AmpliSeq-custom capture design used that demonstrated 100x (tumour) or 80x (normal)
coverage. e) Comparison of variant allele frequencies (VAF) obtained from WES and
IonTorrent validation for each sample. f) AUC for classification of each variant position as
somatic/non-somatic using p-value from a Pearson’s χ2 test comparing the base counts
between tumour and normal or AmpliSeq and WES (tumour only) (left) or Euclidean
distance (right). g) Validation metrics: (top) proportion of variants called as somatic in
WES that were successfully validated (total numbers appear above each bar); (bottom)
accuracy, sensitivity and specificity for each sample; x-axis label colours indicate T/N
(green) or T only (purple).
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Supplementary Figure 6.4. Distribution of variants in recurrently mutated genes. The
position and recurrence of point mutations across the ATC cohort within recurrently
mutated genes from Figure 6.2. Individual non-synonymous variants found in 3 or more
patient tumours are labelled with the predicted amino acid change.
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Supplementary Figure 6.5. Co-occurrence of key genomic features. a) Point mutations
in EIF1AX tend to co-occur with RAS mutations, b) as do BRAF with PIK3CA mutations.
c) A one-way ANOVA was used to assess the relationship between each trinucleotide
signature and CNA subtypes; no associations were detected. d) Enrichment of patients with
various clinical variables within each ATC-associated CNA subtype; dot size indicates
fold-change (log2[overlapactual / overlapexpected]) within a cluster (x-axis labels) with the
specified variable classification (y-axis labels), with orange indicating over-enrichment
and blue indicating under-enrichment, while background shading indicates p-value from
the hypergeometric test (looking at over- or under-enrichment as defined by dot colour),
after accounting for missing data. For example, Subtype E includes patients with increased
age and tumour aggressiveness (higher rate of T4b relative to T4a disease, nodal
metastases, distant metastasis and leukocytosis). Subtype C has younger patients with
fewer T4b than expected by chance alone. A χ2 test did not identify any difference in
distribution of any of these variables across subtypes. e) CNA subtypes were not associated
with patient outcome. NMF consensus heatmaps for optimal rank are shown for f) ATC (5
clusters) and g) PTC (2 clusters).
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Supplementary Figure 6.6. Tumour progression. a) Ten patients had WES data for both
ATC and paired co-occurring DTC, metastatic or recurrent tumour regions, along with
matched normal tissue; variants with a minimum 80x coverage in both tumour and normal
were selected and variant allele frequencies were compared to assess tumour evolution. b)
Likewise, twenty-one patients had CNA profiles generated for multiple tumour regions.
Each plot shows the genomic CNA profiles for a single patient, with different tumour
regions as rows. Covariates on the right indicate ATC subtype (where available), tumour
type (ATC, co-occurring DTC or metastasis), patient sex, patient age at diagnosis and
BRAF V600E status.
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Supplementary Figure 6.7. Kinase inhibition by molecular interference or
knockdown. a) Normalized growth for each of 2 independent replicates of siRNA
knockdown of kinase species, across 12 ATC cell lines. b) Normalized growth was then
averaged across replicates and d) the top inhibitory genes identified as those with a mean
growth < 0.8 in at least one cell line. d) Activity area for each of 2 independent replicates
of kinase inhibitor exposure, across 13 ATC cell lines. e) Activity area was then averaged
across replicates and f) the top inhibitory compounds identified as those with a mean
activity area > 0.4 in at least one cell line.

173
Supplementary Tables
Supplementary Table 6.1: Sample Characteristics. Clinical characteristics and
summary findings of thyroid tumours and cell lines.
Supplementary Table 6.2: RNA abundance (TPM) in ATC primary tumours and cell
lines. RNA-sequencing was performed on 24 primary ATC tumours and 13 ATC cell lines;
data were normalized and expression values (transcripts per million) calculated using
RSEM and STAR.
Supplementary Table 6.3: Cross-study comparison of gene-wise SNV frequencies in
thyroid cancer. Gene-wise SNV frequencies were calculated for 132 ATC, 19 cooccurring DTC and 112 PTC primary tumours. These were contrasted to mutation
frequencies obtained from TCGA (PTC, n = 481), Kunstman et al. (ATC, n = 22), Landa
et al. (ATC, n = 33; PDTC, n = 78), Pozdeyev et al. (ATC, n = 134; PDTC, n = 182), Ganly
et al. (HTC, n = 56), Gopal et al. HTC, n = 32).
Supplementary Table 6.4: Germline SNVs in cancer predisposition genes. Germline
SNVs were identified in ATC tumours with match normal only. Results were filtered to
remove common variants (<1% in 1000G); SNVs identified in known driver genes are
shown.
Supplementary Table 6.5: STR profiling of ATC cell lines. STR profiles for 13 ATCderived cell lines.
Supplementary Table 6.6: CNA associations with overall survival in ATC. CNA
segments identified by GISTIC as being significant in ATC were evaluated for associations
with overall patient survival; no significant associations were found.
Supplementary Table 6.7: SNV associations with overall survival in ATC. Genes
identified as recurrently altered in ATC were evaluated for associations with overall patient
survival; no significant associations were found.
Supplementary Table 6.8: Cross-study comparison of gene-wise CNA frequencies in
thyroid cancer. Gene-wise CNA frequencies were calculated for 111 ATC, 24 cooccurring DTC and 111 PTC primary tumours. These were contrasted to mutation
frequencies obtained from TCGA (PTC, n = 505).
Supplementary Table 6.9: Overlap of point mutations across tumour components. 19
patients had SNV calls for multiple tumour regions (ATC, co-occurring DTC, metastasis
or recurrent tumour); hypergeometric tests were used to determine whether there was more
overlap than expected by chance alone across regions. A single pair (primary ATC and
cervical metastasis) demonstrated no overlap in SNV profile.
Supplementary Table 6.10: Overlap of CNAs across tumour components. 21 patients
had CNA calls for multiple tumour regions (ATC, co-occurring DTC, metastasis or
recurrent tumour); hypergeometric tests were used to determine whether there was more
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overlap than expected by chance alone across regions. There was frequently less overlap
than expected.
Supplementary Table 6.11: RNA fusions in ATC. RNA-sequencing was performed on
24 primary ATC tumours and 13 ATC cell lines. Fusioncatcher was used to identify gene
fusions; results were filtered to remove fusions with low evidence (required at least two
reads).
Supplementary Table 6.12: siRNA knockdown of kinases in ATC cell lines. An siRNA
screen was performed on 12 cell lines to knockdown expression of 714 kinases. Two
replicates were performed and normalized separately.
Supplementary Table 6.13: Kinase inhibitor drug screen of ATC cell lines. High
throughput drug screening was performed on 13 cell lines using 320 kinase inhibitors. Two
replicates were performed; normalization and calculation of activity area was performed
separately.
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Appendix 2: Research Ethics Board (REB) Approval
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Appendix 3: Animal Use Protocol (AUP) Approval

177

Appendix 4: Curriculum Vitae
Post-Secondary Education and Degrees
•

PhD Candidate: The University of Western Ontario, London, ON, 2014-Present
Department: Anatomy & Cell Biology
Supervisor: Dr. Anthony Nichols

•

Master of Science (MSc): The University of Guelph, Guelph, ON, 2010-2012
Department: Integrative Biology (Comparative Physiology)
Supervisors: Dr. Douglas Fudge & Dr. Todd Gillis

•

Bachelor of Science (BSc): The University of Guelph, Guelph, ON, 2006-2010
Program: Honors, Human Kinetics

Honours and Awards
1. Dean’s PhD Stipend for Graduate Research Excellence, University of Western
Ontario ($25,000/year), 2014-2018
2. Western Graduate Research Scholarship, University of Western Ontario
($4,500/year), 2014-2018
3. Department of Otolaryngology Travel Award for Graduate Students, University
of Western Ontario ($1,500), 2017
4. Centre for Translational Cancer Research Poster Presentation Award, University
of Western Ontario, Oncology Research and Education Day ($100), June 2015
5. Cancer Research and Technology Transfer Program (CaRTT), University of
Western Ontario ($15,000/year), 2014 [declined]
Grants
1. N Pinto, JW Barrett & AC Nichols. “The role of SCRIB in the dedifferentiation of
thyroid cancer.” Lawson Internal Research Fund, London Regional Cancer
Program. London, Ontario. November 2016. ($14,000).
Abstracts
National/International Conferences
1. Highly effective inhibitory agent identified by high-throughput screening of
genetically characterized anaplastic thyroid cancer cell lines. American
Association of Cancer Research 2017, Washington, DC [poster presentation].

178
2. Highly effective agents identified by high-throughput drug testing of genetically
characterized anaplastic thyroid cancer cell lines. Canadian Society of
Otolaryngology 2016, Charlottetown, PEI [oral presentation].
3. Highly effective inhibitory agent identified by high-throughput screening of
genetically characterized anaplastic thyroid cancer cell lines. American
Association of Cancer Research 2016, New Orleans, LA [poster presentation].
4. Highly effective agents identified in genetically characterized anaplastic thyroid
cancer cell lines. Canadian Society of Otolaryngology 2015, Winnipeg, MB [oral
presentation].
Local Meetings
1. Mechanisms of disease progression from well-differentiated to undifferentiated
(anaplastic) thyroid cancer. Al Driedger Thyroid Cancer Symposium 2018,
London, ON [oral presentation].
2. Mechanisms of disease progression from well-differentiated to undifferentiated
(anaplastic) thyroid cancer. Oncology Research & Education Day 2018, London,
ON [poster presentation].
3. Mechanisms of disease progression from well-differentiated to undifferentiated
(anaplastic) thyroid cancer. Student Research Rounds Head and Neck Residents
Research Day 2018, London, ON [oral presentation].
4. Understanding the progression from papillary thyroid cancer to anaplastic thyroid
cancer. Al Driedger Thyroid Cancer Symposium 2017, London, ON [oral
presentation].
5. Understanding the progression from papillary thyroid cancer to anaplastic thyroid
cancer. Head and Neck Disease Site Retreat 2017, London, ON [oral
presentation].
6. Lestaurtinib identified as a highly effective inhibitory agent in anaplastic thyroid
cancer cell lines. Student Research Rounds Head and Neck Residents Research
Day 2017, London, ON [oral presentation].
7. High-throughput drug testing for drug discovery in anaplastic thyroid cancer.
Anatomy & Cell Biology Seminar Series 2017, London, ON [oral presentation].
8. JAK2 as a novel therapeutic target in anaplastic thyroid cancer. Head and Neck
Disease Site Retreat 2016, London, ON [oral presentation].
9. The identification of novel therapeutics for the treatment of anaplastic thyroid
cancer. Donor presentation 2016, London, ON [oral presentation].
10. Highly effective inhibitory agent identified by high-throughput drug testing of
genetically characterized anaplastic thyroid cancer cell lines. Student Research
Rounds Head and Neck Residents Research Day 2016, London, ON [oral
presentation].
11. High-throughput screening for drug discovery in anaplastic thyroid cancer. Grand
Rounds, London Regional Cancer Program 2016, London, ON [oral presentation].
12. Highly effective agents identified using high-throughput screening in anaplastic
thyroid cancer cell lines. London Health Research Day 2015, London, ON [oral
presentation].

179
Publications
1. Nichols AC, Prokopec SD, Lai SY, Pinto N et al. 2018. The genomic and
evolutionary landscapes of anaplastic thyroid carcinoma. [Submitted to Cancer
Cell, March 2019].
2. Pinto N, Prokopec SD, Ghasemi F, Meens J, Ruicci KM, Khan MI, Mundi N,
Patel K, Han MW, Yoo J, Fung K, MacNeil D, Mymryk JS, Datti A, Barrett JW,
Boutros PC, Ailles L, Nichols AC. Flavopiridol inhibits anaplastic thyroid cancer
models via CDK inhibition. [In preparation for resubmission to EndocrineRelated Cancers 2019].
3. Ghasemi F, Prokopec SD, MacNeil D, Mundi N, Gameiro SF, Howlett C, Stecho
W, Plantinga P, Pinto N, Ruicci KM, Khan MI, Yoo J, Fung K, Sahovaler A,
Palma DA, Winquist E, Mymryk JS, Barrett JW, Boutros PC, Nichols AC. 2019.
Mutational analysis of head and neck squamous cell carcinoma stratified by
smoking status. JCI Insight 10;4(1).
4. Pinto N, Prokopec SD, Vizeacoumar F, Searle K, Lowerison M, Ruicci KM, Yoo
J, Fung K, MacNeil D, Lacefield J, Leong HS, Mymryk JS, Barrett JW, Datti A,
Boutros PC, Nichols AC. 2018. Identification of Lestaurtinib as a potent inhibitor
of cell growth and angiogenesis in anaplastic thyroid cancer cell line models.
PLoS One 12;13(11):e0207152. doi: 10.1371/journal.pone.0207152.
5. Ruicci KM, Meens J, Sun R, Rizzo G, Pinto N, Yoo J, Fung K, MacNeil D,
Mymryk JS, Barrett JW, Boutros PC, Ailles L, Nichols AC. 2018. A controlled
trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3Ka
inhibition in controlling tumour growth. Int J Cancer.
6. Ruicci KM, Pinto N, Khan MI, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett
JW, Nichols AC. 2018. ERK-TSC2 signalling in constitutively-active HRAS
mutant HNSCC cells promotes resistance to PI3K inhibition. Oral Oncol 84:95103
7. Ghasemi F, Black M, Sun R, Vizeacoumar F, Pinto N, Ruicci KM, Yoo J, Fung
K, MacNeil D, Palma DA, Winquist E, Mymryk J, Ailles L, Datti A, Barrett JW,
Nicholas AC. 2018. High-throughput testing in head and neck squamous cell
carcinoma identifies agents with preferential activity in human papillomaviruspositive or negative cell lines. Oncotarget 9(40):26064-26071.
8. Ghasemi F, Black M, Vizeacoumar F, Pinto N, Ruicci KM, Le CCSH, Lowerison
MR, Leong HS, Yoo J, Fung K, MacNeil D, Palma DA, Winquist E, Mymryk JS,
Boutros PC, Datti A, Barrett JW, Nichols AC. 2017. Repurposing albendazole:
new potential as a chemotherapeutic agent with preferential activity against HPVnegative head and neck squamous cell cancer. Oncotarget 8:71512-71519.
9. Theurer JA, Stecho W, Yoo J, Kwan K, Wehrli B, Harry B, Black M, Pinto N,
Winquist E, Palma D, Richter S, Barrett JW, MacNeil DS, Fung K, Howlett CJ,
Nichols AC. 2015. Feasibility of Targeting PIK3CA Mutations in Head and Neck
Squamous Cell Carcinoma. Pathol Oncol Res 22(1):35-40.
10. Nichols AC, Black M, Pinto N, Fernandes A, Haibe-Kains B, Boutros PC, Barrett
JW. 2014. Exploiting high-throughput cell line drug screening studies to identify
candidate therapeutic agents in head and neck cancer. BMC Pharmacol Toxicol
15(1):66.

180
11. Pinto N, Black M, Patel K, Yoo J, Mymryk JS, Barrett JW, Nichols AC. 2014.
Genomically driven precision medicine to improve outcomes in anaplastic thyroid
cancer. J Oncol 2014:936285.
12. Mundi N, Um S, Yoo J, Rizzo G, Black M, Pinto N, Palma DA, Fung K,
MacNeil D, Mymryk JS, Barrett JW, Nichols AC. 2014. The control of anaplastic
thyroid carcinoma cell lines by oncolytic poxviruses. Virus Research 190:53-9.
13. Pinto N, Yang FC, Negishi A, Rheinstädter MC, Gillis TE, Fudge DS. 2014. Selfassembly enhances the strength of fibres made from vimentin intermediate
filament proteins. Biomacromolecules 15(2): 574-581.
Extracurricular Activities
1. Strong Bones, Strong Minds, Strong Muscles – Retiring with Strong Minds CoChair, September 2016 -August 2017
2. Anatomy and Cell Biology Graduate Student Council – Virtual Communications,
September 2016 – August 2017
Other Contributions
1. Attendance and participation at weekly disease site team meetings and weekly
seminar series focused on cancer research, 2014 – Present

